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GENERAL ASPECTS OF PSORIASIS 
Psoriasis is a common, chronic skin disease, characterized by epidermal 
hyperproliferation, impaired differentiation and cutaneous inflammation. Clinical 
manifestations of psoriasis range from the erythematous scaly plaques of chronic plaque 
psoriasis to the waves of erythematous sheets of pustules of the von Zumbusch type of 
pustular psoriasis. In this thesis the severe forms of psoriasis are highlighted i.e. the 
extensive forms of chronic plaque psoriasis, insufficiently responding to topical therapy, 
the erythrodermic forms of psoriasis and the pustular forms of psoriasis, in which the 
inflammatory component dominates. 
I . I Clinical aspects of chronic plaque psoriasis 
1.1.1 Epidemiology 
Psoriasis appears to be most common in northern Europe and North America. 
Incidences of 1.5-3% are reported.[1] In certain ethnic groups no psoriasis is seen, such 
as the American Indians and Eskimos. Psoriasis is equally common in men and women.[2] 
The age of onset of psoriasis is variable; the first manifestations may occur at any age. A 
study on the age of onset of psoriasis carried out in 2147 patients revealed two peaks of 
incidence: one occurring at the age of 16 years (women) or 22 years (men), and another at 
60 years (women) or 57 years of age (men).[3] 
1.1.2 Cutaneous manifestations 
Chronic plaque psoriasis, also designated as psoriasis vulgaris, is characterized by 
sharply demarcated erythematosquamous plaques as demonstrated in Fig. 1. The lesions 
can vary in shape and size, with a fairly symmetrical distribution pattern. Areas of 
predelection are the elbows, knees, scalp and sacral region. Phenomenons characteristic for 
psoriasis are the candle phenomenon, which means that when the scales are scraped off a 
lesion, they detach as small flakes (like wax flakes scraped from a candle). Further the 
focal bleeding after removal of the parakeratotic scales, also known as Auspitz's 
phenomenon, is characteristic. Various cutaneous expressions of psoriasis may occur. 




Different forms of psoriasis can coexist in one patient, or may appear at different moments 
in the same patient. In one family the members may show different forms. For a detailed 
description of the clinical variants of psoriasis various reviews are available.[1,4] Guttäte 
psoriasis is a form in which numerous erythematosquamous papules can be observed all 
over the body, particularly occurring in children or young adults. Often systemic triggering 
factors like a streptococcal throat infection are of relevance in this psoriatic phenotype.[5] 
Flexural psoriasis or psoriasis inversa occurs in about 30% of patients with chronic plaque 
psoriasis. I t is an isolated symptom in 2-6% of the patients with psoriasis.[4] In this form 
the silvery scales are lost due to warmth and humidity in intertriginous areas. 
The most severe form is erythrodermic psoriasis characterized by generalized 
erythema and scaling. This reaction pattern is not unique to psoriasis but may be due to 
other skin disorders like atopic dermatitis. Hospitalization is indicated to prevent systemic 
dysregulation due to dehydration and heat and protein loss.[6] 
The pustular forms of psoriasis will be extensively discussed in the following chapter. 
1.1.3. Extracutaneous manifestations 
Nail changes occur in about 30-50% of all patients with psoriasis.[7] Fingernails are 
more frequently involved than toenails.[8] Characteristic nail changes in psoriasis are 
pitting, onycholysis, discoloration and subungual hyperkeratosis. 
Psoriatic arthropathy is a complication of psoriasis that occurs in 5-10% of the 
patients.[9] I t is also seen in patients without cutaneous lesions. Most often arthritis of 
the distal interphalangeal joints of the fingers and a negative serological test for 
rheumatoid factors are seen. In patients with psoriatic arthropathy an increased frequency 
of HLA B27 and HLA Bw38 is found.[10] 
1.2 Histopathology 
The histological aspects of psoriasis vulgaris vary considerably, depending on the 
stage of development of the lesion. Histological features of the epidermis in the fully 
developed psoriatic lesion are orthokeratosis, focal absence of the granular layer with 
additional parakeratosis (comeocytes in the stratum corneum containing nuclear 
remnants), acanthosis and elongation of the rete ridges with suprapapillary thinning of the 
epidermis (Fig. 2). In an early stage of the lesion and in active psoriasis 
polymorphonuclear leukocytes (PMN) penetrate into the epidermis accumulating as 
spongiform pustules of Kogoj and Munro microabscesses. Munro microabscesses represent 
an accumulation of PMN within the parakeratotic stratum corneum. Spongiform pustules 
are seen beneath the keratin layers and consist of small accumulations of PMN and 
occasional lymphocytes intermingled with the epidermal cells in foci of spongiosis.[ll] The 
phenomenon of cyclic migration of PMN transepidermally from the blood vessels in the 
dermal papillae to the stratum corneum, is also known as the squirting papillae 
phenomenon.[12] The dermis shows elongation and oedema of the papillae and 
perivascularly a chronic inflammatory infiltrate is present composed of Lymphocytes and 
PMN. 
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Figure 2. The histological features of 
psoriasis: orthokeratosis, focal parakera-
tosis, acanthosis and elongation of the 
rete ndges and dermal a mixed inflam-
matory infiltrate. A spongiform micropu-
stule of Kogoj is present in the upper 
part of the stratum spmosum. 
1.3 Aetiology and pathogenesis 
The causes of psoriasis are unknown. Psoriasis is undoubtedly an inherited disease, 
but the heterogeneity of the disease probably results from the interaction of multiple gene 
abnormalities with environmental factors. 
1.3.1 Genetics 
For a detailed review on the genetics of psoriasis we refer to the paper of van 
Steensel and Steijlen.[13] A genetic base for psoriasis is confirmed by family and twin 
studies. In twin studies the concordance rate was 73% for monozygotic twins, compared to 
20% for dizygotic twins, suggesting a significant heritability of psoriasis.[14] Lomholt 
found in a study of 20.000 inhabitants of the Färoer islands that 91% of his patients with 
psoriasis had at least one affected relative (1st or 2nd degree).[15] The risk of becoming a 
psoriatic patient in case one of the relatives is affected varies between 50% (both parents 
affected) and 4% for second degree relatives. [10] An early age at onset of psoriasis 
increases the chance of sibs developing psoriasis.[16] Several studies indicate an 
association of psoriasis with HLA subtypes B13, B17, A13, A17, B37 and Cw6.[17-19] The 
frequency of HLA Cw6 was significantly higher in patients with age of onset between 10 
and 20 years. HLA Cw6 has a stronger influence on disease expression than other HLA 
genes.[17] Hypothesized is that HLA-antigens function as modifiers, decreasing the 
threshold for developing psoriasis. [20] Other loci associated with psoriasis include the оц-
antitrypsin gene locus (the frequency of rare types (MaZ and M2Z) was significantly 
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increased among psoriatics)[21] and a polymorphism of the IL-1 receptor antagonist 
gene.[22] 
Recently, several groups have started genome-wide searches for genes conferring 
susceptibility to psoriasis. A locus on chromosome 17q[23] was identified, however other 
investigators were unable to confirm linkage.[24,25] Furthermore, linkage was reported 
with a locus on chromosome 4q[26] and within the major histocompatibility complex 
cluster on chromosome 6.[27] 
1.3.2 Environmental factors 
Several triggering factors have been identified which play an important role in the 
initiation of psoriasis in a genetically predisposed patient. Different physical, chemical, 
and inflammatory skin insults have been reported to induce psoriasis.[28] The observation 
that local irritation or trauma of the uninvolved skin resulted in psoriatic lesions is known 
as the Koebner phenomenon, as described by Koebner in 1872.[1] The incidence of the 
Koebner phenomenon ranged from 38 to 76% in psoriatic patients.[2] Infections have also 
been noted as systemic triggering factors that induce or exacerbate psoriasis. Tonsillitis 
and upper respiratory infections are significantly associated with acute guttäte psoriasis in 
childhood psoriasis.[29] Throat infection with beta-haemolytic streptococci are associated 
with the initiation and exacerbation of plaque type psoriasis.[30] HIV-infection can 
deteriorate psoriasis.[31] Several drugs such as lithium,[32] beta-adrenergic blocking 
agents,[33] antimalarials, and the withdrawal of systemically administered corticosteroids 
can induce or exacerbate psoriasis. Endocrine factors can influence psoriasis as is shown 
by peaks of incidence at puberty and at the menopause[3] and alterations during 
pregnancy.[34] Furthermore, photosensitivity resulting in deterioration of psoriasis has 
been reported in 5.5% of patients.[35] The relevance of psychological stress in psoriasis is 
not fully understood.[36] 
1.3.3 Pathogenesis 
Chronic plaque psoriasis is histopathologically characterized by hyperproliferation of 
the epidermis, accumulation of inflammatory cells and elongation and increased tortuosity 
of dermal papillary blood vessels. Abnormal keratinocyte differentiation and 
hyperproliferation of keratinocytes are secondary to altered growth and maturation 
kinetics.[37] Previously i t was assumed that the cell cycle of a proliferating psoriatic 
keratinocyte is shortened to about 1.5 days (normal 13 days), and the maturation and 
shedding phase to about 4 days (normal 26 days).[38] However, evidence against this 
classic assumption is cumulating: a recent study by van Erp et αι. using flow cytometry in 
combination with IdUrd labelling showed that there seems to exist no major difference 
between normal and hyperproliferative skin with respect to cell cycle time and duration of 
individual cell cycle phases.[39] 
Evidence for an important role of Τ lymphocytes in the pathogenesis of psoriasis is 
given by a case-report of a patient without neutrophils and monocytes in the peripheral 
circulation, who developed psoriasis.[40] Depletion of circulating Τ lymphocytes by 
intravenous administration of anti-CD3/CD4 monoclonal antibodies resulted in 
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improvement of psoriasis.[41] Furthermore, cyclosporin A, an immunomoduLating drug with 
high specificity for inhibition of cytokine production of T-cells, is very effective in the 
treatment of psoriasis. All these observations are indirect evidence for an important role of 
CD4+ Τ lymphocytes and their cytokines in the pathogenesis of psoriasis. In a review by 
Prens et α/.[42] the involvement of Τ lymphocytes in early psoriatic lesions is described, 
supporting the hypothesis that psoriasis is a disease of keratinocyte proliferation induced 
by Τ lymphocytes and Τ cell derived proinflammatory mediators. Τ cells from peripheral 
blood of psoriatic patients, in the absence of added antigen, show a clear proliferative 
response in vitro to autologous epidermal cells from lesionai as well as uninvolved 
skin.[43,44] At present, i t is unclear whether this response is antigen driven. 
Keratinocytes contain a wide variety of cytokines, immune and inflammatory 
modulators, which are released after damage to the skin. Three theories have been 
proposed for the relationship between epidermal keratinocyte and immunocyte activation, 
as summarized by Weinstein and Krueger.[45,46] Epidermal keratinocytes are activated 
directly by physical, chemical or ultraviolet injury (Koebner phenomenon) to increase the 
synthesis and release of cytokines, which trigger T-lymphocyte activation in an antigen-
independent fashion. The other 2 theories propose that persistent T-lymphocyte 
stimulation may occur as a result of either antigen/superantigen presentation or as a result 
of autoreactivity. 
In the antigen/superantigen dependent hypothesis, antigen presenting cells 
(epidermal Langerhans cells or dermal macrophages) interact with resting CD4+ "helper" Τ 
lymphocytes, resulting in release of cytokines which activate resting epidermal 
keratinocytes. Staphylococcus aureus and streptococci secrete a large family of exotoxins, 
which can act as a superantigen, capable of binding to major histocompatibility complex 
class I I proteins on antigen-presenting cells outside the antigen peptide-binding groove 
and thereby stimulating cytokine release from macrophages. In contrast to conventional 
antigens, superantigens bypass intracellular processing and bind directly to the MHC class 
I I molecule. The superantigen then cross-links the MHC class I I molecule on the antigen-
presenting cell with Τ cells expressing spécifie variable segments of the T-cell receptor β 
chain, (called Vß), leading to polyclonal T-cell activation. In this respect M proteins of 
group A ß-haemolytic streptococci[47] may be of importance. Studies have shown 
increased representation of Vß2 and, to a lesser extent, Vß5-expressing Τ cells in lesionai 
skin of patients with guttäte and chronic plaque psoriasis when compared with peripheral 
blood Τ cells from the same patient.[48] 
In the autoreactive hypothesis, CD8+ "killer" Τ cells generated in the skin or 
systemically are inappropriately specific to epidermal keratinocytes, producing sublethal 
damage that triggers regenerative or wound-healing activation. 
Considering the genetic heterogeneity and the different theories, i t is possible that 
different pathogenic mechanisms could be linked to different genetic loci. 
17 
I GENERAL ASPECTS OF PUSTULAR PSORIASIS 
2.1 Clinical aspects 
Pustular psoriasis comprizes those forms of psoriasis in which macroscopic pustules 
appear. Two main types can be distinguished: localized and generalized forms. The 
localized forms can be divided in pustulosis palmoplantaris and acrodermatitis continua of 
Hallopeau; the generalized forms are classified as the acute generalized pustular psoriasis 
of von Zumbusch, impetigo herpetiformis, annular pustular psoriasis, juvenile and infantile 
pustular psoriasis and localized forms (not acrai or palmoplantar).[49] 
2.1.1 Localized forms of pustular psoriasis 
Pustulosis palmoplantaris (PPP) is a common condition in which erythematous and 
scaly plaques with sterile pustules develop on the palms and soles. I t is a disease of adults 
and i t seldomly occurs in children. The lesions are often symmetrical, especially on the 
feet (Fig. 3a). The pustules may vary in size from 1 mm t i l l 1 cm. The pustules are yellow 
when fresh, but later become yellow-brown and even dark brown (Fig. 3b). Typically, 
pustules at all stages of evolution are apparent. The differential diagnoses includes tinea 
and vesicular eczema. The term pustular bacterid as introduced by Andrews[50], describes 
an acute monomorphic sterile pustular eruption of hands and feet, which in most cases 
simply represents an acute exanthematous variant of PPP. The lesions are in general not 
provoked by a remote form of bacterial infection. The relationship of PPP to psoriasis is 
controversial. Sometimes the presence of typical psoriasis elsewhere, or a personal or 
strong family history of psoriasis or the future development of psoriasis vulgaris, 
established the relationship. However, typical PPP often occurs in the absence of such 
evidence. Signs of psoriasis elsewhere on the body occur in 2%[51] to 19%[52] of all 
cases. Furthermore, HLA associations of plaque psoriasis are different from PPP, indicating 
that PPP is genetically distinct from psoriasis vulgaris. 
In acrodermatitis continua of Hallopeau chronic, sterile pustules are located on the 
tips of fingers and toes. The skin of the distal phalanx becomes red and scaly and pustules 
develop. The nail plate may be completely destroyed and bony changes may occur with 
osteolysis of the tuft of the distal phalanx. Acrodermatitis continua of Hallopeau may 
evolve into generalized pustular psoriasis, especially in the elderly.[53] The tongue may 
become involved with fissuring or may adapt the pattern of the annulus migrans.[54] A 
patient with such a clinical picture is described in chapter 4. 
2.1.2 Generalized forms of pustular psoriasis 
A few studies on large series of patients with generalized pustular psoriasis (GPP) 
have been reported. By far the largest study was by Baker and Ryan[53], who reported on 
104 patients with GPP, 24 of these were their own patients. In these patients information 
was obtained through questionnaires sent to dermatologists in Great Britain. Baker and 
Ryan described 2 subgroups in the 104 cases of GPP. The first subgroup had an early onset 
of psoriasis, with a typical psoriatic morphology, a long pre-pustular phase and the 
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Figure За. Pustulosis palmoplantaris: 
symmetrical erythematous and scaly 
plaques with stenle pustules. 
Figure 3b. In detail: pustules at all stages 
of evolution. 
generalized flare was frequently provoked. The second subgroup is characterized by late 
onset of the disease, with atypical pre-pustular morphological features and a rapid 
spontaneous progression to GPP. Furthermore, they divided their patients in 4 categories, 
depending on the clinical pattern: the Zumbusch pattern, the annular pattern, the 
exanthematic type and the localized pattern. Besides the classification of Baker and Ryan, 
a slightly different classification is proposed by Zelickson and Muller, based on 63 cases 
seen in a 29-year period.[55] The patients were classified in 4 categories based on the 
dynamics of onset and clinical pattern of their disease, i.e. acute GPP von Zumbusch type, 
subacute annular GPP, chronic aerai GPP and mixed GPP. With this classification, guidelines 
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for treatment and prognosis were proposed. The prevalence of GPP in Japan was 
7.46/million, indicating the rarity of the disease.[56] 
The first clinical description of acute GPP was published by von Zumbusch in 
1910.[57] The clinical picture of acute GPP von Zumbusch type consists of erythema and 
pustulation in the form of isolated pustules or lakes of pus involving particularly the 
flexures and genital regions, but also resulting in generalized erythroderma (Fig. 4). In a 
later phase, exfoliation of the dried pustules occurs. The skin manifestations are 
accompanied by high fever and severe malaise. Hypoalbuminaemia may be profound, 
perhaps because of a sudden loss of plasma protein. The acute phase is a life-threatening 
situation.[58] The buccal mucosa and tongue can be involved with frank pustules or an 
acute geographic tongue.[59] Geographic tongue was seen in 17% of patients with GPP, 
the prevalence in the normal population is 2%. A subdivision of patients with GPP von 
Zumbusch type is by the presence or absence of a preceding history of psoriasis 
vulgaris.[56] In the study of Ohkaware et αι. 143 of 208 cases (69%) with acute GPP of the 
von Zumbusch type had no history of ordinary psoriasis. The patient groups differ in 
incidence of HLA antigens, age of onset, the precipitating factors and the distribution of 
skin lesions. In the study of Zelickson and Muller, 11 of 35 patients (31%) with acute GPP 
had no history of psoriasis vulgaris before the flare.[55] 
Impetigo herpetiformis is a form of GPP occurring during pregnancy. Essentially, the 
histological and clinical features are as in GPP, with a predilection to flexural areas. No 
consensus has been reached whether impetigo herpetiformis is a separate entity or a 
variant of pustular psoriasis.[60] A case report of a patient with impetigo herpetiformis is 
presented in chapter 10. 
Annular pustular psoriasis presents as a subacute or chronic form of generalized 
pustular psoriasis. Lesions begin as discrete areas of erythema which become raised and 
oedematous.[61] The lesions spread centrifugally, with pustules at the edge, and a central 
healing of the lesion. In chapter 11 a patient with annular pustular psoriasis is described. 
Juvenile and infantile pustular psoriasis is very rare (less than 100 cases have been 
reported), and has often a benign course.[62] Cucinate and annular forms are common. 
Systemic symptoms are often absent and spontaneous remissions occur. 
A more appropriate term for the localized forms of GPP is "psoriasis with pustules". 
One or more plaques of psoriasis vulgaris may develop pustules following prolonged irritant 
topical therapy. Resolution is usually prompt with bland topical treatment. 
The differential diagnosis of GPP includes the subcorneal pustular dermatosis of 
Sneddon-Wilkinson, in which the spongiform pustules are located subcorneal. In both, 
pustular psoriasis and subcorneal pustular dermatosis, the characteristic feature is the 
accumulation of PMN in the upper part of the epidermis. Several authors believe that the 
original criteria of Sneddon and Wilkinson for the diagnosis of subcorneal pustular 
dermatosis (i.e. the histology of a subcorneal pustule and the response to dapsone) are 
not specific enough to make subcorneal pustular dermatosis as a unique disease which can 
be differentiated from pustular psoriasis.[63,64] Furthermore, acute generalized 
exanthematous pustulosis must be differentiated from GPP.[65] It differs from GPP in the 
mild general symptoms and the fact that the skin lesions are usually self-limiting, with 
short duration. Included in the differential diagnosis are Reitera disease and acute 
pemphigus foliaceus. 
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Figure 4a. Generalized pustular 
psoriasis von Zumbusch type: ery­
thema and scaling with isolated 
pustules and confluated pustules. 
Figure 4b. In detail. 
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Figure 5. The histological features 
of pustular psoriasis: intra-epider-
mal large accumulations of PMN 
form a spongiform pustule. 
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2.2 Histopathology 
The histological picture of pustular psoriasis differs from psoriasis vulgaris in that 
the spongiform pustule occurs as a macropustule and is the characteristic lesionali ] As 
the spongiform pustule increases in size, the epidermal cells die, with resulting central 
cavation. At the edges a shell of thinned epidermal cells remains, which causes the 
spongiform appearance. Eventually PMN accumulate into the horny layer and intra-
epidermal large accumulations of PMN are seen, which is a "macro" of the microabscess of 
Munro (Fig. 5). Otherwise the epidermal and dermal features are similar to those of 
psoriasis vulgaris. 
2.3 Aetiology and pathogenesis 
2.3.1 Genetics of pustular psoriasis 
HLA association with pustular psoriasis differs from psoriasis vulgaris, indicating 
that pustular psoriasis is genetically distinct from psoriasis vulgaris. In pustular psoriasis 
no association with HLA A13 and A17 was found, in contrast to increased expression in 
psoriasis vulgaris.[20] HLA typing was performed on 93 unrelated patients with 
palmoplantar pustulosis, revealing an increased frequency of HLA B8. The incidence of HLA 
B13 or B17 was not significantly increased.[66] 
2.3.2 Triggering factors 
Provocative factors for development of GPP as described by Baker and Ryan in their 
review of 104 cases, included pregnancy, infections, hypocalcaemia and reduction or 
withdrawal of corticosteroid therapy.[53] The pregnancy induced forms of GPP were later 
described as impetigo herpetiformis,[67] the exanthematous forms of GPP occurring after 
infection were later described as acute generalized exanthematous pustulosis.[65] In the 
Baker and Ryan series, in only 5 patients of 57 patients with GPP hypocalcaemia was 
reported, which was transient in 4 patients. None of the 104 patients was known to have 
hypocalcaemia before the GPP episodes. Hypocalcaemia precipitating GPP was reported in 
a patient with surgical hypoparthyroidism.[68] In 21 of 37 patients with GPP, who were 
treated with corticosteroids systemically before the onset of the first attack of GPP, this 
was provoked by this therapy. Pustulosis occurred for the first time within a few days or 
weeks of reduction or complete withdrawal of steroids.[53] Of these 21 patients, 17 had 
preceding a psoriasis of the ordinary pattern. 
2.3.3 Pathogenesis of pustular psoriasis 
Acute inflammatory changes in the form of massive infiltration of PMN in the 
epidermis are predominant in the lesions of pustular psoriasis. This suggests that an 
increased concentration of a leukotactic factor is present in pustular psoriasis, with a 
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highest concentration at the subcorneal portion. Several chemotactic factors for 
neutrophils have been detected in lesionai skin of psoriasis vulgaris. Such factors include 
anaphylatoxin C5a[69] and its degradation product C5a des Arg,[70] platelet-activating 
factor,[71] leukotriene B4 (LTBJ[72] and interleukin 8.[73] However, in none of these 
studies a significant difference between the levels of chemotactic factors in plaque and 
pustular psoriasis could be shown. The chemotactic activity of PMN of 50 patients with 
psoriasis vulgaris and 20 patients with pustular psoriasis to LTB4 was studied.[74] This 
study demonstrated that PMN of patients with a pustular psoriasis had a significantly 
higher PMN chemotactic response than PMN of patients with psoriasis vulgaris. This result 
could be confirmed by Petrini et o/.[75] In contrast, Lundin eí al. found a decreased 
chemotactic activity of both PMN from plaque psoriasis patients and from pustular 
psoriasis patients compared to normal PMN.[76] Serial measurement of various cytokines in 
serum of a patient with generalized pustular psoriasis demonstrated an increase of TNF-a 
during the pustular stage of the disease.[77] It was hypothesized that TNF-a, by 
stimulation of interleukin 8 expression in keratinocytes[78], may contribute to the 
activation and Chemotaxis of neutrophils in pustular psoriasis. 
In conclusion, to date the pathogenesis of the pustule formation in pustular 
psoriasis is unclear. A primary involvement of chemotactic factors could not be confirmed 
despite intensive studies on scale extracts. PMN of pustular psoriasis patients might have 
an increased chemotactic response. Recently, i t was shown that an antileukoproteinase is 
produced in the skin. In part I I I of this thesis the possible role of this skin-derived 
antileukoproteinase in the pathogenesis of pustular psoriasis is further discussed. 
CURRENT ΑΝΤΙ-PSORIATIC TREATMENTS 
Different topical and systemic anti-psoriatic treatments are available. All treatments 
minimize the symptoms but provide no definitive cure. Treatment has to be individualized 
for each patient, depending upon factors like the form of psoriasis, age, sex, general 
health and concomitant medication. The first choice treatments are topical treatments, 
which are associated with mild side effects. However, in erythrodermic psoriasis and 
pustular forms of psoriasis like palmoplantar pustulosis, acrodermatitis continua of 
Hallopeau or generalized pustular psoriasis, topical treatments are not sufficient and 
systemic treatments are required for a substantial therapeutic effect. A summary of the 
different treatment modalities is presented. Because the scope of this thesis are the severe 
forms of psoriasis, the available systemic therapies are discussed more extensively. 
3.1 Topical therapies 
To improve skin-penetration of the active agents, keratolysis is of importance using 
topical keratolytics containing salicylic acid, urea or lactic add. Pix lithantracis is 
produced by heating coal in the absence of air, solutio carbonis detergens is an extraction 
23 
of pix lithantracis with alcohol and subsequently addition of Tween 80. Pix lithantracis is 
composed of thousands of different compounds, including hydrocarbons, phenols, sulfur 
and nitrogen compounds (for review [79]). Tar is not recommended in erythrodermic or 
pustular forms of psoriasis, because of irritation. Disadvantages of tar therapy are the odor 
and staining of clothes. 
Topical corticosteroids are effective in the treatment of psoriasis and cosmetically 
very acceptable. However, misuse of corticosteroids can lead to skin atrophy and very rare 
to suppression of the pituitary-adrenal axis due to systemic absorption. Topical steroids 
act via binding to a cytoplasmatic glucocorticoid receptor, which subsequently binds to a 
glucocorticoid responsive element on the DNA, which can stimulate or inhibit transcription 
of genes involved in the inflammatory process.[80] 
Dithranol, also known as anthralin, has different anti-proliferative and anti­
inflammatory targets (for review [81]). Different treatment regimens are used; beside the 
long application times (12-24 h) with pastes in increasing concentrations, a short-contact 
therapy with dithranol in a different base, which easily can be washed off, is available. 
This therapy is more convenient for the patient and can be used in an out-patient setting. 
Side effects of dithranol are irritation of the skin, which can occur after more than 24 
hours,[82] and a brownish staining of the skin and clothes. 
Calcipotriol is a vitamin D3 analogue with equal affinity for the vitamin D receptor, 
but less potent than 1,25-dihydroxyvitamin D3 in producing hypercalcaemia. The 
antipsoriatic effect of calcipotriol ointment 50 pg/g is comparable with a medium strength 
corticosteroid.[83] Skin irritation is the only important local side effect, occurring in 15% 
of the patients.[83] A dose below 100 g/week is supposed to have no effect on calcium 
metabolism.[84] 
3.2 Photo(chemo)therapy 
Phototherapy with ultraviolet В (wave length of 290-320 nm) or photochemotherapy 
with psoralens combined with UVA (320-400 nm) are options for psoriasis patients, who 
are responding insufficiently on topical treatment, prior to systemic therapy. The most 
common side effects are acute phototoxic reaction and pruritis. Long-term side effects 
comprise an increased risk of photodamage of the skin and skin cancer related to the 
cumulative exposure to radiation. 
3.3 Systemic therapies 
Systemic treatments are indicated in patients with psoriasis resistant to local 
therapy or photo(chemo)therapy. Especially in cases where psoriasis takes a particularly 
severe course, for example in erythrodermic psoriasis or in the generalized pustular 
psoriasis, systemic treatment is inevitable. In general, systemic therapies are very 
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effective, but side effects are common and might be serious. Therefore, a proper patient 
selection and intensive monitoring are necessary to achieve a good clinical response with 
as few side effects as possible. 
3.3.1 Corticosteroids 
Systemic corticosteroids are rarely used in the treatment of psoriasis. In the 
treatment of chronic plaque psoriasis there is no place for treatment with systemic steroids 
because of the risk of precipitating a pustular form of psoriasis. Very occasionally the use 
of systemic corticosteroids is justified in generalized pustular or erythroderma psoriasis, in 
patients who are unresponsive to other treatments. Furthermore, in impetigo herpetiformis 
systemic corticosteroids are used because of the extreme debility of the patient and 
because the teratogenicity of other therapies.[60] In an early evaluation of 104 patients 
with pustular psoriasis has been found that the high incidence of side effects limit the 
value of systemic corticosteroids, despite the control of the pustular phase.[85] Systemic 
steroids should be withdrawn slowly to minimize the risk of rebound flaring. 
3.3.2 Methotrexate 
Methotrexate (MTX) is an established and highly effective systemic drug for the 
treatment of severe psoriasis, including the pustular and erythrodermic forms. The long-
term side effects of MTX are well known, in contrast to other relatively new systemic 
treatments like cyclosporin A and retinoids. Low dose MTX therapy is a relatively safe 
therapy, provided that a careful patient selection and regular monitoring for side effects 
and drug interactions during MTX therapy is carried out. The most frequent side effects 
occurring during MTX therapy are abnormal liver function tests, nausea and gastric 
complaints. The most feared side effects are myelosuppressïon and hepatotoxicity. Because 
hepatotoxicity is related to a high cumulative dose of MTX, rotational therapy or an 
intermittent instead of a continuous treatment schedule are advised. Performing liver 
biopsies, according to the international guidelines, remains the gold standard for detection 
of liver damage, until equally reliable non-invasive screening methods for liver damage like 
dynamic hepatic scintigraphy or measurement of serum levels of PIIINP are well evaluated. 
A review of the risks and benefits of MTX is provided in chapter 2 of this thesis. 
3.3.3 Retinoids 
Oral retinoids are synthetic derivatives of vitamin A. For the treatment of psoriasis 
etretinate and nowadays acitretin, which are both monoaromatic second generation 
retinoids, are frequently used. Acitretin is the active metabolite of etretinate, and is the 
retinoid of choice in the Netherlands. Oral retinoids are most effective in treating pustular 
and erythrodermic psoriasis, and somewhat less effective in treating chronic plaque 
psoriasis.[86] Acitretin and etretinate are equally effective in the treatment of long-standing 
psoriasis.[87] Also the relapse rate after discontinuation of treatment was similar for both 
treatments, with 50% of patients experiencing relapse within 6 months.[88] In general, 
etretinate monotherapy appears to induce complete remission in about 30-50% of patients 
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with moderate to severe chronic plaque psoriasis within 4-8 weeks.[86] Response rates for 
patients with pustular psoriasis are much higher than for chronic plaque psoriasis and 
retinoids are the first drug of choice in this form of disease. Response to etretinate is 
dramatic and rapid, occurring within 2-10 days of initiating treatment.[89,90] Etretinate is 
also effective in treating erythroderrrn'c psoriasis.[91] Retinoids may be used alone, but 
frequently retinoids are combined with other anti-psoriatic treatments, like PUVA (RePUVA), 
corticosteroids and calcipotriol.[86,92] 
In addition to profound effects on proliferation, keratinization and differentiation of 
epidermal cells, retinoids have significant immunomodulatory effects. Retinoids interfere 
with the arachidonic acid pathway, suppressing the production of neutrophilic 
chemoattractants.[93] Retinoids may, therefore, act to reduce the migration of inflammatory 
cells into the psoriatic lesion. The exact mechanism of retinoid-induced phenomena needs to 
be elucidated. Retinoids are assumed to enter the cells by non-receptor mediated processes. 
The cellular retinoic acid binding protein (CRABP) and the cellular retinol binding protein 
(CRBP) were proposed to serve as specific transport proteins of retinoic acid or retinol to the 
nucleus.[94] However, probably other binding proteins distinct from CRBP and CRABP are 
present, because etretinate did not bind to these receptors, although i t exhibited all the 
typical retinoid effects. Intracellularly, retinoids interact with nuclear receptors, the retinoic 
acid receptor and the retinoid X receptor, both member of the steroid-thyroid hormone 
superfamily. These induce expression of genes which bear specific DNA sequences recognizing 
the retinoid/receptor complex. Acitretin, however, does not bind to but activates the retinoic 
acid receptor.[95] The described pathways have been well investigated for ail-trans retinoic 
acid but they may not be valid for all retinoids. 
Acitretin has a characteristical spectrum of side effects, similar to chronic 
hypervitaminosis A syndrome (for review [96]). The frequency of retinoid-induced cheilits is 
nearly 100%, and is therefore regarded as a marker of sufficient absorption. Besides cheilitis, 
other mucocutaneous effects are xerosis, conjunctivitis, skin fragility and/or stickiness, 
retinoid dermatits, alopecia, and palmoplantar desquamation. Nearly all these symptoms are 
dose-dependent in incidence and severity and fully reversible on reducing the daily dose or 
withdrawal of the drug. Other adverse effects include elevation of serum triglycerides and 
liver enzymes. Furthermore, hyperostosis and extraskeletal calcifications have been reported 
after long term retinoid treatment. However, the data in the literature on this subject are 
conflicting.[97] Retinoids are highly teratogenic, and therefore retinoids are strictly 
contraindicated in pregnancy. Because of these adverse effects, several contra-indications for 
retinoid treatment should be considered and careful clinical monitoring during therapy is 
necessary (for guidelines [98]). 
New retinoids with a more specific activity and minimal adverse effects are the subject 
of ongoing research. Recently, two new third generation retinoids, which are classified as 
arotinoids because of the two aromatic rings, have been developed for topical use: 
adapalene[99] (effective in acne) and tazarotene[100] (effective in psoriasis). The imidazol 
derivative liarozole, an inhibitor of cytochrome P450, causes (via inhibition of 4-hydroxylation 
of retinoic acid) an increased concentration of retinoic acid in the cell.[101] Clinical 
investigation with a dosage between 75-150 mg twice daily showed considerable 
improvement in patients with chronic plaque psoriasis.[102] The cell-biological effects of 
liarozole will be described in chapter б of this thesis. 
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3.3.4 Cyclosporin A 
Although the pathogenesis of psoriasis is controversial, i t is generally accepted that 
Τ lymphocytes play an important role in psoriasis.[42] Activated Τ cells, as indicated by 
their expression of the interleukin-2 receptor, are abundantly present in the lesionai skin 
of psoriatic patients.[103] During the last decade, much research has been focused on the 
development of Τ cell specific immuno-modulating agents for the treatment of psoriasis. 
Cyclosporin A, an immunosuppressive agent used primarily for organ transplantation, has 
been studied extensively for the treatment of severe psoriasis. I t is recommended to start 
with an initial daily dose of 3 mg/kg, in 2 divided doses, and to increase to a maximum of 
5 mg/kg/day, with subsequent tapering to the minimum effective dose. Several studies 
show a dose-response relationship with regard to both the number of patients who respond 
and the time to response (for review [104]). In a multicentre prospective study 251 
patients with severe plaque psoriasis were treated with cyclosporin A in a dosage of 2.5 or 
5 mg/kg/day, which resulted in a succesful treatment is respectively 52 and 92% of the 
patients.[105] Besides in plaque psoriasis, cyclosporin A is effective in the treatment of 
erythrodermic psoriasis[106] and in pustular forms of psoriasis. In generalized pustular 
forms of psoriasis high dosages up to 12 mg/kg/day may be required.[107] In pustulosis 
palmoplantaris succesful treatment was achieved with low dose cyclosporin A (1,25 
mg/kg/day) in 50% of the patients.[108]. After discontinuation of treatment, relapse 
occurred within 2 months, varying between 2 weeks and 4 months.[109] 
Cyclosporin A engages the active site of cycLophilin, a family of isomerases found in 
almost all mammalian cells. This complex inhibits the enzyme calcineurin, which is a key 
enzyme in calcium dependent signalling processes. Calcineurin is essential for signal 
transduction from the T-cell receptor to the cytokine promoters, triggering the 
transcription of many cytokines, including the T-cell growth factors IL-2 and IL-4 (for 
review[104]). 
The side effects which may occur during treatment with cyclosporin A include renal 
side effects, hypertension, an increased incidence of tumors, gastrointestinal problems, 
hypertrichosis, gingival hyperplasia, paresthesia, headache, vertigo, muscle cramps and 
tremor. The renal effects of cyclosporin A comprise functional and structural changes 
involving.tubules and blood vessels. Detailed analysis showed that patients with a 
creatinine increase t i l l 30% had no nephropathy.[110] To minimize the incidence of side 
effects a careful patient selection and careful monitoring is indicated. The exclusion 
criteria for cyclosporin A treatment and guidelines for monitoring are reviewed by de Rie 
and Bos.[104] 
In the group of cyclic immunosuppressants are, besides cyclosporin, other agents 
subject of study at the moment, which belong to the group of macrolides. Tacrolimus 
(FK506) proved to be effective in psoriasisfll l] and probably can be used topically as the 
molecular weight is lower than that of cyclosporin. Furthermore, ascomycin and sirolimus 
are macrolides which might be promising topical therapies in the treatment of psoriasis. 
3.3.5 Other systemic therapies 
Azathioprine and hydroxyurea have been reported to be effective in psoriasis and can 
be an alternative, if more conventional treatments do not succeed because of lack of 
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effectivity or side effects.[112,113] Also sulfasalazine is effective in psoriasis with only 
minor side effects.[114] For patients with common systemic disorders such as 
hyperlipaedemia, mild renal insufficiency or hepatic impairment, who may not be 
candidates for other systemic treatments may be potential candidates for this therapy. 
Fumarie acid derivatives are prescribed in the treatment of severe psoriasis for 30 years, 
although these are not registered for the treatment of psoriasis. In 83 patients with severe 
psoriasis treated with fumarie acid, a mean reduction in PASI of 76% was achieved. In 62% 
of the patients side effects were seen, most frequently flushing and gastro-intestinal 
complaints.[115,116] 
THE POLYMORPHONUCLEAR LEUKOCYTE IN CUTANEOUS INFLAMMATION 
4.1 General aspects of the PMN 
The immune system protects higher animals from microbial infections by infectious 
agents and comprises both cellular and molecular components. The cells of the immune 
system include the phagocytes (polymorphonuclear leukocytes and macrophages) and the 
lymphocytes (primarily Τ and В cells). These cells function in close collaboration with the 
molecular components, which include complement, acute-phase proteins, antibodies and 
cytokines. The cell types classified as polymorphonuclear leukocytes include neutrophils, 
basophils and eosinophils, which can be recognized by the staining properties of their 
cytoplasmic contents. In this thesis we will focus on the neutrophilic polymorphonuclear 
leukocytes, to which we will refer as PMN. 
PMN are the first line of defence of the body against bacterial and fungal infections. 
The sequence of events in activation of PMN are in short as follows: chemotactic factors, 
which may be derived from bacteria, from damaged host cells, from complement activation 
or due to cytokine production by tissues or immune cells, are generated at the site of 
infection. These chemoattractants are "sensed" via plasma membrane receptors on the PMN 
and they also affect the function of endothelial cells that secrete factors that signal to the 
circulating neutrophils. The PMN roll onto and attach to the endothelial cells 
(margination) and leave the circulation by diapedesis. The initial attachment of leukocytes 
to venular endothelial cells before their firm adhesion and diapedesis is mediated by the 
selectin family of adhesion molecules (for review [117]). Subsequently, integrins such as 
CDllb/CD18 and immunoglobulin superfamily members such as ICAM-1 interact to arrest 
leukocyte rolling and mediate firm adhesion between leukocytes and vascular endothelium, 
with subsequent diapedesis between endothelial cells. They migrate up the 
chemoattractant gradient and will reach the site of inflammation. Potent chemoattractants 
are N-formylated peptides such as f-Met-Leu-Phe, which is of bacterial origin and LTB4, 
which is generated via the activities of lipoxygenases on arachidonic acid (for review 
[118]). Arachidonic acid is generated via the activity of phospholipase A2 on membrane 
phospholipids. Furthermore, complement fragment C5a, which is generated either by the 
classical or alternative pathways of complement activation, is chemotactic for neutrophils 
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and monocytes. C5a is cleaved by an anaphylatoxin inactivator which is present in serum, 
generating C5a des Arg. Other effective chemoattractantia include platelet activating 
factor (PAF), histamine, and a large number of cytokines, especially interleukin-8. Beside a 
chemotactic effect, all mentioned activators have other effects on PMN activity. Binding of 
the chemoattractans to specific plasma membrane receptors on the PMN results in an 
altered transmembrane potential, ion fluxes and activation of metabolic processes.[119] 
4.1.1 The respiratory burst 
PMN can destroy pathogens by proteolytic enzymes and by the formation of oxygen 
metabolites. The respiratory burst of phagocytes is catalysed by a membrane-bound NADPH 
oxidase that is responsible for the formation of superoxide (02-). This enzyme is composed 
of different components located on the plasma membrane, in the cytosol and on the 
membranes of specific granules. NADPH is the substrate for the oxidase, and accepts 
electrons from NADPH to reduce 02 to 02-. Two molecules of 02- then interact 
spontaneously (dismutation reaction) to generate 1 molecule of hydrogen peroxide (H202) 
Furthermore, i t is assumed that PMN can generate a more powerful oxidant, OH- (hydroxyl 
radical), however this has never been shown directly.[120] Myeloperoxidase, which is 
located in the cytoplasmic granules, can utilise H202 to generate hypochlorous acid (HOCl), 
the most potent neutrophil oxidant. At neutral pH, 106 maximally triggered neutrophils 
produced approximately 2x107 mol of HOCl during a two-hour incubation,[121] which is 
enough to destroy 150 million E coli organisms.[122] 
4.1.2 PMN-derived proteinases 
Besides the formation of oxygen metabolites, the cytoplasmic granules, containing a 
range of proteins with cytotoxic properties, have an important function in pathogen 
killing. Neutrophil granules contain a large family of over 20 enzymes,[123] which are able 
to attack key components of the extracellular matrix, which is composed of a complex mix 
of collagens, elastin, proteoglycans and glycoproteins. The 3 proteolytic enzymes with the 
greatest potential to act as mediators of tissue destruction are elastase, and the two 
metalloproteinases collagenase and gelatinase.[124] Human leukocyte elastase (HLE) 
belongs to the serine proteinases, that is a group of closely related enzymes, with a serine 
residue in position 195 of the enzyme's primary sequence.[125] Serine proteinases are 
responsible for triggering the inflammatory cascades of the plasma such as coagulation, 
kinin release, fibrinolysis and complement activation.[126] HLE has several isoenzyme 
forms that differ in the levels of glycosylation. HLE is active at neutral pH and is stored in 
the azurophilic granules of PMN in amounts ranging up to 3 picogram per cell.[125] 
Monocytes contain small amounts of a serine proteinase, closely resembling HLE, both in 
physical-chemical properties and antigenic behaviour.[127] The substrate of HLE includes 
normal skin constituents such as keratin,[128] elastin[129] and different types of 
collagen.[130-132] Proteinase 3 is a human neutrophil derived serine proteinase, with a 
substrate specificity similar to that of HLE. I t is the target antigen of anti-neutrophil 
cytoplasm auto-antibodies associated with Wegener's granulomatosis.[133] 
There are only a few reports indicating that HLE is microbicidal, but i t is clear that i t 
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can enhance the activity of other neutrophil antimicrobial proteins, for example elastase 
potentiates the lytic effects of lysozyme and cathepsin G in vitro.[134] Furthermore, HLE is 
probably functional in the degradation of cell walls of killed bacteria, thereby exposing 
target sites for attack by other neutrophil antimicrobial systems. One of the putative 
functions of HLE is to facilitate migration of PMN through connective tissue and basal 
membranes towards inflammatory foci. Briggaman et al. showed that incubation of split-
thickness skin with HLE in the range of 10-700 nM damaged the lamina densa. The 
anchoring fibrils were scattered and disorganised, with normal appearing collagen fibres. 
Immunohistochemically, type IV collagen and laminin were absent. Cathepsin G degraded 
the lamina lucida, however less damage was found compared to HLE.[135] Both normal 
and chronic granulomatous disease neutrophils, the latter being unable to mount a 
respiratory burst during phagocytosis, were able to degrade the subendothelial matrix 
secreted by human endothelial cells via an elastase-dependent process.[136] Whether 
activation of pro-gelatinase B, a metallo-proteinase which is mainly activated by HLE, is 
the major contribution of HLE in PMN-migration across the basement membrane, as 
suggested by Delclaux et al., is undear.[137] 
REGULATION OF INFLAMMATORY PROCESSES; PROTEINASE INHIBITORS 
5.1 Proteinase inhibitors 
PMN are the first line of defence of the body against bacterial and fungal infections; 
they are the first cells to be recruited to a site of infection, and contain different 
cytotoxic mechanisms that are capable of killing a range of microbial pathogens, including 
proteinases and the generation of reactive oxygen metabolites. Although the primary 
function of PMN is host protection against infection, the response of PMN can also be 
targeted against host tissues. PMN are known to cause tissue damage in many diseases: 
arthritis,[138,139] glomerulonephritis,[140] emphysema,[141] adult respiratory distress 
syndrome[142] and bullous dermatoses.[143] In order to control proteolysis by these 
enzymes, three principal mechanisms are available to prevent unwanted proteolytic tissue 
damage: The proteinases in PMN are "packaged" within granules. Furthermore, enzymes 
may be secreted in a latent form, that requires activation to degrade proteins, as is the 
case for metalloproteinases and most of the serine proteinases. The last precaution to 
prevent proteolytic tissue damage is the presence of proteinase inhibitors, which form an 
inactive complex with their target proteinase. Proteinase inhibitors are present either 
systemically, such as оц-proteinase inhibitor (α Γ ΡΙ) , also known as ^-antitrypsin, or a2-
macroglobulin. Welt-known is the systemic reaction to injury and inflammation, the acute-
phase response, which includes the upregulation of a number of proteinase inhibitors that 
are consumed during inflammation. The enhanced synthesis of proteinase inhibitors is 
interpreted as a feed-back mechanism to regulate excessive proteolysis by PMN-derived 
proteinases. One group of closely related serine proteinase inhibitors are the serpins, 
which share a common molecular structure and mechanism. The inhibitor present at the 
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highest concentration in human plasma is сц-РІ, which is extensively studied because of 
the relation with the development of premature emphysema.[141] The serpins have as 
major feature an exposed loop containing the reactive centre, for which the specificity is 
substantially dependent on a single amino acid at its reactive centre. The exposed loop is 
susceptible to proteolytic cleavage, providing irreversible inactivation of the serpins. For 
ctj-PI the reactive centre is formed by the amino acid methionine, which is susceptible 
for oxidation (for review [126]). 
Locally synthesized proteinase inhibitors, regulating the inflammatory response at 
the level of the injured tissue, include secretory leukocyte proteinase inhibitor (SLPI), 
also known as antileukoproteinase (ALP),[144] and skin-derived antileukoproteinase 
(SKALP). Before focusing on the role of locally produced proteinase inhibitors in 
inflammatory skin diseases, the synergism between HLE and PMN oxidizing systems is 
discussed. 
5.1.1 Inactivation of the anti-proteinase shield 
The presence of powerful antiproteinases like a^PI and ct2-macroglobulin in plasma 
and interstitial fluids prevents HLE from attacking extracellular substrates. Calculated is 
that in vivo the half-life of active elastase is only about 0.6 msec, indicating a very 
effective anti-elastase shield.[145] It might be reasonable to assume that HLE would not 
have the opportunity to mediate extracellular tissue damage. However, as pointed out 
before, several studies indicate that PMN are able to use their discharged elastase to 
attack and destroy host tissues. 
In 1984 structural and functional analyses of c^-PI revealed a critical methionine 
in its reactive centre, which is sensitive to oxidation by triggered human neutrophils. 
Oxidation caused a 2000-fold decrease in the rate of association between HLE and the 
oxidised antiproteinase,[124] thereby increasing the half-Life from 0.6 msec to 1.2 sec. 
Also cx2-macroglobulin and SLPI are sensitive to oxidative inactivation.[124,146] The 
concept for elastase-mediated damage in an anti-elastase environment as formed by 
Weiss[124] is as follows: an oxidising microenvironment is generated by HOCl produced 
by the PMN, resulting in inactivation of αα-ΡΙ. In this way PMN can penetrate an 
antiproteinase barrier, allowing released elastase to attack the surrounding tissue. 
5.2 Proteinase inhibitors in the skin; skin-derived antileukoproteinase 
In a study of Wiedow et al. the presence of HLE activity at the skin surface in 
lesionai psoriatic skin was greatly increased compared with uninvolved skin of the same 
patients and skin of healthy controls. Since PMN contain HLE in large amounts and can be 
considered as the major cell population containing HLE, i t appears likely that skin surface 
HLE reflects the neutrophil infiltration of lesionai skin.[147] Considering this, detailed 
knowledge about inhibitors present in the skin is of particular interest. The serum-derived 
proteinase inhibitor a2-macroglobulin could be shown in the papillary dermis using 
immunohistochemical techniques.[148] Also a^PI, which is the main HLE inhibitor of 
human serum, has been demonstrated in the human horny layers of the skin.[149] 
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Figure 6 Schematic representation of 
the organisation of the SKALP gene and 
the resulting mRNA (a) hydrophobic 
signa! sequence encoding region (22 
ammo acids), (b) transglutaminase sub-
strate domain encoding legion (45 
amino acids), (c) proteinase inhibiting 
domain encoding region (50 amino 
acids) (adapted from Molhuizen et al, 
Biol chem Hoppe-Seyler. 1995,3762) 
In a previous study the presence of elastase inhibiting activity was observed in scaling 
skin disorders, characterized by a mixed infíltrate of PMN and mononuclear cells, whereas 
normal skin was negative.[150] Especially in scales of psoriasis, but also in scales of 
patients with Netherton syndrome and erythrodermic autosomal recessive lamellar 
ichthyosis, a pronounced anti-elastase activity was found. The inhibiting activity was 
caused by a low-molecular weight, acid-stable inhibitor, which was further characterized. 
Psoriatic scales were used as a source to purify the inhibitor for characterization 
experiments. The elastase-inhibiting activity could be contributed to an 18 kDa molecule, 
which revealed a 40% homology with the C-terminal half of antileukoproteinase 
(comprising the reactive site), a serine proteinase inhibitor present in mucous secretions. 
The molecule was therefore named skin-derived antileukoproteinase or SKALP.[151] In this 
thesis we will focus on the proteinase inhibitor SKALP. In the next sections the 
biochemical, structural and cell biological aspects of SKALP will be described. Furthermore, 
we will speculate about the function of SKALP in skin diseases. 
5.2.1 Biochemical properties of SKALP 
SKALP, also known as elafin[152] or ESI[153], is a very cationic molecule, which is 
present in an intact form with a calculated molecular weight of approximately 9.9 kDa (the 
main form in cultured keratinocytes), whereas the degraded form of 6 kDa was the 
predominant form in psoriatic scales.[151] These molecular weights differ from the 
previous apparent molecular mass found on SDS-PAGE of 18 kDa and 11 kDa, respectively. 
The strong cationic nature of SKALP probably explains the significant deviation of the 
apparent molecular mass found on SDS-PAGE from the calculated molecular mass, since 
strongly cationic proteins migrate much slower on SDS-PAGE. Extraction and purification of 
SKALP involved boiling of homogenates of psoriatic scales and the use of buffers ranging 
from pH 3.0 to 11.0, indicating that SKALP is a very heat stable and pH stable 
molecule.[151,152] SKALP inhibits human leukocyte elastase with high affinity 
(dissociation constant (Ki)<1010), but also porcine pancreatic elastase and proteinase 3, 
an elastin-degrading proteinase also derived from neutrophils.[154] No activity against 
human cathepsin G, plasmin, trypsin or ct-chymotrypsin could be demonstrated.[155] A 
single SKALP molecule binds to a single site on the HLE molecule, blocking the reactive 
serine at the enzyme's catalytic centre. Dissociation of the enzyme-inhibitor complex 
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5.2.2 Structural aspects of SKALP 
SKALP was purified from cultured human keratinocytes, followed by aminoterminal 
sequencing.[157] SKALP is synthesised as a precursor molecule, consisting of 117 amino 
acids including a hydrophobic signal peptide of 22 amino acids. The presence of this 
hydrophobic signal peptide suggests that translation of SKALP takes place at the rough 
endoplasmic reticulum. Cleavage of this signal peptide results in a mature protein of 95 
amino acids with a calculated molecular mass of 9.9 kDa. The carboxyterminal part of 
SKALP shows 40% homology with the carboxyterminal part of ALP; 100% identity was 
found with б amino acids in the carboxyterminal part of ALP, which sequence is part of the 
active site of ALP. Based on the homology between parts of SKALP and ALP we denoted the 
carboxyterminal part of the mature SKALP molecule as being the proteinase inhibiting 
domain.[157] The aminoterminal part of the SKALP protein isolated from cultured human 
keratinocytes contains four repeats which match with a consensus sequence for 
transglutaminase cross-linking. The aminoterminal part can act as a substrate domain for 
epidermal transglutaminase.[157] It was shown by direct sequencing of cross-linked 
peptides from human foreskin epidermis that SKALP is cross-linked in vivo to loricrin and 
cytokeratin 1,[158] which are structural proteins of the terminally differentiating 
keratinocyte. The cross-linked SKALP is proteolytically processed further by unidentified 
proteinases to yield low molecular weight carboxy-terminal fragments containing the 
antiproteinase activity, as shown by amino-terminal sequencing of purified SKALP from 
epidermal scale extracts.[157,159] 
The SKALP gene was isolated independently by several groups.[160-162] The SKALP 
gene is approximately 1.7 kbp long and contains 3 exons and 2 introns (Fig. 6). The first 
exon contains the 5'-noncoding region and the first 79 nucleotides of the coding sequence, 
encoding the hydrophobic signal sequence as well as the first 4 amino acids of the mature 
protein. The second exon encodes the rest of the protein and the first nucleotide of the 3'-
noncoding region. The rest of the З'-noncoding region, including the polyadenylation 
signal, is completely encoded by the third exon. We were able to locate the SKALP gene at 
human chromosome 20, region ql2 • ql3.[162] Recently, we described the Trappin-gene 
family, of which SKALP is a member.[163] 
In a recent study multiple transcription start sites were found 13 to 24 basepairs 5' 
of the translation startsite of the SKALP gene, with a preference for the positions -16, -17, 
and -18.[164] 
5.2.3 Cell biological aspects of SKALP 
Immunohistochemical studies have demonstrated the localization of SKALP in 
different normal human tissues. SKALP appeared, in general, to be present in stratified 
squamous epithelia like tongue, gingiva, epiglottis, pharynx, oesophagus, cervix, vagina 
and hair follicle, whereas pseudostratified epithelia and simple/glandular epithelia are 
negative.[165] Normal epidermis' and skin adnexae are negative, except for the 
keratinocytes lining the epidermal part of the sweat gland ducts and the infundibular part 
of the hair follicle. The histological findings were largely confirmed by Northern blot 
analysis. In situ hybridisation as performed by Nonomura et al. demonstrated mRNA 
expression in the granular layer of both normal and non-lesional epidermis.[166] However, 
we could not confirm these data. With in situ hybridisation we found no mRNA expression 
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in normal epidermis,[165] which parallels the immunohistochemical data. The focal SKALP 
expression observed by Nonomura et αι. may be expression in the epidermis near hair 
follicles and acrosyringia. Fetal tissues and neonatal tissues were stained for SKALP. SKALP 
is expressed in the third trimester and downregulated in neonatal skin.[165] In the 
epithelium of tongue and tonsils, SKALP expression continued to be present after birth. 
Using tape-stripping as a model for standardised epidermal injury, SKALP expression could 
be induced in normal human epidermis, with a peak in SKALP activity after 48 h.[159] 
Abo SKALP expression in pathological conditions has been extensively studied. Using 
immunohistochemistry, a strong cytoplasmic staining in the upper layers of the suprabasal 
compartment of psoriatic epidermis was found, whereas the uninvolved skin was negative. 
The basal cell layer was negative.[167] SKALP is associated with the cornified envelope, 
which might be explained by the fact that the aminoterminal part of the mature SKALP 
protein contains 4 repeats which show significant homology with a consensus sequence for 
transglutaminase cross-linking. In situ hybridisation revealed expression of mRNA in the 
suprabasal layers in a psoriatic lesion. Intense staining was seen near the subcorneal 
microabscess in psoriasis vulgaris and under the subcorneal pustule in Localized pustular 
psoriasis.[166] In several types of epidermal tumors SKALP expression could be shown. In 
well-differentiated squamous cell carcinoma SKALP expression is high, whereas in poorly 
differentiated squamous cell carcinomas and in basal cell carcinomas SKALP expression is 
absent.[168,169] In excisional wounds SKALP was induced within 48 h and was expressed 
in the suprabasal keratinocytes of the wound edge and the migrating epidermal sheet. In 
venous ulcers, SKALP was strongly expressed in the keratinocytes of the wound edge in all 
types of ulcers (venous or mixed venous/arteriolar), whereas the wound bed was negative 
for SKALP.[170] 
5.2.4. Regulation of SKALP expression 
As mentioned before, SKALP is an inducible molecule in human epidermis, either by 
spontaneous inflammation (psoriasis) or induced trauma/inflammation. Because the target 
enzyme of SKALP is HLE, one would expect that expression of SKALP can be induced by the 
presence of PMN. This is in line with the hypothesis, that SKALP is a local acute phase 
reactant which acts as a negative feedback on inflammation by interfering with PMN 
migration and preventing elastase dependent tissue damage. As we demonstrated before, 
SKALP appeared, in general, to be present in stratified squamous epithelia. The tissues 
that are positively stained are in direct contact with the environment subjected to a 
constant load of inflammatory stimuli. Low-grade PMN infiltration in some of these tissues 
is almost physiological. 
Different in vivo studies are performed to study the time-dependent relationship 
between SKALP and PMN. Kinetic studies after standardised injury suggest that SKALP 
expression follows the influx of PMN.[171] In excisional wounds a PMN influx was seen 
rapidly after wounding and was maximal between day 2 and day 4, then subsided. SKALP 
was induced within 48 h and was maximally expressed on day 4 and was downregulated at 
the time of complete reepithelialization (7-14 days).[170] A functional assay was used to 
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measure the distribution of SKALP activity in the spreading psoriatic lesion. SKALP activity 
was found to be maximal in the centre of the lesion and decreased towards the marginal 
zone.[172] PMN are rather modest present in the central zone of a psoriatic lesion, while 
the peripheral rim contains a relatively high number of PMN.[173] 
In vitro culture systems were developed in which the normal differentiation program 
and the psoriatic differentiation program could be induced.[174] By switching confluent 
keratinocyte cultures grown in keratinocyte growth medium (KGM) to KGM depleted of 
growth factors a normal differentiation phenotype (low proliferative rate; high expression 
levels of cytokeratin (CK) 1 and CK 10; moderate expression of involucrin and 
transglutaminase; low expression levels of SKALP and CK 16) was induced. By switching to 
KGM supplemented with fetal calf serum the psoriatic phenotype (sustained 
hyperproliferation; high levels of CK 16, transglutaminase and involucrin) with high levels 
of SKALP expression was induced, in the absence of inflammatory cells or stimuli.[159]. In 
psoriasis both the keratinocytes and the infiltrating inflammatory cells produce a large 
number of immune-and growth-modulatory factors (for review [175]). In a recent study the 
induction of SKALP gene expression by different cytokines and growth factors was studied, 
using the described culture models.[164] Tumor necrosis factor α was shown to be the 
most potent inducer of SKALP gene expression, whereas interferon-γ and transforming 
growth factor α showed a milder induction of SKALP gene expression. Further experiments 
showed that induction of SKALP expression by TNF-a was preceded by activation of the 
mitogen activated protein (MAP) kinase family member c-jun N-terminal kinase 1 (JNK-1). 
5.2.5. Clinical aspects of SKALP 
In view of its physico-chemical properties, SKALP will easily cross the basal lamina, 
penetrate the connective tissue, and reach the circulation. Because small cationic proteins 
are readily excreted in the urine, we investigated whether SKALP could be found in urine 
from psoriatic patients. Anti-elastase activity could be measured in urine of psoriatic 
patients and healthy controls using a functional assay. With SDS-PAGE and western blot 
analysis the anti-elastase activity could be contributed to SKALP. A correlation of SKALP in 
urine with the severity of the disease could be demonstrated. The most severe cases of 
psoriasis (erythroderma and pustular psoriasis) showed the highest urinary SKALP 
levels.[176] Furthermore, a sensitive competitive-type ELISA was developed for 
measurement of SKALP concentrations in serum and in urine of psoriatic patients with 
extensive psoriasis, who were treated with cyclosporin A during 16 weeks.[177] Serum 
levels of SKALP correlated well with the clinical course of psoriasis as calculated with the 
PASI score. It was concluded that SKALP measurement in serum of patients with severe 
psoriasis provides a tool for monitoring disease activity. 
5.2.6 The epidermal presence of secretory leukocyte proteinase inhibitor 
Besides SKALP another locally produced proteinase-inhibitor is highly expressed in 
psoriatic epidermis, secretory leukocyte proteinase inhibitor (SLPI), also known as 
antileukoproteinase (ALP).[144,178] We recently showed that epidermal keratinocytes can 
produce SLPI. Furthermore, SLPI is produced by mucosal surfaces and therefore found in 
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body fluids such as bronchial mucus[179] and parotid secretions.[180] SLPI inhibits HLE 
and cathepsin G, thereby overlapping and complementing the inhibitory spectrum of 
SKALP. In contrast to SKALP, SLPI does not inhibit pancreatic elastase.[181] From SLPI is 
known that i t can be inactivated by oxidation.[146] ImmunohistochemicaL staining of 
normal skin and non-lesional skin showed a weak staining of the stratum granulosum. 
Psoriatic skin revealed a strong staining of the suprabasal compartment and in the 
reticular dermis a marked staining of the elastic fibres was seen.[178] In contrast to 
SKALP, which contains multiple transglutaminase substrate motifs that enable crosslinking 
to stratum corneum proteins like loricrin, SLPI is found in the dermal compartment, 
protecting the elastic fibres against PMN-dependent proteolysis. 
In the pulmonary antiproteinase defense system α Γ Ρ Ι plays an important role. 
Wellknown is the link between hereditary cq-PI deficiency and the development of 
emphysema, supporting the concept that a proteinase-antiproteinase imbalance causes 
emphysema.[141] The contribution of the low molecular-weight inhibitors SKALP and SLPI 
to the proteinase defence mechanism of the lung was 22%, which could be contributed for 
87% to SLPI.[181] No data are available of the exact contribution of SKALP and SLPI to 
the proteinase defence mechanism in the skin. 
5.3 The function of SKALP in cutaneous inflammation; the proteinase-
antiproteinase balance 
The acute-phase response is a systemic reaction to injury and inflammation, which 
includes the enhanced synthesis by the liver of a number of proteinase inhibitors that are 
consumed during inflammation (such as сц-РІ, α-1-antichymotrypsin). The enhanced 
synthesis of proteinase inhibitors is interpreted as a feed-back mechanism to regulate 
excessive proteolysis by PMN-derived proteinases such as elastase, proteinase-3 and 
cathepsin 6. The acute phase response can be regarded as a systemic reaction to injury. 
During skin injury, either by non-specific mechanisms such as trauma, or by skin 
diseases such as psoriasis, keratinocyte derived mediators are released that contribute to 
the inflammatory response. Most of these mediators, including IL-1, IL-6, IL-8 and TNF-ct, 
promote the recruitment of inflammatory cells, the expression of adhesion molecules and 
the secretion of inflammatory mediators. Very few locally produced factors are known that 
downregulate the inflammatory response. The specificity of SKALP for the PMN-derived 
proteinases elastase and proteinase 3, and its constitutive expression in epithelia that are 
subjected to inflammatory stimuli[165] suggests a role for SKALP in the control of 
inflammation. We hypothesise that SKALP can be considered as a locally produced acute 
phase protein, which is absent in normal skin but can be induced after skin injury or 
inflammation. SKALP provides a gradient from the upper epidermal layers towards the 
dermis thereby interfering with proteolysis by PMN-derived proteinases and with PMN 
migration. When the acute inflammatory phase subsides, SKALP expression is rapidly 
downmodulated and homeostasis is restored. 
In an in vitro study we investigated whether SKALP expression could protect against 
elastase-dependent cell damage.[165] Human epidermal keratinocytes were cultured in 
KGM to form a confluent monolayer, with subsequently switching to KGM with fetal calf 
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serum, resulting in induction of SKALP expression. The keratinocytes were exposed to 
purified HLE and activated PMN. In both settings SKALP-expressing keratinocytes were 
fully protected against cell detachment, whereas control keratinocytes negative for SKALP 
synthesis and secretion, were fully detached from the tissue culture dish. This shows that 
expression of SKALP provides protection against elastase-mediated detachment in vitro. 
As outlined in a previous section, disturbance of the local proteinase-antiproteinase 
balance is associated with several diseases, including: arthritis[138,139], 
glomeruLonephritis[140], emphysema[141], adult respiratory distress syndrome[142] and 
bullous dermatoses[143]. In view of its specificity for leukocytic proteinases, i t was 
hypothesised that SKALP provides protection against excessive proteolysis of extracellular 
matrix components. In vitro, free elastase can be detected in fluids recovered from 
mixtures of neutrophils triggered in the presence of serum or epithelial lining fluid.[182]. 
Also in vivo, under conditions of excessive elastase secretion, when all available anti-
proteinases are consumed, one would expect free elastase activity. 
Pustular psoriasis is a manifestation with an extremely dense infiltrate of PMN. Since 
we assume that SKALP is in vivo involved in the regulation of elastase/proteinase-3 
activity during cutaneous inflammation, we hypothesized that in pustular psoriasis the 
protective capacity of epidermal SKALP was insufficient. We indeed found that the mean 
levels of epidermal SKALP in pustular psoriasis are decreased with 75% compared to plaque 
type psoriasis. In 30% of the pustular psoriasis patients an absolute deficiency for SKALP 
was found; in these patients free elastase activity was present. These results form the 
basis for part of this thesis and will be presented in chapter 7. 
In a previous section we described that HOCL, produced by PMN, is capable of 
oxidizing the anti-elastase shield, thereby inactivating the antiproteinases and allow the 
released HLE to attack surrounding tissue. Both the serum anti-proteinases сц-РІ and a2-
macroglobulin as the locally produced SLPI are susceptible for oxidation, resulting in an 
ineffective inhibition of HLE. Whether SKALP is susceptible for oxidation is not known. 
AIMSOFTHISTHESIS 
This thesis focuses on the severe forms of psoriasis, i.e. extensive forms of plaque 
psoriasis, insufficiently responding to topical therapy, the erythrodermic forms of psoriasis 
and the pustular forms of psoriasis. A common feature of these subtypes of psoriasis is the 
dominance of the inflammatory component. The pustular forms of psoriasis represent the 
most extreme form of inflammatory psoriasis. Furthermore, they have in common that 
insufficient improvement is achieved with topical treatment, and systemic treatment or a 
combination therapy is required as a rule. 
As outlined in the previous sections, we assume that SKALP, a locally produced 
proteinase inhibitor, acts as a negative feedback mechanism, controlling the inflammatory 
response. SKALP inhibits PMN-derived proteinases, thereby preventing elastase-mediated 
tissue damage and interfering with PMN-trafficking. We hypothesized that the protective 
capacity of SKALP in pustular forms of psoriasis might be insufficient. Furthermore, the 
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effect of anti-psoriatic treatment, either topical or systemical, on SKALP production has 
not been studied to date. So far we are not informed whether treatments of psoriasis 
exert their antipsoriatic effects through SKALP production. 
This thesis is divided into three parts, with the following aims: 
1. To study the efficacy and safety of systemic treatments, either as mono or 
combination therapy, in severe forms of psoriasis (Part I ) . 
2. To study the cell biological effects of topical and systemic treatments, focusing 
on the expression of SKALP as a marker of disease activity (Part I I) . 
3. To study the role of SKALP in the pathogenesis of pustular psoriasis (Part I I I ) . 
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THE EFFICACY AND SAFETY OF 
SYSTEMIC AND COMBINED 
TREATMENTS IN SEVERE FORMS OF 
PSORIASIS 
Introduction 
The currently used systemic antipsoriatic therapies comprise methotrexate, acitretin 
and cyclosporin A. Besides monotherapy the simultaneous use of two different treatments, 
systemic or topical, is a therapeutic option in the management of psoriasis. The major 
advantage of combination of treatments might be increased efficacy by combinations of 
treatment with a different mode of action and reducing side effects by reduction of the 
dosage. Especially in forms of psoriasis that are difficult to treat, the search for new, 
effective combinations is necessary. 
In chapter 2 the efficacy and side effect profile of long-term MTX treatment in the 
treatment of severe psoriasis is discussed. This chapter is based on 3 studies. In the first 
study a retrospective analysis of 113 patients with severe psoriasis, who have been treated 
with low-dose MTX, was performed. We recorded the side effects occurring during MTX 
therapy and the results of liver biopsies. The classification of the liver biopsies was related 
to cumulative dosage and duration of MTX therapy and liver function tests. In the second 
study the value of 2 novel non-invasive screening methods for MTX-induced liver damage 
were evaluated in a pilot study. These methods are serum measurement of aminoterminal 
propeptide of type I I I procollagen and dynamic hepatic scintigraphy. In the third study the 
value of interruption of long-term MTX treatment in psoriasis in diminishing the 
cumulative MTX dose has been evaluated. 
In chapter 3 three patients with erythrodermic psoriasis are described, who are 
treated with the combination of acitretin and cyclosporin A. Chapter 4 describes the 
combination of acitretin and calcipotriol in the treatment of a patient with acrodermatitis 
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Summary 
Methotrexate (MTX) is an established and highly effective systemic treatment of severe 
psoriasis, including the pustular and erythrodermic forms. It has been widely used during 
the last 3 decades. This is the reason that the long-term side effects of MTX are well known, 
in contrast to other relatively new systemic treatments like cyclosporin A and retinoids. The 
most frequent side effects occurring during MTX therapy are abnormal liver function tests, 
nausea and gastric complaints. The most feared side effects are myelosuppression and 
hepatotoxicity. Because hepatotoxicity is related to a high cumulative dose of MTX, 
rotational therapy or an intermittent instead of a continuous treatment schedule are 
advised. The histological assessment of liver biopsies, according to the international 
guidelines, remains the gold standard for detection of liverdamage until equally reliable non-
invasive screening methods for liver damage, tentatively dynamic hepatic scintigraphy or 
measurement of serum levels of PIIINP, are well evaluated. Low dose MTX therapy is a 
relatively safe therapy, provided that a careful patient selection and regular monitoring for 
side effects and drug interactions during MTX therapy is carried out. The long-term clinical 
efficacy and relative safety of MTX remain impressive. 
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Introduction 
MTX is an established and highly effective systemic drug for the treatment of severe 
psoriasis. I t is indicated in patients with psoriasis resistant to local therapy or 
photo(chemo)therapy.[l-3] 
The use of MTX in psoriasis has a long history. In 1951 Gubner noted a beneficial 
effect of the folic acid antagonist aminopterin.[4] In 1958 MTX treatment was introduced 
by Edmundson and Guy.[5] MTX seemed to be somewhat less effective than aminopterin, 
but i t had fewer and less severe side effects. From 1971 on, the weekly divided oral 
"Weinstein schedule" is generally used, i.e. three dosages per week at 12-hour intervals.[6] 
Despite the clinical efficacy of MTX, dermatologists have developed a slightly restrictive 
attitude towards this drug because of many reports concerning long-term hepatotoxic side 
effects.[7-10] Because of the introduction of new systemic treatments like retinoids and 
recently also cyclosporin A, a new evaluation of the risks and benefits of MTX therapy is 
appropriate. In the present communication the efficacy and the side effects of MTX in the 
treatment of severe psoriasis are evaluated. Beside a review of the literature, we include 
into a greater detail our own investigations regarding MTX induced side effects, 
hepatotoxicity and clinical results of an intermittent treatment schedule. 
Mechanism of action 
MTX has a well established position in the treatment of various malignancies and 
psoriasis. Direct anti-proliferative effects of MTX have been the presumed mechanism of 
action of MTX in these conditions.[ll] MTX has a rather similar structure as folic acid. I t 
differs at two sites from folic acid and therefore acts as a folic acid antagonist.[1] By 
competitive inhibition of dihydrofolate reductase it decreases the supply of reduced folate 
cofactors necessary for the synthesis of thymidin monophosphate (one of the four 
nucleotides necessary for DNA synthesis). Hence, DNA synthesis and epidermal cell division 
are directly interfered with by MTX. However, different observations indicate that other 
mechanisms than inhibition of DNA synthesis are of relevance in the low-dose MTX 
therapy. Co-administration of folinic acid, which counters the antifolate actions of MTX, 
does not reduce the antipsoriatic effect of low-dose MTX.[12,13] Furthermore, MTX is 
effective in different non-proliferative inflammatory diseases like rheumatoid arthritis,[14] 
systemic lupus erythematosus,[15] systemic sclerosiselo] inflammatory bowel disease[17] 
and bronchial asthma.[18] 
In vitro i t has been shown that MTX induces differentiation in keratinocytes, as 
indicated by an increase in the proportion of cells expressing involucrin.[19] Besides 
effects on differentiation, MTX also has immunomodulating properties. In vivo, the 
penetration of polymorphonuclear leukocytes into the epidermis following topical 
application of leukotriene B4 or intradermal injection of C5a proved to be inhibited in 
patients treated with MTX.[20,21] In an in vivo model i t has been shown that MTX inhibits 
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leukocyte accumulation at inflamed sites by increased adenosine release due to inhibition 
of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase.[22] Recently has been 
shown in vitro that MTX significantly inhibits proliferating lymphoid tissue but has little 
effect on epidermal cells.[23] In a review of Weinstein et al. i t is speculated, based on 
experimental studies in rheumatoid arthritis and graft versus host disease, that MTX exerts 
a direct effect on the proliferation of T-cells, thereby preventing activation of 
macrophages.[24] Studies on the effect of MTX on the production of interleukin-1 (IL-1) by 
activated macrophages in adjuvant arthritis did not show a decreased production of IL-1, 
however MTX proved to inhibit two functions of IL-1 in experimental systems.[25,26] 
Locally adminstered (intralesional or topical) MTX, which provides adequate tissue delivery 
comparable to that obtained with low-dose MTX therapy,[27] does not produce significant 
clinical improvement of psoriatic skin lesion.[28] This finding suggests that the main 
target of action of MTX are not the psoriatic epidermal cells, but a target which is not 
located in the skin, like proliferating lymphoid cells in various tissue compartments.[29] 
In conclusion, the exact mechanism of action of MTX is not known to date. Besides 
inhibition of epidermal cell proliferation, low-dose MTX therapy for psoriasis exerts its 
antipsoriatic action via interference with various aspects of cutaneous inflammation. 
Pharmacokinetics and drug interactions 
The absorption of MTX following oral or intramuscular administration is rapid, with a 
peak serum MTX concentration reached 1.6 h and 1 h after MTX administration, 
respectively.[30] Other studies confirmed that an oral dose of MTX up to 31 mg/m2 was 
completely and rapidly absorbed, although absorption was incomplete at higher dosages. 
[31] Several studies showed that there is no significant difference in the absorption of MTX 
following either intramuscular or oral administration of MTX.[30,32] However, in some 
psoriatic patients the absorption is impaired.[33] MTX should be taken on an empty 
stomach, because concurrent food (especially dairy products) can decrease the absorption 
of MTX.[34] Serum MTX levels of patients on long-term MTX therapy, whose psoriasis was 
well controlled, varied widely, indicating that serum MTX levels are not useful as indicator 
of therapeutic effect.[30] 
Fifty to 70 percent of MTX in serum is reversibly bound to protein, mainly 
albumin.[35,36] Alterations in plasma protein binding affects the amount of free 
extracellular MTX, which can result in increased toxicity. Concomitant medication that 
decrease MTX plasma protein binding either by competitive displacement of MTX or by 
altering albumin's binding affinity for MTX, such as salicylates, tetracyclin and 
sulfonamides, may increase free MTX resulting in toxicity.[35,37] 
Fifty to 90% of MTX is excreted within 24 h in the urine primarily as the unchanged 
drug through a combination of glomerular filtration, active tubular transport and 
concentration dependent tubular resorption.[35,38] Biliary excretion accounts for less than 
10% of the excretion of the drug. With doses used in the treatment of psoriasis, the 
tubular reabsorption process becomes saturated resulting in increased renal MTX 
clearance.[39] Saturation of the tubular secretory mechanism is unlikely to occur at the 
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dosages as used in psoriasis.[40] Any drug which interferes with renal elimination of MTX 
is likely to potentiate its toxicity.[41] Important is the possible interaction with NSAIDs, 
prescribed for coexisting psoriatic arthritis[42,43]. NSAIDs reduce the renal elimination of 
MTX and probably also interfere with plasma protein binding. 
Another mechanism of drug interaction, besides interference with plasma protein 
binding and interference with renal elimination, is an increase of the antifolate effect. The 
most important interactions are with trimethoprim or sulphamethoxazole, which can lead 
to a pancytopenia.[44-46] Co-medication with this medication is therefore strictly 
contraindicated. An extensive overview of possible drug interactions with MTX is given by 
Evans and Christensen.[47] 
Dosage schedules of M T X 
There are currently two common MTX dosage schedules used in the treatment of 
patients with psoriasis: a single weekly oral or intramuscular dose and a triple dose 
regimen, consisting of 3 divided oral doses given at 12-hour intervals once weekly 
(Weinstein schedule).[6] The efficacy achieved with the divided schedule might be higher 
compared with a single dose, because the area under the plasma concentration-time curve 
is increased by almost factor 2.[48] However, the superiority of one of these schedules 
never has been shown convincingly. An advantage of the divided schedule is that side 
effects like nausea and abdominal discomfort are less frequent.[29] On the other hand, the 
divided schedule is more complicated for the patient, with a risk of MTX overdosage. After 
a testdose of 5 mg/week, the dosage of MTX can be gradually increased with steps of 2.5 
mg t i l l the maximum weekly dosage of 15 mg is achieved.[49] Other clinicians increase to 
weekly dosages up to 30 mg, with an increased risk of toxicity. The goal of MTX therapy is 
not a total clearance of the psoriasis, but to establish a situation in which the psoriasis 
can be managed with adjuvant topical therapy. Subsequently, the dosage of MTX can be 
gradually tapered until the lowest maintenance dose is achieved. 
Efficacy of M T X 
In a retrospective study of Collins and Rogers comprizing 40 patients, a good to 
excellent effect of MTX was reported in 85% of the patients. Patients with erythrodermic or 
generalized pustular psoriasis did better than those with plaque psoriasis.[50] Recently, 
MTX was reported to be effective in 7 children with psoriasis.[51] In a retrospective study 
we reported the efficacy of MTX treatment in 113 patients with severe psoriasis, who were 
treated at our department with MTX in a maximum weekly dosage of 15 mg (Weinstein 
schedule).[52] The estimated mean treatment period was 8 years and 11 months, the 
estimated mean cumulative dose was 4803 mg. In 92 patients (=81%) the response was 
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good, in 19 patients (=17%) moderate and in 2 patients (=2%) poor. The frequency of 
hospital admissions during treatment with MTX decreased with a factor 10 compared to the 
pre-treatment situation. Before MTX therapy the mean number of hospital admissions was 
0.4 per patient per year and during therapy 0.04. 
Table I summarizes the efficacy of MTX in the various manifestations of psoriasis. 
Although Baker reported that only б out of 21 patients with persistent palmoplantar 
pustulosis responded favourably to MTX treatment,[53] the present study shows 
comparable efficacy of MTX in the different manifestations of psoriasis, and also a good 
response in 3 out of 5 patients with persistent palmoplantar pustulosis. 
Etretinate and acitretin have a failure rate of 30% in chronic plaque psoriasis.[54] In 
contrast, cyclosporin A and MTX seem equally effective in all manifestations of 
psoriasis.[52,55] Compared to other treatments, MTX is especially effective in psoriatic 
arthritis and psoriasis of the nails.[56,57] 
I t is born out of clinical practice and out of patient surveys such as indicated above 
that MTX is a very effective treatment for severe psoriasis. However, so far, controlled 
clinical trials are not available to support this statement. Obviously, the question arises to 
what extent a controlled clinical trial might contribute to our understanding of the 
efficacy of MTX in psoriasis as the antipsoriatic efficacy is very substantial. 
Table I. Ffficacy of MTX in the various manifestations of psoriasis (n= I 13). 
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4.1 Course after discontinuation of MTX therapy 
In the Nijmegen study 71 patients discontinued MTX therapy for different reasons, 
most frequent because of adverse feelings towards systemic therapy and a poor clinical 
result. [52] Forty-five percent of the patients experienced a full relapse in the first half 
year after cessation of MTX therapy, requiring major treatments like in patient treatment 
with dithranol, PUVA therapy, oral retinoids or cyclosporin A. Following discontinuation of 
acitretin the relapse rate was reported to be 41% in the first half year.[58] Following 
discontinuation of cyclosporin A a relapse, defined as PASI increasing again to more than 
50% of baseline value, occurred after a mean period of 2 months, varying from 2 weeks to 
4 months.[54] 
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Side effects of M T X therapy; general overview 
Because of reported side effects, dermatologists have adopted a reserved attitude 
with respect to MTX. We performed a retrospective study on the side effects of low-dose (s 
15 mg/week) MTX therapy in 113 patients with severe psoriasis, who had been treated at 
our department between 1970 and 1992.[52] In our study 83 patients (=73%) showed one 
or more clinical side effects or abnormal laboratory data at some time during the treatment 
period with MTX. However, we could not find a relationship between the incidence of side 
effects and the patients' age at the start of MTX therapy: in the patients suffering from 
side effects, MTX therapy was started at the mean age of 45.6 years; in the patients 
without side effects this was 45.2 years. It is important to realise that the maximum dose 
in this series was 15 mg/week. Table I I summarizes the frequency of the side effects. In 
the Nijmegen series the following side effects were recorded: 
Gastro-intestinal side effects 
The most frequent side effect was gastro-intestinal discomfort. The complaints 
usually were restricted to the first 2-3 days following MTX ingestion. In a study by 
Duhra et αι. suppletion with folic acid 5 mg daily controlled the gastrointestinal 
complaints satisfactory and did not decrease the therapeutic efficacy of MTX.[59] 
Subjective side effects 
Episodes with fatigue, headache and dizziness were occasionally experienced by 
several patients. 
Haematopoietic suppression 
Haematopoietic suppression occasionally occurred during MTX treatment. 
Normalization of blood counts was seen in all patients following reduction of the 
dosage or (temporary) discontinuation of therapy. 
Mucocutaneous side effects 
Apart from some hair loss in 7 patients no mucocutaneous side effects were 
encountered. Remarkably, no patients complained of ulceration of mucosal 
membranes or "burning sensation" of the skin. 
Infections 
Six patients had minor infections. These infections were not more serious as can 
be seen in normal subjects without MTX treatment. 
Neoplasmata 
In 5 patients a malignancy was diagnosed during therapy. Two patients developed 
a basalioma, one patient had a cutaneous melanoma, one patient a sigmoid 
carcinoma and one patient had both a basalioma and a lung tumour. 
Side effects like erosions of skin and mucosal membranes, as reported in the literature, 
were not seen in our series. Also MTX-induced osteopathy, [60] ventricular arrhythmias[61] 
and altered taste sensation[62] are uncommon side effects of MTX treatment, which we 
failed to observe in our patient group. Painful erosion of psoriatic plaques has been 
reported to be an early sign of MTX toxicity.[63] At our department we did not observe 
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Table II Patients with one or more side effects during MTX therapy (n=83) 

















































"MTX-pneumonitis", a condition especially seen with the use of MTX in rheumatoid 
arthritis.[14] Fatalities did not occur. I t is attractive to hypothesize that the relatively low 
maximum dose of 15 mg per week might be relevant in this respect. Furthermore is of 
importance that prevention of pregnancy is essential while on MTX therapy because of it's 
mutagenic and teratogenic effects. Advised is (as well for men as for women) that 
pregnancy should be delayed at least 1 month, but preferably 3 months after discontinuing 
MTX.[29] 
The repertoire of side effects observed in our study confirms and extends previous 
reports.[l,64] Side effects may occur in any phase of MTX treatment and it is important to 
realize that patients who have been on MTX for some years without serious problems do 
not have a guarantee to be "protected" from side effects. 
As our study is a retrospective analysis without a control group, a clear 
interpretation of the causal relation of adverse events to MTX therapy is not possible. In 
particular this concerns the neoplasias observed during MTX treatment (5 out of 115 
patients). As patients with severe psoriasis usually have been exposed to treatments with a 
carcinogenic potential, the influence of MTX in itself on the development of skin cancers 
could never be investigated. The incidence of internal malignancies following treatment 
with MTX has been reported to be equal or lower compared to a matched control 
population.[65,66] 
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MTX and hepatotoxicity 
The development of liverdamage during long-term MTX treatment is one of the most 
feared side effects. The Psoriasis Task Force has developed guidelines for the administration 
and monitoring of methotrexate, beginning in 1972, with several later revisions. Currently 
the latest guidelines of 1988[49] are revised. In the new international guidelines a liver 
biopsy has to be performed after a cumulative dose of 1.5 gram and repeated after 3.0 and 
4.0 gram in patients with no significant risk factor for liver abnormalities (i.e. history of 
past or current excessive alcohol intake, persistent abnormal liver chemistry results, history 
of prior liver disease, history of intravenous drug abuse, diabetes or obesity, history of 
exposure to known hepatotoxic drug).[29] In patients with risk factors, the liver biopsy 
should be performed in the in i t ia l phase of the treatment. The most common method for 
grading liver histolgy is as used in the international classification: 0, not évaluable; grade 
I, normal histology or minimal disturbances; grade I I , moderate to severe fatty inf i l t rat ion; 
grade I I IA , mild portal fibrosis; grade HIB, moderate to severe portal fibrosis, and grade IV, 
cirrhosis.[49] The clinical interpretation of biopsy results are as follows: patients, with grade 
I or I I changes can continue to receive MTX therapy; patients with grade I I IA may continue, 
but should have a repeat liver biopsy after 6 months of MTX therapy; patients with grades 
HIB and IV changes should not be given further MTX therapy. The mechanism by which 
hepatic fibrosis develops is not fully understood. Polyglutamates of MTX may be involved via 
accumulation within hepatocytes during long-term administration. They compete with 
hepatocyte folate polyglutamates, leading to chronic hepatocellular folate deficiency, which 
may be responsible for the hepatotoxicity.[67,68] 
Table 111 Results of liver biopsy classification (LBC) after low-dose MTX therapy, for each patient the hig-
hest histology grade is presented (n=55) 
LBC No. % 
1 0 2 4 
I 35 62 
II 9 17 
IIIA 6 I I 
HIB I 2 
IV 2 4 
total 55 100 
In our retrospective study we evaluated the incidence of liver fibrosis and cirrhosis.[52] In 
tota l 105 liver biopsies were performed in 55 patients. Pre-MTX values were available in 12 
patients. The results of liver biopsy classification (LBC) are presented in Table H I . In 
patients who underwent consecutive biopsies, the highest histology grade is presented in 
the table. Nine of the 55 patients had a LBC grade I I IA , HIB or IV once or more frequently. 
In 7 patients (=13%) fibrosis was seen and cirrhosis in 2 patients (=4%). The occurrence 
of severe liver fibrosis and liver cirrhosis in the Nijmegen series was relatively low 
compared to most investigations (Table IV) . 
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Figure I a. Relation between liver biopsy 















Figure I b, Relation between liver biopsy 
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liver biopsy classification 
There was no clear relation between LBC and cumulative dosage or duration of therapy 
(Fig. l a , b). The lack of a dose relationship with respect to hepatotoxicity might be 
interpreted by the supposition of a multifactorial pathogenesis of liver fibrosis and liver 
cirrhosis. There was also no clear relation between liver histology and liver function tests 
(LFT's): in 28 of the 46 patients with a normal LBC (grade 0, I and I I ) , LFT's were normal 
and in 18 they were disturbed. Of the 9 patients with LBC grade ΠΙΑ, HIB and IV, only 5 
had abnormal LFT's. In accordance with other authors[69,70] we concluded that 
monitoring of liverenzymes is of limited value in the detection of histological liver 
damage, as in 4 out of 9 patients with fibrosis or cirrhosis (=44%) the LFT's were normal. 
Although the progression of liver cirrhosis is slow during continuation of MTX,[71] a 
later report concerning the same patient group showed a further development of cirrhosis 
in a substantial amount of patients and the development of liver failure in 1 patient.[72] 
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Three other patients are described, who developed liver failure after MTX treatment for 
psoriasis.[73] In 49 patients on long-term MTX treatment for psoriasis 5 of 11 patients 
with hepatic fibrosis at the time of the first liver biopsy (mean cumulative dose 2743 mg) 
showed improvement in their liver histology grading despite continuation of MTX, in none 
of them the histology grading deteriorated.[74] These findings suggest that uncomplicated 
fibrosis alone may not necessarily be a contraindication to continued MTX therapy, in 
contrast to cirrhosis. 
Novel monitoring techniques for M T X induced hepatic damage 
At present, histological evaluation of liver biopsies is the gold standard to assess 
MTX-induced liver damage. However, serious complications like haemorrhage, 
pneumothorax and sepsis may occur incidentally. The reported morbidity figures range from 
0.02-10%[75,76] and the mortality rate is 0.01-0.1%.[76,77] Liver biopsies are relatively 
expensive and uncomfortable for the patients. Several attempts are made in the search for 
a non-invasive screeningsmethod for MTX-induced liverdamage. Magnetic resonance 
imaging,[78] ultrasound scanning[79,80] and static scintigraphy of the liver[81] have 
been reported as not sufficiently reliable. Salivary antipyrine clearance was correlated with 
fatty changes in the liver but not with fibrosis.[82] Low concentration of folate and high 
concentration of MTX in erythrocytes were associated with an increased risk of changes in 
liver histology.[83] Two promising screening techniques have been described in the recent 
literature: dynamic hepatic scintigraphy and serum PIIINP measurement. 
Dynamic hepatic scintigraphy 
McHenry et σ/.[84] reported promising results on dynamic hepatic scintigraphy (DHS) 
according to the methodology of Ferguson et o/.[85] In short: the uptake of "mTc sulphur 
colloid in the spleen is proportional to the arterial uptake by the liver. By subtracting this 
arterial contribution from the total liver uptake, the portal contribution to the total liver 
now can be computed. The low-pressure portal vein system is more sensitive for changes 
in the structure of the liver parenchyma than the high-pressure arterial system and the 
portal contribution decreases in case of fibrosis or cirrhosis. For details concerning the 
performance of the DHS, we refer to the manuscript of van Dooren-Greebe et o/.[86] 
Measurement of serum PIIINP 
Another interesting screening test is the measurement of serum aminoterminal 
propeptide of type I I I procollagen (PIIINP).[87-90] Hepatic fibrosis is characterized by 
increased synthesis and deposition of collagen, predominantly type I I I . Collagen molecules 
are derived from procollagen molecules by cleaving the terminal peptides, which are 
subsequently released into the circulation.[91] Measurement of PIIINP with a 
radioimmunoassay^] may be suitable to detect and monitor liver damage.[93] This test 
is not organ-specific, as increased PIIINP levels have also been demonstrated in systemic 
sclerosis, localized scleroderma and rheumatoid arthritis.[94,95] 
59 
7.1 The value of dynamic hepatic scintigraphy and PIIINP 
In a prospective study we investigated the value of dynamic hepatic scintigraphy 
and serum PIIINP levels alone and in combination as screening methods for early 
detection of MTX-induced hepatic damage.[86] These relatively non-invasive procedures 
were compared with the liver biopsy classification, until now the gold standard to assess 
MTX-induced liver damage. Twenty-five MTX patients (12 males and 13 females) could be 
included in the study. Twenty-four patients had severe psoriasis and one patient had 
Reitera disease. The mean age of the patients was 52 yrs (31-75 yrs). The mean 
cumulative MTX dose was 3.9 gram (0.2-11.1 gram) and the mean duration of treatment 
was 90 months (4-288 months). Six of the 25 patients also had psoriatic arthritis. Twenty-
one patients (84%) had a normal liver histology (grade I), 3 patients (12%) had steatosis 
(grade II) and one patient (4%) mild fibrosis (grade I l ia) . Seven additional patients (3 
males and 4 females) with non-MTX related hepatic cirrhosis were included as disease 
controls. Their mean age was 53 yrs (43-75 yrs). In 4 patients cirrhosis was induced by 
alcohol abuse and in 3 patients by auto-immune hepatitis. 
DHS could be performed as described[86] in 22 of the 25 MTX patients. The portal 
contribution computed at 35 s post injection had the highest discriminating power and 
was used for further analysis. The mean portal contribution at 35 s was 50.4% (standard 
deviation (SD) 13.1). In the 18 patients with LBC grade I the mean portal contribution was 
54.8% (SD 9.5), the 3 patients with LBC grade I I had portal contributions of 20.4%, 
28.9% and 38.0% and the patient with grade I I I LBC had a portal contribution of 37.0%. 
Figure 2a shows the portal contribution of all patients in relation to their LBC (grade I-
I I I ) . The portal contributions of 5 cirrhosis patients are shown in a separate column of 
Figure 2a (grade IV). Their mean portal contribution (31%), was in the same range as that 
of the MTX patients with grade I I-I I I LBC. By means of discriminant analysis i t was 
demonstrated in our study that a portal contribution of >52% in an MTX patient was 
associated with a >95% chance to a LBC grade I. If this cut-off value of 52% would have 
been used to postpone the liver biopsy, this would have reduced the number of biopsies 
with at least 55% in the patients with a normal liver histology. No false negative results 
were obtained. In summary, we could demonstrate a clear-cut separation between the 
portal contribution of the MTX patients with a LBC grade I and all other patients. DHS 
appeared not to be suitable for the determination of the severity of hepatic damage, 
because the values of the patients with grade I I and grade I I I LBC were in the same range. 
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The patients with steatosis (grade II) had a much lower mean portal contribution than the 
patients with grade I LBC (29.1% vs. 54.8%), this suggests that a grade I I LBC indeed 
reflects early MTX induced hepatic damage. McHenry et al. [84] performed 87 paired DHS 
and liver biopsies in 63 psoriatic MTX patients. The authors reported a high predictive 
value of a normal DHS for fibrosis grade 0-1 (98.5%) and a low predictive value of an 
abnormal DHS for fibrosis of grade 2 or worse (25%). McLaren ef. σ/.[96] reported a 
significant reduction in the portal contribution in 41 non-MTX related cirrhosis patients 
compared to 33 healthy controls. 
The mean PIIINP in all 25 MTX patients was 3.8 pg/L (SD 1.3). In the patients with a 
LBC grade I the mean PJIINP was 3.6 pg/l (SD 1.0), the 3 patients with LBC grade I I had 
PIIINP values of 3.2 μς/Ι, 3.0 pg/l and 7.0 pg/l and the patient with LBC grade I I I had a 
PIIINP value of 6.2 pg/l. Figure 2b shows the PIIINP values of all patients in relation to 
their LBC (grade I-III). Although the mean PIIINP values in patients with grade I I- I I I LBC 
were significantly higher than those of the patients with grade I LBC, isolated values did 
not discriminate between individuals with and without hepatic damage. The six patients 
with psoriatic arthritis all had a LBC grade I and their mean PIIINP was 3.7 pg/l. The 
PIIINP values of 5 cirrhosis patients are shown in a separate column of Figure 2b (grade 
IV). Their mean PIIINP (8.0 pg/l), was significantly higher than that of the MTX patients, 
with an overlap for the individual results. If the MTX and the cirrhosis patients are 
combined, three of the 9 patients (33%) with abnormal histology had normal PIIINP 
values. 
Zachariae et o/.[87,88] reported on PIIINP levels in 170 patients with psoriasis. 
Patients with liver fibrosis or cirrhosis and patients with psoriatic arthritis had 
significantly elevated mean PIIINP levels. The authors claimed that the number of liver 
biopsies performed on MTX patients might be reduced to a minimum in case of normal 
PIIINP levels. In concert with Kanzler and Gorsulowsky[97] we cannot confirm their 
conclusions, as a considerable number (6-8/24, 25-33%) of patients without arthritis and 
with fibrosis had normal values of PIIINP. Furthermore, 4/18 (22%) of patients with both 
arthritis and liver fibrosis had normal PIIINP values. Ristelli et σ/.[90] reported elevated 
PIIINP levels in 8/9 patients with fibrosis or cirrhosis and concluded that the number of 
biopsies could be significantly reduced in patients with normal PIIINP values, despite the 
fact that 6/15 patients (40%) with PIIINP values in the normal range had fibrosis or 
cirrhosis. In a recent study of Boffa et al. it was confirmed that some patients with fibrosis 
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have normal PIIINP values.[98] Oogarah et al. performed an electron microscopic 
examination of liver histology and could show fibrosis in the perisinuoidal space of Disse 
in 82% of MTX-treated patients, which can explain the raised PIIINP levels in MTX treated 
patients with normal liver histology, compared to untreated control patients with psoriasis. 
No relation could be shown by the degree of Disse space fibrosis and PIIINP levels. 
Mitchell et al. [89] reported on a controlled study with 51 MTX-treated psoriatics and 
concluded that isolated PIIINP measurements can not discriminate between individuals 
with and without significant liver pathology. The conclusion from our study is in 
accordance with Mitchell et α/.[89] There was a global relation between PIIINP values and 
hepatic damage, but one-off readings appeared to be unreliable for the screening of 
individual patients. The patients with psoriatic arthritis had PIIINP levels in the same 
range as the other patients. 
Our study indicates that the relatively non-invasive DHS procedure is very promising 
for the detection of early MTX-induced hepatic damage. This approach may lead to a 
considerable reduction of the number of liver biopsies in the near future. The value of a 
single PIIINP measurement is limited, whereas the use of PIIINP values for regular 
monitoring of individual patients, as is suggested by Boffa et α/.,[98] may reduce the need 
for liver biopsies. Pending further studies, the performance of liver biopsies according to 
the international guidelines[29] remains the gold standard for safe prolonged use of MTX 
in the treatment of psoriasis. 
Management of patients on M T X therapy 
The limiting factor for MTX use, as outlined in the previous chapters, has been its 
toxicity profile; therefore, proper patient selection and close monitoring are crucial in 
achieving a good clinical response. Indications and contra-indications for MTX therapy and 
guidelines for monitoring of MTX therapy are presented in the international 
guidelines[29,49] and in a recent paper by Boffa et σ/.[99] Whenever possible, the lowest 
dose should be administered and the return to conventional topical therapy encouraged, as 
i t is the cumulative dose and not the duration of therapy that causes toxicity.[100] MTX is 
generally used as a monotherapy rather than in combination. In an effort to minimise 
toxicity, some studies have shown that combination therapy using MTX with UVB,[101] 
PUVA[102] or retinoids[103] is effective in resistant cases, using considerably lower doses 
of both agents than are required in monotherapy. However, an increased risk of acute[104] 
or long-term side effects must be kept in mind. In addition, alternating MTX with other 
treatment modalities can offer the various organ systems targeted for toxicity a chance to 
rest and repair while the alternative agent is used. With this "rotational therapy" the use 
of MTX can be periodically changed with other treatments (PUVA, UVB, etretinate, etc.) to 
minimize the long-term toxicity of each therapy. [105,106] 
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8.1 The value of interruption of MTX therapy 
Another approach to reduce the cumulative dose of MTX is periodically discontinuing 
MTX therapy instead of continuous treatment. For the treatment of psoriasis, MTX is often 
continued for many years, especially when the achieved clinical result is satisfactory and 
no major side effects occur. However, a high cumulative dose of MTX is associated with an 
increased frequency of liver damage.[9,100] Whether intermittent treatment with MTX is 
successful depends on the relapse-time after discontinuation and on the opinion of the 
patients. We therefore designed a study to investigate whether treatment with MTX in 
intervals is better than a continuous schedule.[107] The MTX regimen was temporarily 
discontinued in 10 psoriatic patients on long-term treatment with oral MTX according to 
the Weinstein-schedule. At the moment of discontinuation all patients were in a stable 
clinical condition with minimal skin-lesions and their weekly MTX dose had already been 
tapered off to an optimal dose with respect to efficacy and side effects. The clinical course 
after discontinuation and re-introduction of MTX was evaluated. Treatment was re-
introduced when a partial relapse of psoriasis occurred (for the definition of partial relapse 
see [107]). For each patient the difference between the expected and the real cumulative 
MTX dose was calculated. The expected cumulative dose is the cumulative dose that the 
patient would have received if treatment had not been interrupted. For patients who 
restarted and continued on the same dose schedule as prescribed before the 
discontinuation, this difference was computed by multiplying the pre-study weekly dose by 
the number of MTX-free weeks. For patients with severe relapsing psoriasis who needed a 
temporary "loading-up" dose after re-introduction to get a favourable clearing of their 
lesions, this additional MTX was comprised in the calculation. If the expected cumulative 
dose was higher than the real cumulative dose, this resulted in a reduction in cumulative 
dose due to treatment interruption. Whether the patients preferred a continuous treatment 
schedule to a treatment in intervals was investigated by means of a short questionnaire. 
The reason for this preference was also evaluated. 
Figure 3. Reduction (positive values) or 
increase (negative values) in cumulative 
MTX dose due to interruption of MTX 
treatment for each patient. 
I 2 3 4 5 6 7 8 9 
patients 
Three patients experienced a quick relapse and MTX was re-introduced within 4 weeks. In 7 
patients the MTX-free interval was at least 11 weeks. One patient did not relapse at all 
within a follow-up period of 41 weeks. In 3 patients the MTX treatment had to be re-
introduced before the criteria for a partial relapse were met, because of recurrence of skin 
lesions at cosmetically disturbing localizations or because of rapidly progressing pin-point 
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lesions, indicating the onset of a severe relapse. The mean MTX-free period of the 7 patients 
with a MTX-free period of at least 11 weeks was 23 weeks (11-41, n-7). The individual 
reduction or increase in cumulative MTX dose due to interruption of MTX treatment is shown 
in Figure 3. One patient had to be excluded in this calculation because i t appeared that she 
had previously been treated with arsenic; acitretin was prescribed at the moment of a 
relapse. The mean reduction of the cumulative MTX dose was 76 mg (range 67.5-255 mg). 
Recalculation for those patients with a MTX-free period of at least 11 weeks resulted in a 
mean reduction of the cumulative MTX dose of 117.5 mg (range 23.8-255 mg). 
The 3 patients resuming their MTX regimen shortly after discontinuation (within 4 
weeks) all preferred a continuous treatment. Of the 7 patients with prolonged MTX-free 
periods, 3 patients preferred interval treatment because of the reduced toxicity potential 
of such a regimen. The other patients preferred a continuous treatment in spite of a long 
MTX-free period because of fear of a relapse and practical problems with the more 
cumbersome local therapy. This indicates that patients have to be carefully instructed and 
persuaded to become motivated for an interval treatment schedule. Treatment of severe 
psoriasis with MTX in intervals can be a good alternative to a continuous dose schedule. 
Treatment interruption resulted in a substantial reduction of the cumulative dose and 
reduces the hepatotoxic load of MTX. Patients on a low maintenance MTX dose may 
particularly benefit from regular interruptions of their MTX regimen. It is necessary to 
persuade patients on long-term MTX treatment to interrupt their regimen at regular 
intervals to achieve a further reduction of their cumulative dose. 
Place of M T X in the treatment of severe psoriasis 
The efficacy of low-dose oral MTX in severe psoriasis is well established. Besides 
gastro-intestinal complaints, the most notorious side effects of MTX therapy concern 
haematological abnormalities and hepatic damage. Although several promising non-
invasive screening methods for early detection of MTX-induced liverdamage are currently 
evaluated, performing liver biopsies according to the international guidelines remains the 
gold standard for the safe and prolonged use of MTX in the treatment of psoriasis. No 
comparative studies with other systemic treatments for severe psoriasis like cyclosporin A 
or retinoids are performed. But in comparison with these other therapies MTX is 
inexpensive,[74] and the side effects after long-term treatment are extensively studied. On 
the basis of the results of the reviewed literature data and personal experience, i t is our 
view that the long-term clinical efficacy and relative safety of MTX, remain reassuring and 
impressive, provided a careful patient selection and treatment according to the established 
guidelines are adhered to strictly. 
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Psoriatic erythroderma is a serious condition which requires a fast response to 
therapy, preferably during an in-patient treatment. Therapeutic options include various 
topical treatments and photo(chemo)therapy, but in most cases systemic treatment is 
necessary.[l] Combination of cyclosporin A and methotrexate (MTX) resulted in serious 
adverse events after a short treatment period, and therefore is not recommended.[2] 
Combination of etretinate and MTX may lead to increased hepatotoxic risks, by increasing 
the MTX plasma levels.[3,4] Because of the different mechanisms of action and a different 
side effect profile combined treatment of cyclosporin A and retinoids might be successful. 
Three patients with psoriatic erythroderma, who did not respond to monotherapy with 
acitretin in adequate dosages, were treated with combined therapy consisting of acitretin 
and cyclosporin A. They did not use co-medication known to interact with cyclosporin A 
metabolism or with nephrotoxic potentials. Serum creatinine level, liver enzymes, serum 
electrolyte levels, haematological parameters and blood pressure were measured before 
initiating combination treatment and once weekly during therapy. Clinical scores were 
evaluated using the Psoriasis Severity Score modified according to Perkins et аі.[Ъ] 
The individual dosages, clinical efficacy and side effects of each patient are summarized in 
Table I. 
Table I Clinical efficacy and side effects after combined therapy with acitretin and cyclosporin A (CyA) in 
3 patiens with erythrodermic psonasis [PSS=Psonosis Seventy Score] 
patient age CyA-acitretin CyA dose Acitretin dose Initial PSSat side effects < 
period (wks) (mg/kg/day) (mg/kg/day) PSS the end 
1 5 8 6 3 03 44 55 retinoid dermatitis 
blood pressure » 
serum creatinine 
serum cholesterol 
2 83 4 3 04 66 5b dry lips 
conjunctivitis 
3 67 h 3 04 33 33 dry lips 
dry nose 
serum creatinine « 
blood pressure 
Casel 
A 58-year-old man was admitted because of a biopsy proven psoriatic erythroderma. 
He had been treated with acitretin in a dosage of 0.5 mg/kg/day during 12 weeks. Because 
of lack of clinical improvement, combination therapy was started with cyclosporin A in a 
dosage of 3 mg/kg/day. After 1 week of combined treatment, acitretin was decreased to 
0.3 mg/kg/day because of a retinoid-induced dermatitis. After б weeks the serum 
creatinine level was elevated >40%, and the serum cholesterol level and the blood pressure 
were raised. No clinical improvement was achieved during б weeks treatment. Both 
therapies were stopped and MTX was started at a dosage of 7.5 mg/week. After 2 weeks 
the blood pressure and the cholesterol level had normalized, the serum creatinine level 




An 83-year-old man with a history of psoriasis during 5 years was admitted with an 
erythroderma psoriasis, which was treated subsequently with MTX during 2 weeks, 
prednisone during 2 weeks and acitretin 0.4 mg/kg/day during 3 weeks. These therapies 
were not successful. Cyclosporin A 3 mg/kg/day was combined with acitretin 0.4 
mg/kg/day. After 4 weeks of combined treatment, only minimal clinical improvement was 
observed. The patient complained of dry lips and dry eyes. All serological parameters and 
the blood pressure were stable during therapy. Acitretin treatment was stopped and the 
cyclosporin A dose was raised to 5 mg/kg/day and combined with topical calcipotriol. This 
resulted in a good clinical improvement after 6 weeks. 
Case3 
A 67-year-old man suffering from psoriasis for more than 40 years was admitted with 
an erythrodermic psoriasis. The psoriasis did not respond to local steroids or coal tar both 
in combination with acitretin 0.5 mg/kg/day during 8 months. Cyclosporin A (3 
mg/kg/day) was started combined with acitretin 0.4 mg/kg/day. After 11 weeks of 
combination therapy the serum creatinine level was raised with 90% and the blood 
pressure had increased. The clinical response was unsatisfactory. Subsequently, both 
therapies were stopped and treatment with MTX 7.5 mg/week was initiated. However, 5 
weeks later patient had a cerebrovascular accident, complicated by fatal pulmonary 
embolism. 
Considering the different modes of action and different side effect profiles, 
combination therapy of retinoids and cyclosporin A is a promising approach. However, 
because both retinoids and cyclosporin A are metabolised in the liver via a cytochrome 
P450-dependent system, a risk for interaction resulting in increased cyclosporin A levels is 
present. Recently, the effect of etretinate on the cyclosporin A metabolism was studied in 
an in vitro assay, using microsomes from normal human liver.[6,7] With cyclosporin A 
levels of 5 μΜ and etretinate levels of 100 μΜ no metabolic interaction could be shown.[7] 
However, in a similar study with 100 μΜ etretinate and cyclosporin A levels up to 30 μΜ, 
cyclosporin A metabolism was inhibited by 33-45%.[6] If this finding is of relevance in 
cyclosporin A treatment in which the normal trough and peak serum levels are far lower 
than 30 μ M needs further study. 
The results of combination therapy in in vivo studies in patients with chronic plaque 
or erythrodermic psoriasis previously described in the literature are summarized in Table 
II.[7-11] The efficacy of combination therapy in plaque psoriasis is poor.[9,10] Frequently 
reported side effects are retinoid dermatitis and raised serum creatinine levels. However, 
the 3 patients with erythrodermic psoriasis previously reported in the literature showed a 
satisfactory improvement.[8,ll] This is in contrast with the patients described here, who 
achieved poor clinical results. Two patients showed cyclosporin Α-induced side effects 
already after a short treatment period. Because of the relatively high age of our patients, 
they might be more susceptible to the development of side effects. 
Although no decisive conclusions can be drawn regarding the value of combined 
treatment with acitretin and cyclosporin A in erythrodermic psoriasis, it proved not to be a 
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Treatment of acrodermatitis continua of Hallopeau (ACH) is difficult and often 
disappointing. We describe a patient with an extensive ACH of all finger- and toetips, who 
was treated with acitretin combined with calcipotriol. A within-subject left/right 
comparison was carried out between calcipotriol ointment (50 pg/g) and the ointment 
base to investigate the additional value of calcipotriol above the ointment base. The side 
treated with calcipotriol as adjunct therapy showed an impressive improvement, well 
beyond the degree of improvement at the side treated with the ointment base only. 
Introduction 
Acrodermatitis continua of Hallopeau (ACH) is characterized by pustular eruptions 
predominantly involving the distal phalanges of fingers and toes with marked involvement 
of the nail bed. This specific localization and the fact that lesions are often painful imply 
that ACH is a disabling condition. While some authors consider ACH as a variant of pustular 
psoriasis, others distinguish ACH as a separate entity.[1] Unfortunately, as other forms of 
localized pustular psoriasis, ACH is very resistant to treatment. 
We describe a patient with an extensive ACH of all finger- and toetips, improving 
during combined treatment with acitretin and calcipotriol. The present case report suggests 
a synergistic effect of the combination of acitretin and topical calcipotriol in ACH. 
Case report 
A 73-year-old woman presented with a 3-year history of redness, scaling and 
pustulation of all the finger- and toetips. From time to time, she had also pustular 
eruptions elsewhere on the body. The lesions appeared for the first time on the elbows and 
on one finger as discrete pustular changes and rapidly progressed to a disabling condition. 
Prior to disease onset there was no history of trauma or infection. Treatment with potent 
topical steroids, crude coal tar, UVB and UVB combined with dithranol had been ineffective. 
Also treatment with calcipotriol 50 pg/g monotherapy during 3 weeks did not result in 
improvement of the lesions. Before attending our hospital, the patient had been treated 
with acitretin 35 mg/day (0.5 mg/kg) during 3 months. Initially, acitretin had a beneficial 
effect on lesions on the body but no effect on the aerai lesions. Treatment with acitretin 
was discontinued because of the lack of further improvement. 
On clinical examination, 3 months after discontinuation of acitretin treatment, the 
patient presented with erythema and scaling at the dorsal side of the distal phalanges of all 
fingers and toes. Most nail plates were absent and the nail beds showed multiple pustules. 
77 
from pinhead size to a few millimeters (Fig. 1). In addition, on elbows, legs and knees 
sharply demarcated erythematous, indurated lesions with pustule formation were present. 
Acitretin was re-introduced in a dosage of 35 mg/day (0.5 mg/kg) once daily. Because 
of a moderate cheilitis, hairloss and a dry skin i t was not possible to increase the dosage of 
acitretin further. On the lesions of the left hand and foot calcipotriol 50 pg/g ointment 
(Daivonex®, Leo Pharmaceutical products, Weesp, the Netherlands) was applied twice daily. 
On the right hand and foot placebo ointment (Leo Pharmaceutical products) was applied 
twice daily. After 1 month of combined treatment a substantial improvement of the lesions 
at the placebo treated sides was present (Fig. 2a). However, the calcipotriol-treated side 
was far more improved (Fig. 2b). Pustulation had disappeared completely, and only slight 
erythema and desquamation remained. 
1 Discussion 
ACH is difficult to treat, which is reflected in several reports on different treatment 
modalities applied in ACH. No controlled studies have been performed and most 
communications are casuistic. Local therapies, which are reported to be effective, comprise 
coal tar preparations,[2] dithranol,[2] fluorouracil[3] and mechlorethamine.[4] Systemic 
treatments which may be effective are systemic steroids,[5] methotrexate, [2] cyclosporin 
A,[6,7] etretinate[l,8,9] and the non-steroidal inflammatory agent nimesulide.[10] 
The present case report illustrates the possible additional effect of calcipotriol 
ointment above systemic treatment with acitretin in ACH. A synergistic effect of etretinate 
and topical calcitriol has been demonstrated in chronic plaque psoriasis.[11] 
Several groups have studied the effect of acitretin and calcipotriol on the 
polymorphonuclear leukocytes (PMN), the cells that dominate in pustular psoriasis. 
Acitretin 25-75 mg/day inhibits the in vivo migration of PMN using leukotriene-B4-induced 
intra-epidermal accumulation of PMN as an in vivo model.[9,12,13] in vitro, acitretin 
inhibits the migration of PMN but does not interfere with arachidonic acid release by these 
cells.[14,15] Calcipotriol has been shown to inhibit the release of arachidonic acid from 
the PMN[16] and to inhibit Chemotaxis in w'fro.[17] During treatment of psoriatic plaques 
with calcipotriol, PMN faded from the psoriatic plaque already during the first week of 
treatment, in contrast to the relatively long persistence of other infiltrate cells.[18] 
So far, we can only speculate on the putative synergism of calcipotriol and acitretin. 
Further controlled studies are worthwhile to explore to what extent the combination of 
both treatments has to be recommended. 
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Figure I a. Acrodermatitis continua of 
Hallopeau before treatement with aci-
tretin and calcipotnol. Right hand. 
Figure I b. Acrodermatitis continua of 
Hallopeau before treatement with aci-
tretin and calcipotnol. Left hand. 
Figure 2a. Acrodermatitis continua of 
Hallopeau after I month of treatment 
with acitretin 35 mg/day and placebo 
ointment twice daily (nght hand). 
Figure 2b. Acrodermatitis continua of 
Hallopeau after I month of treatment 
with acitretin 35 mg/day and calcipotnol 
twice daily (left hand). 
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EXPRESSION OF SKALP AS A 
MARKER FOR DISEASE ACTIVITY IN 
PSORIASIS; EFFECT OF TOPICAL 
AND SYSTEMIC TREATMENT 
Introduction 
As outlined in the introduction, SKALP is a proteinase inhibitor, which is absent in 
normal and uninvolved skin and expressed in the upper layers of the suprabasal 
compartment in psoriatic epidermis.[l] SKALP provides a gradient of anti-proteinase 
activity from the upper epidermal layers towards the dermis, thereby interfering with 
proteolysis by PMN-derived proteinases. We hypothesised that SKALP can be considered as 
a negative feed-back mechanism of the skin, to regulate excessive proteolysis. Up to now, 
no data are available on the expression levels of SKALP in psoriatic skin after local or 
systemic anti-psoriatic treatment. 
As introduced under 3.3.3, the effects of retinoids are well established in the 
treatment of psoriasis. Recently the cytochrome P450 inhibitor liarozole proved to be an 
important new treatment modality with retinoid-modulating features. The clinical efficacy 
of liarozole in psoriasis has already been shown in a previous study.[2] Until now, no 
comparative study with acitretin was performed. 
In chapter 5 the effect of topical treatment of a psoriatic lesion with a mild potency 
corticosteroid on SKALP expression is studied. Both expression at the protein and mRNA 
level is described. Comparison was made with other markers of the psoriatic phenotype. 
Chapter 6 describes the effects of systemic treatment with acitretin or Liarozole on SKALP 
expression at the protein level. Furthermore, serum levels of SKALP during acitretin or 
liarozole treatment are correlated with disease activity as represented by the PASI score. 
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Recently we have described two novel markers for disturbed epidermal 
differentiation, which are strongly upregulated in psoriatic epidermis: skin-derived 
antileukoproteinase (SKALP) and epidermal fatty acid binding protein (E-FABP). No data 
are available on the kinetics of SKALP and E-FABP expression in vivo and the relation with 
epidermal growth and differentiation. We used treatment of lesionai psoriatic skin with 
topical steroid as a model to correlate the expression pattern of SKALP and E-FABP with 
known cell biological events during regression of the psoriatic lesion. Expression of these 
markers was studied using immunohistochemistry and Northern blot analysis. After 4 weeks 
of treatment a substantial clinical improvement was induced by the topical steroid, 
whereas no significant improvement had occurred at the placebo-treated sides. The 
expression of SKALP following treatment with steroid was nearly undetectable at the 
protein and mRNA level. Mitotic activity, as measured by Ki-67 staining, and cytokeratin 
16 expression were downregulated to normal levels in the steroid-treated epidermis. In 
contrast, although there was a marked decrease of E-FABP mRNA, the staining pattern for 
E-FABP at the protein level was not affected. After 4 weeks of treatment with steroid the 
complete suprabasal compartment remained positive after 4 weeks of treatment, even after 
considerable clinical improvement of the lesion. We conclude that SKALP and cytokeratin 
16 are markers that are downregulated even before complete macroscopic clearance of the 
lesion. The kinetics of E-FABP expression is distinct from the other molecules and lags 
behind the clinical signs of psoriasis. 
Introduction 
In the psoriatic lesion epidermal hyperproliferation, inflammation and a disturbed 
differentiation are well-known histological features. These aberrations can be visualised by 
immunohistochemical staining of different marker molecules. Some of these molecules, 
such as cytokeratin 16 (CK 16), are absent in normal epidermis but are expressed in 
lesionai psoriatic skin. In psoriatic skin CK 16 is present in the upper layers of the 
suprabasal compartment.[l,2] Other differentiation-related proteins which are restricted to 
the granular layer in normal skin, are strongly expressed in the stratum spinosum of the 
psoriatic epidermis. Well-known representatives of this class of differentiation markers are 
involucrin [3,4] and transglutaminase.^] 
Recently two new epidermal proteins were described: skin-derived antileukoproteinase 
(SKALP) and epidermal fatty acid binding protein (E-FABP). SKALP, identical to elafin [6], 
is a potent inhibitor of human leukocyte elastase and proteinase 3, enzymes which are 
released by activated PMN.[7] I t is speculated that SKALP provides protection against 
elastase-mediated damage and inhibits PMN migration. Immunohistochemical staining 
located the expression of SKALP in the upper layers of the suprabasal compartment in 
psoriatic skin, whereas uninvolved psoriatic skin and normal skin showed no expression.[8] 
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The expression of mRNA for SKALP, examined by in situ hybridization, revealed an intense 
staining of the suprabasal compartment in psoriatic skin.[9] 
The second novel epidermal protein is E-FABP, described by others as psoriasis-
associated fatty acid-binding protein (PA-FABP)[10], which binds fatty acids with high 
specificity.[ll] In previous investigations the presence of an epidermal FABP distinct from 
other tissue-FABP was established.[12] Expression levels of E-FABP were upregulated in 
psoriatic skin and cultured keratinocytes compared to normal skin, suggesting that the 
stage of keratinocyte differentiation is related to the expression of E-FABP.[10,11] 
Immunohistochemical staining of E-FABP showed expression in the stratum granulosum and 
in the upper third of the stratum spinosum in normal skin and non-lesional psoriatic skin. 
In psoriatic epidermis E-FABP is expressed in all suprabasal layers.[ll] 
Topical application of corticosteroids represents an effective treatment of chronic 
plaque psoriasis.[13] The effect of corticosteroids on histological parameters in dermis and 
epidermis has been investigated previously.[14,15] Both the number of cycling cells, as 
marked by positive nuclei in a Ki-67 staining, and the CK 16 expressing cells showed a 
marked decrease already after only 1 week of treatment.[16] Dermal polymorphonuclear 
leukocyte infiltration also diminished early, in contrast to the mononuclear cells, which 
remained unchanged after treatment. 
The aim of this study was to investigate the effect of topical corticosteroid on the 
expression levels of two novel markers of the psoriatic differentiation program. We were 
particularly interested to study whether steroids would affect the presumed anti-
inflammatory part of the program (SKALP expression) or the regenerative part of the 
program (E-FABP expression). The changes of these markers were related to the expression 
of two established markers for epidermal proliferation: the Ki-67 nuclear antigen and CK 16. 
Materials and methods 
Patients 
Twelve patients (7 males and 5 females, mean age 52, range 30-67) with chronic 
plaque psoriasis participated in a randomised, double-blind left-right study. Permission of 
the medical ethical committee and written informed consent from all patients were 
obtained. The patients had not used topical corticosteroids for at least 2 weeks. In this 
left-right study hydrocortisone 17-butyrate 0.1% (Locoid® Crelo®, Yamanouchi, Leiderdorp, 
the Netherlands) was compared with vehicle. Patients applied the creams thinly on the 
psoriatic lesions twice daily during 4 weeks. In one lesion on the left side and one on the 
right side of the body clinical scores were recorded before treatment and after 4 weeks of 
treatment. Erythema, induration and scaling of the lesions were assessed using a five-point 




In 6 patients punch biopsies (4 mm) were taken for histological examination. 
Biopsies were taken from one lesion before treatment and from both sides after 4 weeks of 
treatment. Biopsies were fixed in buffered 4% formalin for at least 24 h and processed for 
routine histology. Tissue was embedded in paraffin and 5 pm sections were cut. 
In the other six patients two shave biopsies for RNA measurement were taken before 
therapy, one from uninvolved skin and one from lesionai skin. Subsequently, biopsies were 
taken from both sides after 2 days and 4 weeks of treatment. Biopsies were snap frozen in 
liquid nitrogen and stored at -80°C until use. 
All biopsy places were marked on a transparent sheet before treatment was started. 
Immunohistochemical staining 
Staining to assess epidermal proliferation and keratinization was carried out using 
the following antibodies: MIB (Immunotech S.A., Marseille, France), which binds to the 
nuclear antigen Ki-67 present in cycling cells [17], and Ks8.12 (Sigma, St. Louis, MO, 
USA), which detects CK 16. CK 16 is expressed by hyperproliferative keratinocytes.[l] Anti-
E-FABP serum and anti-SKALP serum were prepared as previously described.[8,11] 
Paraffin sections were deparaffinised and rehydrated and immunostaining was 
performed. An indirect peroxidase technique was used for staining with anti-CK 16 
antibodies and the antisera against E-FABP and SKALP. First, the sections were pre-
incubated with normal swine serum (E-FABP, SKALP) or normal rabbit serum (CK 16). For 
staining with the anti-CK 16 antibodies, slides were incubated with the antibody in a 
dilution of 1:25 for 30 min. For SKALP and E-FABP staining, sections were incubated with 
anti-SKALP serum at a dilution of 1:500 and anti-E-FABP serum at a dilution of 1:100 for 
60 min. After incubation with peroxidase-conjugated rabbit-anti-mouse Ig (CK 16 staining) 
or peroxidase-conjugated swine-anti-rabbit Ig (SKALP- and E-FABP-staining), the sections 
were developed with amino-ethylcarbazol as the chromogenic substrate. 
For staining of the Кі-67-antigen sections were pre-incubated with normal horse 
serum. Subsequently, slides were incubated with anti-Ki-67 antibodies in a dilution of 1:50 
for 60 min. After incubation with biotinylated horse-anti-mouse IgG (dilution 1:200) for 
30 min, complexes were formed between biotin and avidin using the Vectastain Elite ABC 
peroxidase kit, according to the manufacturer's instructions (Vector Laboratories, 
Burlingame, USA). The sections were developed with metal-enhanced diaminobenzidin as 
the chromogenic substrate. 
Histological examination 
Semiquantitative assessment of the histology was carried out by an observer who 
was unaware of whether sections were derived from steroid- or placebo-treated sites. 
Epidermal proliferation was measured by counting the number of Кі-67-positive nuclei per 
mm length of the section. The CK 16-, SKALP- and E-FABP-staining in the epidermis were 
assessed using a five-point scale: 0 - no staining, 1 = sporadic staining, 2 = weak 
staining, 3 = moderate staining, 4 = pronounced staining. 
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RNA isolation and Northern blot analysis 
Total RNA was extracted from shave biopsies, using RNAzol B, as suggested by the 
supplier (Сіппа/Biotex Laboratory, Inc., Houston, TX, USA). For Northern blot analysis, 10 
pg of total RNA was electrophoresed on a 1% agarose gel containing 18% formaldehyde 
following standard procedures [18] and blotted onto a nylon membrane (Boehringer, 
Mannheim, Germany) by capillary transfer. After transfer, RNA was fixed to the membrane 
by ultraviolet irradiation (312 nm, 0.2 J/cm!). Hybridization was performed as described 
previously using an 0.42 kbp PvuII/FcoRI fragment of the SKALP cDNA clone pGESKA as a 
probe.[18] Subsequently, after stripping of the membranes with 0.1% SDS 15 mM NaCl 1.5 
mM NaCitrate in RNAsefree water, hybridization was performed as described previously 
using the PA-FABP cDNA clone 1592 as probe, which was a kind gift of Dr. P. Madsen, 
Institute of Medical Biochemistry and Danish Centre for Human Genome research, Aarhus 
University, Denmark.[10] Control hybridizations for equal loading were performed using a 
human 28 S ribosomal RNA probe. All probes were labelled with 32P by random priming 
following standard procedures. Autoradiography was performed on X-0mat S film (Kodak, 
France) at -80° С with an intensifying screen. 
Statistical analysis 
The Wilcoxon ranking test for matched pairs was used for the statistical analysis. 
i Results 
Clinical response 
The clinical response to treatment with steroid and placebo is summarised in Fig. 1. 
Comparing the efficacy of treatment (= scores before treatment - scores after treatment) 
with steroid and efficacy of treatment with placebo, a significant difference in favour of 
the steroid in erythema score and desquamation score could be established. No significant 
difference in induration score was found. 
Immunohistochemical observations 
Semiquantitative data on the staining patterns of the different antibodies are 
presented in Table I. In the untreated psoriatic lesion SKALP expression is seen in the 
suprabasal compartment (Fig. 2a). After 4 weeks of treatment with steroid, a significant 
decrease in SKALP expression could be seen (Fig. 2b). In two patients a slight staining 
was still present after treatment with steroid. SKALP expression was completely absent in 
the other patients. The placebo-treated lesions showed no significant decrease of SKALP-
positive cells (Fig. 2c). 
Before treatment, the E-FABP staining was prominent in all the suprabasal layers of 
the epidermis (Fig. 3a). In contrast to all other markers stained, E-FABP expression in the 
steroid-treated lesions did not return to the normal pattern (i.e. expression limited to the 
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before after before after 
hydrocortionsone 17-butyrate placebo 
Figure I. The clinical scores as rated for 
erythema (black bars), induration (white 
bars) and desquamation (gray bars) 
before and after treatment with hydro-
corotisone 17-butyrate and placebo, 
expressed as mean values ± SEM. 
Comparing the efficacy of treatment 
(=scores before treatment - scores after 
treatment) with steroid and with place-
bo, a significant difference in favour of 
the steroid in erythema score (p<0.03. 
Wilcoxon ranking test) and desquama-
tion score (p<0.05, Wilcoxon ranking 
test) was found. 
Figure 2a. The SKALP expression before 
treatment. SKALP is seen in the supraba-
sal layers of the epidermis. 
Figure 2b. The SKALP expression after 4 
weeks of treatment with hydrocortisone 
17-butyrate. SKALP was only slightly 
expressed. 
Figure 2c. The SKALP expression after 4 
weeks of treatment with placebo is 
comparable with the expression we 
observed before the treatment period. 
Figure За. E-FABP staining before treat­
ment. E-FABP is expressed in all supra-
basal layers of the epidermis, the basal 
layer being completely negative. 
3b Figure 3b. The E-FABP expression after 
4 weeks of steroid treatment. There was 
a slight reduction in the expression of E-
FABP, but it did not return to normal. 
Figure 3c. The E-FABP expression after 
4 weeks of treatment with placebo is 
comparable with the expression we 
observed before the treatment penod. 
stratum granulosum as described before). The E-FABP staining in the steroid-treated 
lesions (Fig. 3b) is similar to that in the placebo-treated lesions (Fig. 3c), showing 
positive staining in the entire stratum spinosum. 
In this study we found a strong effect of topical steroid on CK 16 (nearly 
undetectable in most biopsies) and Ki-67 expression, which was downmodulated almost to 
the level found in normal skin (12.8 ± 1.5 cells per mm).[19] 
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Figure 4. Northern blot of SKALP and E-FABP mRNA in skin biopsies of 2 representative psonatic 
patients treated in a left-nght study with hydrocortisone 17-butyrate and placebo. Lane I = unmvolved 
skin; lane 2 = psoriatic skin before treatment; lanes 3-6 represent biopsies taken in 2 representative 
patients after 2 days of treatment (lanes 3 + 4 and lanes 5 + 6, respectively); lanes 3 + 5 = after 2 days 
treatment with steroid, lanes 4 + 6 = after 2 days treatment with placebo; lanes 7-10 represent biopsies 
taken in 2 representative patients after 4 weeks of treatment (lanes 7 + 8 and lanes 9 + 1 0 , respectively); 
lanes 7 + 9 = after 4 weeks treatment with steroid, lanes 8 + 1 0 = after 4 weeks treatment with place­
bo. In the upper lanes a probe for 28S nbosomal RNA was used for control hybndizations to check for 
equal RNA loading. 
28S 
SKALP 
LU LU Ш 
ÌLI m 
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Lower panel. Before treatment no 
expression of SKALP could be 
demonstrated in unmvolved skin (lane 
I ), whereas psoriatic skin showed a 
strong expression (lane 2). After 2 days 
of treatment the expression in the 
stenod-treated lesions (lanes 3 + 5) and 
the placebo-treated lesions (lanes 4 + 6) 
was equal. After 4 weeks of treatment 
no significant decrease in SKALP mRNA 
was found in the placebo-treated lesions 
(lanes 8 + 10). Compared with placebo, 
the mRNA expression in the steriod-
treated lesions (lanes 7 + 9) is strongly 
decreased, wich is in agreement with the 
data on the protein level 
28S 
E-FABP 
· · · · · .'• 8 9 
Lower panel. Before treatment no 
expression of E-FABP could be 
demonstrated in unmvolved skin (lane 
I ), whereas psonatic skin showed a 
strong expression (lane 2). After 2 days 
of treatment the expression in the 
steroid-treated lesions (lanes 3 + 5) was 
decreased, whereas placebo-treated 
lesions (lanes 4 + 6) showed no 
decrease. After 4 weeks of treatment 
the mRNA expression in both the 
steroid-treated lesions (lanes 7 + 9 ) and 
the placebo-treated lesions is decreased 
with a more pronounced decrease in 
the placebo-treated lesions (lanes 8 + 
10). 
Northern blot analysis 
Before treatment, shave biopsies were taken from six patients from lesionai and non-
lesional skin. Biopsies were repeated after 2 days and 4 weeks from a steroid- and a 
placebo-treated lesion. Fig. 4 shows the presence of SKALP mRNA (Fig 4a) and E-FABP 
mRNA (Fig 4b) in the biopsies taken from 2 representative patients. In untreated psoriatic 
skin a strong expression of SKALP mRNA could be demonstrated, whereas the uninvolved 
skin showed no expression. After 2 days SKALP mRNA in the steroid-treated lesions showed 
no decrease, remaining equal to the placebo-treated lesions. After 4 weeks of treatment 
with placebo SKALP mRNA expression was still high, whereas a weak signal was found in 
the steroid-treated lesions. However, in none of the patients did steroid treatment result in 
complete downregulation as observed in uninvolved skin. 
The expression of E-FABP mRNA in untreated psoriatic skin is strong; uninvolved skin 
shows no detectable expression (Fig 4b). Remarkably, after 2 days treatment with steroid, 
E-FABP mRNA expression was substantially decreased. After 4 weeks both placebo- and 
steroid-treated psoriatic skin showed a marked decrease of E-FABP mRNA expression, with 







3 2 ± 0 4 
3 4 1 0 5 
16 3 2 ± 0 5 
980 ± 31 5 
week 4 
steroid 
0 3 ± 0 5 * 
2 8 ± 0 7 
0 2 ± 0 4 * 
12 5 ± 5 0* 
week 4 
placebo 
33 + 05 
35 ±05 
31 ± 0 9 
725 + 33 
Tabic I Mean values of the markers for 
proliferation and differentiation ± SD 
The CK 16, SKALP and E-FABP staining 
in the epidermis was assessed using a 
five-point scale 0 = no staining, I = 
sporadic staining, 2 = weak staining 3 = 
moderate staining, 4 = pronounced stai­
ning Ki-67 staining was measured by 
counting the number of positive nuclei 
per mm length of the section 
Companson was made between values 
before treatment and after treatment 
with hydrocortisone 17-butyratc 0 1% 
and placebo respectively ( * ρ < 001 
Wilcoxon ranking test) 
Discussion 
Since the aetiology of psoriasis is unknown and the pathogenesis is only partially 
understood, we still do not know the rational base of most antipsoriatic therapies used. 
Studying the sequence of events at the cell biological level in the regression phase of a 
lesion during treatment could provide us with clues to the mode of action of a specific 
treatment and contribute to our understanding of the pathogenesis. 
We have investigated the response of several markers of the psoriatic phenotype 
to treatment with topical steroid. In a previous study[16] we have shown that keratin 
16 staining and Ki-67 expression in psoriatic epidermis were markedly downregulated 
under steroid treatment. Despite the use of a less potent class I I steroid in present 
study for 4 weeks, a significant improvement of the lesions was seen compared to 
placebo. Remarkably, cellular proliferation, CK 16 expression and SKALP expression 
were found to be completely normalised in most patients, despite the fact that clinical 
scores were not completely normalised (compare Table I and Fig. 1). E-FABP, however, 
continued to be expressed throughout the entire suprabasal compartment after 4 weeks 
of treatment, in all patients. These findings show that cell biological alterations found 
in psoriatic epidermis do not necessarily display similar kinetics. 
Previous studies from our group have shown that SKALP is absent in normal skin 
and that i t is induced in psoriatic skin and during injury.[8,20] We have described the 
distribution in the margin zone of psoriatic plaques[21], and the induction and 
regression in annular pustular psoriasis.[22] Based on the finding that SKALP is a 
potent and specific inhibitor of PMN-derived proteinases[7] we assume that i t controls 
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PMN-dependent proteolysis in cutaneous inflammation. In vivo SKALP expression is 
putatively linked to the presence of elastase-containing cells (PMN and monocytes) in the 
inflamed skin. In this study we have shown that SKALP is downmodulated after 4 weeks of 
topical steroid. The finding that after 2 days of therapy the levels of SKALP mRNA are similar 
in steroid- and placebo-treated skin indicates that i t is unlikely that SKALP is affected at the 
transciptional level by steroid. SKALP downregulation is probably not a direct effect of the 
steroid at the transcriptional level but is rather a consequence of normalisation (healing) of 
the tissue. We therefore assume that steroid-treatment decreases the cellular infiltrate and 
that consequently SKALP-expression in the epidermis is downmodulated. 
E-FABP, also known as psoriasis-associated fatty acid binding protein[10], is a 
recently described member of the cytoplasmic fatty acid binding proteins.[12,23] I t is 
expressed at relatively low levels in normal epidermis (restricted to the granular layer), but 
is strongly upregulated in psoriatic epidermis.[10,11] The mechanism of its induction and 
its precise function are not understood at the moment. E-FABP has a high affinity for C-18 
fatty acids, but is not involved in arachidonic acid binding. A function of E-FABP as a 
scavenger of arachidonic acid to control inflammation is therefore unlikely. This agrees with 
the finding that E-FABP is still increased after 4 weeks of steroid therapy. In contrast to the 
persisting expression of E-FABP in the suprabasal layers even after 4 weeks treatment, 
Nothern blot analysis revealed a decrease in mRNA expression after 2 days of treatment with 
steroid. Whether this finding implicates that steroids have a direct influence at the 
transcriptional level requires further study. 
Speculatively, increased E-FABP expression in psoriasis could be involved in barrier 
function (enhanced transport of lipids). Studies on restoration of barrier function in healing 
psoriatic lesions have shown that barrier function is still impaired even after complete 
clearing of the lesions after dithranol treatment.[24] We therefore speculate that the 
persistent E-FABP expression is associated with a continuous high fatty acid transport, 
which is needed for restoration of barrier function. We have recently completed a study on 
the cell biological alterations during irritant contact dermatitis, which strongly suggests 
that E-FABP expression is increased following barrier disruption. 
In conclusion, E-FABP expression in psoriatic skin is a cell biological marker that is 
distinct from other markers such as CK 16, SKALP and cellular proliferation, which are 
downregulated even before complete clinical normalisation. Our study indicates that E-FABP 
expression lags behind the clinical signs of psoriasis. 
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The imidazole derivative liarozole is a potent inhibitor of cytochrome P^-dependent 
4-hydroxyLation of endogenous all-irons retinole acid, thereby increasing the levels of all-
trans retinoic acid in both plasma and skin. As a part of a large, double-blind, randomized 
clinical study, we investigated the cell biological alterations in uninvolved and lesionai 
skin of 20 patients with severe plaque psoriasis, who were treated either with liarozole or 
acitretin. The extent and severity of the skin lesions, as recorded by the Psoriasis Area and 
Severity Index score, was significantly reduced (p «s 0.05) after 12 weeks of treatment in 
both the acitretin- and in the liarozole-treated group. A significant decrease in the 
markers for inflammation (neutrophils), epidermal proliferation (Кі-67-positive cells), 
normal differentiation (transglutaminase) and abnormal differentiation (cytokeratin 16 and 
SKALP, also known as elafin) was seen in both groups. No significant differences were 
noted in clinical scores or cell biological scores between the liarozole and acitretin treated 
group. None of the markers returned to the levels seen in uninvolved skin or normal human 
skin. The expression of epidermal fatty acid binding protein (E-FABP) was only minimally 
decreased after 12 weeks of treatment, a substantial part of the stratum spinosum 
remaining positive. SKALP levels in serum fell in both groups with similar kinetics and 
showed a statistically significant correlation with clinical scores. A remarkable finding in 
the uninvolved skin of patients treated with Liarozole or acitretin was the distinct focal 
expression of SKALP in the granular layer and the expression of E-FABP in the spinous 
layers, which is not found in normal human skin. Although the mechanism of action differs 
fundamentally, liarozole and acitretin show similar effects with respect to clinical effects 
and cell biological changes of the lesionai and non-lesional skin. 
Introduction 
The imidazole derivative liarozole is known to block cytochrome P450-dependent 
catabolism of endogenous all-trans retinoic acid (RA).[1] In rats, monotherapy with 
liarozole increases RA plasma levels and, to a greater extent, endogenous tissue RA levels, 
leading to retinoid like effects.[2] Kang et al. demonstrated in vivo that topically applied 
liarozole is an effective inhibitor of 4-hydroxylase and can amplify the clinical effect of 
topical retinoids.[3] These findings provided a rationale for examining the efficacy of 
liarozole in psoriasis. In an open study, 31 patients with severe psoriasis vulgaris were 
treated with liarozole with a maximum dose of 150 mg twice daily, resulting in a decrease 
in PASI score of 77% after 12 weeks.[4] The side effect profile was very similar to that 
reported for etretinate or acitretin. One potential advantage of Liarozole over synthetic 
retinoids could be that, when treatment is discontinued, the metabolism of retinoic acid is 
no longer inhibited and the levels decrease rapidly. Synthetic retinoids, which are released 
slowly from body fat, can be teratogenic for a period of 2 years. [5,6] In addition to its 
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antipsoriatic effect, liarozole has been shown to be effective in various forms of severe 
ichthyosis.[7] Immunohistochemical studies on the cell biological effects of liarozole in 
the aforementioned study revealed a statistically significant induction of the expression of 
keratin 4, which is a known retinoid effect.[8] In cultured fibroblasts, the expression of 
cellular retinoic acid binding protein I I (CRABP II) was found to be a measure of retinoid 
bioactivity.[9] Liarozole also increased CRABP I I mRNA levels, thereby strongly suggesting 
a retinoid induced effect.[9] These observations provide circumstantial evidence that the 
antipsoriatic effect of liarozole is based on a retinoid-like effect. 
In this study, which was part of a major double-blind, randomized clinical trial, we 
investigated the cell biological changes in lesionai and non-lesional psoriatic skin during 
treatment with liarozole or acitretin. Using immunohistochemistry and an enzyme-linked 
immunosorbent assay (ELISA), we examined epidermal proliferation and the expression 
levels of various markers for normal and disturbed differentiation, such as 
transglutaminase, epidermal fatty acid binding protein (E-FABP), cytokeratin 16 and SKALP 
(also known as elafin). The similarities between liarozole and acitretin with respect to 
clinical effects and cell biological changes in lesionai and non-lesional skin strongly 
suggest a common mechanism of action. 
ι Materials and methods 
Patients 
As part of a multicentre, randomized, double-blind comparative study, 20 patients 
(17 men and 3 women; mean age 52.7 years, range 28-79 years) with severe psoriasis 
vulgaris were treated with liarozole or acitretin. Patients with hepatic or renal disease, 
diabetes, hyperlipidemia and a history of adrenal cortex dysfunction were excluded. Women 
were included if they were minimally 2 years postmenopausal. Topical as well as systemic 
treatments were stopped 2 and 4 weeks before the start of the study, respectively. 
Treatment was started with 75 mg of liarozole twice daily or 25 mg/day acitretin. For 
patients who showed no change or a deterioration in the clinical scores after 8 weeks of 
treatment, the dosage could be increased to a total daily dose of 150 mg of liarozole twice 
daily or 50 mg/day acitretin. To evaluate the extent and severity of the psoriasis, the 
Psoriasis Area and Severity Index (PASI) score was calculated at the start, after 2 weeks 
and, subsequently, at intervals of 4 weeks up to a total treatment period of 24 weeks. 
Written informed consent was obtained from each patient. The study protocol was 
approved by the medical ethics committee of the University Hospital Nijmegen. 
Skin biopsies 
In all patients, 4 punch biopsies (4 mm) were taken for histological examination. 
Two biopsies were taken from lesionai skin before treatment and two after 12 weeks of 
treatment. The locations for the biopsies at 12 weeks were marked on a transparent sheet 
before treatment was started. To study the effect of liarozole and acitretin on the 
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uninvolved skin, two punch biopsies (4 mm) were taken from uninvolved skin in five 
patients who were treated with acitretin (mean age 59.6 yrs, range 38-72 yrs, mean 
treatment period 52 months, range 22-96 months) and in four patients who were 
participating in a long-term study with liarozole (mean age 48.4 yrs, range 39-73 yrs, 
mean treatment period 4.5 months, range 4-6 months). From each pair of biopsies, one 
biopsy was fixed in buffered 4% formalin for 4 h and processed for routine histology. 
Subsequently, tissue was embedded in paraffin wax, and 7-pm sections were cut. The other 
biopsy was embedded in Tissue-Тек OCT compound (Miles Scientific, Naperville, U.S.A.), 
snap frozen in liquid nitrogen and stored at -80°C until use. Sections of 7 pm were cut, air 
dried and fixed for 10 min in acetone before being stored at -80°C. 
Antisera against SKALP 
A polyclonal rabbit antiserum against recombinant SKALP was obtained as described 
previously.[10] Recombinant SKALP (1 mg) was crosslinked with glutaraldehyde, dialysed 
against distilled water, and emulsified with Freund's complete adjuvant. A goat was 
immunized intracutaneous^, followed by two subcutaneous boosters at weeks 2 and 4. 
Preimmune serum was drawn before the experiments, and immune serum was collected 
after 6 weeks. The two antisera raised in rabbit and goat gave identical staining patterns 
in histological sections. 
Immunohistochemical staining 
Staining to assess epidermal proliferation, inflammation and keratinization was 
carried out using a panel of monoclonal and polyclonal antibodies (Table I ) . Anti-E-FABP 
serum and rabbit anti-SKALP/elafin serum were prepared as described previously.[10,ll] 
The other antisera are commercially available. Paraffin sections were deparaffinized, 
rehydrated and immunostaimng was performed. The stainings for Ki-67, E-FABP and keratin 
4 were performed using the avidin-biotin-complex (ABC) staining method (Vectastain; 
Vector, Burlingame, CA, U.S.A.). All other stainings were performed using indirect 
immunoperoxidase techniques. The staining procedures for Ki-67[12], cytokeratin 16[13], 
E-FABP[13], SKALP[12] and keratin 4[14] were performed as described previously. 
For the elastase staining, endogenous peroxidase activity was blocked by incubation 
with 0.3% H202 in methanol for 20 min. For the staining of elastase and transglutaminase, 
slides were incubated with the monoclonal antibodies (antielastase: 30 min; anti-
transglutaminase: 60 min.). Sections were incubated for 30 min with rabbit antimouse 
antibody conjugated with peroxidase (RAMPO; Dakopatts, Copenhagen, Denmark) diluted 
in phosphate buffer (PB) containing 5% human AB serum. After washing with PB and 
demineralized water, a 3-amino-9-ethylcarbazole (AEC) solution was used for visualization, 
according to standard procedures. 
Histological examination 
Semi-quantitative assessment of the histology was carried out by an observer who 
was unaware of whether sections were derived from a liarozole- or acitretin-treated 
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patients. Epidermal proliferation was measured by counting the number of Кі-67-positive 
nuclei per millimetre length of the section. The CK 16, keratin 4, SKALP and E-FABP 
staining in the epidermis were assessed using a five-point scale: 0 = no staining; 1 -
sporadic staining; 2 = weak staining; 3 = moderate staining; 4 = pronounced staining. The 
same scale was used for the assessment of antielastase in the epidermis. In the dermis, we 
assessed staining with antielastase by semiquantitative enumeration of positively stained 
cells as a percentage of the total number of infiltrate cells: 0 = no positive cells; 1 = 
sporadic; 2 = 1-25%; 3 = 26-50%; 4 = 51-75%; 5 = 76-99%; б = 100%. The 
transglutaminase expression was assessed by calculating the ratio of positive cell layers to 
total cell layers in the viable epidermis. This was done at two sites: above the tip of the 
dermal papilla and between two dermal papillae. 
Enzyme-linked immunosorbent assay for the measurement of SKALP levels in serum 
Sera were collected before start of the treatment and during the course of treatment 
at weeks 2, 4, 8, 12, 16, 20 and 24. In three patients a serum sample was collected after 
discontinuation of the therapy. Samples were stored at -4°C until required. SKALP 
concentrations were measured using a sandwich-type ELISA. Briefly, samples were mixed to 
contain 10% sample, 0.1 M Tris, 0.1% Tween-20 and 1% bovine serum albumin (BSA). 
Microtitre plates (96 flat-bottomed wells) were coated overnight with goat anti-SKALP 
serum. After washing with phosphate-buffered saline (PBS)/0.05% Tween-20, the 
microtitre plates were blocked and probed with the test samples. Subsequently, rabbit anti-
SKALP serum with 2.5% normal goat serum (Vector) was added and developed for 60 min 
with peroxidase-conjugated swine antirabbit immunoglobulin (SWARP0; Dakopatts) with 
2.5% normal goat serum using o-phenylenediamine dihydrochloride (0PD) as chromogem'c 
substrate for 15 min. Human recombinant SKALP in PBS with 0.1% BSA was used as a 
standard: a calibration curve was made, using recombinant SKALP/elafin in the range of 
0.5 - 120 ng/ml. The SKALP concentrations in sera were read from this curve. All ELISA 
steps were performed at 37°C. Data were read with a Biorad ELISA reader and evaluated 
using the Excel spreadsheet program. 
Statistical analysis 
Data are reported as mean ± SEM. For statistical analysis, the Mann-Whitney ranking 
test for unpaired data and the Wilcoxon ranking test for paired data were used; a p-value s 
0.05 was taken to be statistically significant. We tested the homogeneity of correlation 





















υ α ι_υ —-
i l ! UJ -С 
(5 QJ 
"° ε χ ν 









































CU i n 
il ¡I 

































































го го fu π] 
e c c e 
о о о о 








с ΐ с 
b= <v b= 
JO D ffl 






















































c û чО с о — 
= Ι — Ι Λ СО 
Σ с о x¿ чо 
га -о 
Г^ (Λ - к -M 
чО С ¡О £« 
^ 2 tu (U 
äs i 
2 M 
E -£ с LU cu 
ГО -Q rt 
±d ε 
-О O -Q 
. Ω u _Q 




















































E .S га -*-» 
3 « 




Ten patients were treated with liarozole and 10 patients with acitretin. In both 
treatment groups, 3 patients discontinued the treatment before the full 24 weeks for the 
following reasons: (i) acitretin-treated group: insufficient response n=2; inappropriate use 
of medication n=l; (ii)liarozole-treated group: insufficient response n=2; withdrawal n=l. 
The last-mentioned patient in the liarozole-treated group was treated for less than 12 
weeks. The clinical response is summarized in Table I I . After 12 weeks of treatment, a 
statistically significant improvement (p s 0.05) in PASI score could be observed in both 
treatment groups. After 24 weeks in the acitretin-treated group a significant further 
decrease in PASI score was achieved, this in contrast to the liarozole-treated group. The 
individual scores for erythema, induration and desquamation decreased significantly in 
both patient groups during the first 12 weeks of treatment; however, this did not continue 
during extension of the treatment to 24 weeks. The area score showed only a minimal 
decrease in both groups during the first 12 weeks, with a significant decrease during the 
following 12 weeks of treatment only in the acitretin-treated group. After 12 weeks of 
treatment, 2 patients in each group showed an increase of PASI score compared with the 
baseline PASI (non-responders); after 24 weeks one non-responder was observed in the 
liarozole-treated group. 
Immunohistological results 
Before the start of therapy and after 12 weeks of treatment, skin biopsies were 
collected. Only 1 patient treated with liarozole did not complete 12 weeks of treatment. 
All patients, as well as the non-responders, are included in the immunohistological 
evaluations. 
Inflammation 
Small to moderate numbers of elastase-positive cells, representing polymophonuclear 
leukocytes (PMN), were found in the epidermis and dermis of all but 1 patient before 
treatment (Table HI). After both treatments, a decrease in elastase-positive cells was 
seen. Only 3 patients showed a sporadic epidermal staining (2 acitretin-treated, 1 
liarozole-treated), and sporadic elastase-positive cells in the dermis were seen in 13 
patients (6 acitretin-treated, 7 liarozole-treated). 
Epidermal proliferation 
Epidermal proliferation, as assessed by the presence of Ki-67, a nuclear antigen present 
in cycling cells,[16,17] is demonstrated in Table I I I . A statistically significant decrease in 
the number of Кі-67-positive nuclei was observed in both acitretin- and liarozole-treated 
groups. However, the values did not reach the levels of the in uninvolved skin. 
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Table III. Immunohistochemical scores (mean ± SEM) for epidermal inflammation, proliferation and 
differentiation of involved skin before and after 12 weeks of treatment with acitretin or liarozole and of 













2 + 0.3 
2 + 0.1 
304 ± 22.2 
3.0 ± 0.3 
55 + 3.9 




0.18 + 0.1 
0.72 + 0.2 
121 + 19.7 
0.7 ± 0.4 
35 ± 4.9 





42 + 4.5 
0 
20+ 10.4 
26 + 7.9 
weekO 
(n=9) 
2.4 + 0.3 
2.3 + 0.2 
301 +28.7 
2.8 + 0.3 
56 ± 3.2 
90 ± 1.9 
liarozole 
• week 12 
(n=9) 
0.2 ± 0.2 
0.7 ± 0.2 
86 + 27.4 
0.5 ± 0.4 
38 + 8.2 




0.2 + 0.2 
21 ± 1.9 
0 
23 ± 2.0 
19 + 2.1 
Epidermal differentiation 
Staining with the Ks8.12 antibody was used for detection of keratin 16, which is a 
hyperproliferation-associated cytokeratin that is not normally present in the suprabasal 
layers.[18] Table I I I shows that, in both treatment groups, a significant reduction of 
keratin 16 expression was found in the lesionai skin. 
Transglutaminase type 1 is normally restricted to the granular layer, but is expressed 
throughout the spinous layers in lesionai skin.[19,20] A significant reduction in 
transglutaminase expression was found in both groups. However, no downregulation to 
levels of uninvolved skin was noticed. 
SKALP is a member of the Trappin multigene family that we have recently 
described.[21] SKALP, also known as elafin, is a proteinase inhibitor absent in normal skin 
but highly expressed in lesionai psoriatic skin (Fig. la ) . SKALP is known to be 
downregulated rapidly during therapeutic regression of lesion skin by corticosteroid or 
cyclosporin A.[12,22] After 12 weeks of treatment with acitretin and liarozole, a 
significant decrease in SKALP expression was seen (Figs la and 2a,b). However, in 8 
patients in the acitretin-treated group and in 5 patients in the liarozole-treated group, a 
substantial expression of SKALP was still visible. A remarkable finding was the induction of 
SKALP expression in uninvolved skin of all 5 patients treated with liarozole and in 3 
patients treated with acitretin. Although expression was minimal and only present focally 
in the stratum granulosum (Fig. 2c, d), it was conspicuous because we have never found 
the expression of SKALP in normal human skin in previous studies.[23] 
E-FABP is a lipid binding protein that has been shown to be overexpressed in 
lesionai psoriatic epidermis.[24] In contrast to SKALP, E-FABP was previously found not to 
be downregulated in lesionai skin after therapeutic regression induced by 
corticosteroid.[12] In the present study, E-FABP staining was prominent in all suprabasal 
layers of the epidermis in all patients before treatment (Fig. l b ) . After treatment for 12 
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Figure la. Epidermal expression of 
SKALP after 12 weeks treatment with 
acitretm (black bars) or harozole (white 
bars). The values in uninvolved skin are 
after treatment with acitretin or liarozole 
for at least 4 months. The error bars 
represent the SEM. 
Figure I b. Epidermal expression E-FABP 
after 12 weeks treatment with acitretin 
(black bars) or liarozole (white bars). 
The values in uninvolved skin are after 
treatment with acitretin or liarozole for 
at least 4 months. The error bars repre-





week 0 week 12 uninvolved 
skin 
week 0 week I 2 uninvolved 
skin 
Figure 2a. Immunohistochemical staining 
of SKALP in untreated psoriatic skin. 
Almost the complete suprabasal com­
partment is stained. 
Figure 2b. After I 2 weeks treatment 
with liarozole. SKALP is not expressed. 
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Figure 2c. The SKALP expression in 
uninvolved skin after treatment with aci-
tretin. Focal spots of SKALP expression 
can be seen in the stratum granulosum 
after treatment (arrows). 
ι 1 
Figure 2d. The SKALP expression in 
uninvolved skin after treatment with lia-
rozole. Focal spots of SKALP expression 
can be seen in the stratum granulosum 
after treatment (arrows). 
Figure 3a. Immunohistochemical staining 
of E-FABP in untreated psoriatic skin. 
The complete suprabasal compartment 
is stained, the basal layer being comple­
tely negative. 
.•·'_ 
Figure 3b. After I 2 weeks treatment 
with liarozole, E-FABP did not return to 
the normal pattern. E-FABP is still 
expressed in the complete suprabasal 
compartment, despite a clear histological 
improvement. In normal skin, E-FABP 
expression is confined to the granular 
layer and the first layers of the stratum 
spinosum. 
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Figure 3c. In uninvolved skin, several 
layers of the stratum spmosum are 
stained after acitretin treatment. 
*S3&£-
^&^kk^ 
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Figure 3d. In uninvolved skin, the 
complete suprabasal layer is stained after 
liarozole treatment. 
weeks, only 4 patients in each treatment group showed a slight reduction in E-FABP 
expression, which was still increased compared to uninvolved skin (Figs lb and 3a,b). 
Remarkably, in the uninvolved skin of patients treated with liarozole and acitretin, the 
expression pattern is different compared to the pattern found in the skin of healthy 
individuals. Normally, E-FABP expression is confined to the granular Layer and the first 
layer of the stratum spinosum,[24] whereas in the uninvolved skin of the acitretin- or 
liarozole-treated patients, E-FABP expression was found in several layers of the stratum 
spinosum (Fig. 3c). In two patients, all suprabasal layers were found positive (Fig. 3d). 
No significant difference between liarozole and acitretin treatment was found. 
Keratin 4 is a fetal keratin absent in normal adult skin. Its induction in some 
individuals has been described after treatment with topical retinoids and systemic 
treatment with liarozole of patients with different forms of ichthyosis.[7,25] Keratin 4 was 
not expressed before the start of the treatment. Neither acitretin nor liarozole induced 
expression of keratin 4 in our patient groups during the treatment of psoriasis. 
SKALP levels in serum 
We have shown previously that serum levels of SKALP can be used as a quantitative 
marker for disease activity in severe psoriasis during treatment with cyclosporin A.[22] 
Here, we used a specific sandwich-type ELISA to measure SKALP. Sera were collected before 
start of the treatment and after a treatment period of 2, 4, 8, 12, 16, 20 and 24 weeks. 
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Figure 4. SKALP levels in serum measured by ELISA (A.) and clinical scores assessed by PASI ( · ) during 
treatment with acitretin (a-c) or liarozole (d-f). From each treatment group, data from 3 representative 
patients are shown. SKALP levels correlate with PASI score; a pooled r of 0.74 was found. 
Only patients who completed the full treatment period of 24 weeks (n=7 in both groups) 
were included in the evaluation. In the acitretin-treated group, 1 patient was excluded 
because the collection of samples was very incomplete. The SKALP levels and PASI score of 
3 representative patients from each group are shown in Fig. 4 (a-c during treatment with 
acitretin, d-f during treatment with liarozole). SKALP levels before start of the treatment 
varied from 15-300 ng/ml, with the highest levels in patients with the highest PASI score. 
During treatment with both acitretin and liarozole, SKALP levels decreased in parallel with 
the PASI score. However, the values did not fall to the levels found in healthy control 
subjects. In the non-responding patient of the liarozole-treated group (Fig 4d), the level 
of SKALP was not decreased compared with the baseline value. The relation between PASI 
and SKALP levels was tested for the homogeneity of correlation coefficients [15]. As this 
assumption was not rejected, a pooled r of 0.74 was found. In four patients, follow-up 
visits were performed after discontinuation of treatment (Fig. 4a, b, d, f ) . An increases or 




A number of mechanistically different antipsoriatic treatments are available that 
sometimes have different kinetics with respect to clinical parameters, have different side-
effect profiles and often have differential effects on cell biological parameters in the skin. 
Topical therapy with corticosteroids has a rapid effect on all aspects of epidermal 
growth/differentiation and inflammation.[26] This is in contrast to treatment with vitamin 
D3 derivatives, which have prominent effects on epidermal growth/differentiation and 
epidermal PMN accumulation, but a minimal effect on T-cell accumulation.[27,28] 
Dithranol is a selective treatment with major effects on epidermal proliferation and 
differentiation and only minimal effects on inflammation markers.[29,30] Cyclosporin A 
induces a rapid clearance of the lesions and normalizes epidermal differentiation, as 
witnessed by a concomitant decrease in serum SKALP levels.[22] Treatment with systemic 
retinoids induces clinical improvement but has a side effect profile that is not found with 
other antipsoriatic treatments. In this study, we have investigated the cell biological 
changes in lesionai and uninvolved skin of psoriasis patients treated with acitretin or 
liarozole, a new antipsoriatic drug. Liarozole exerts retinoid-like effects as shown in in 
vitro studies,[9] studies in experimental animals[l,2] and the side effect profile in a 
previous clinical study.[4] The clinical findings of this study indicate that liarozole is an 
effective antipsoriatic agent. However, further details will be given in a report on the 
complete multi-center trial (manuscript in preparation). 
The main question that we addressed here was to what extent the epidermal and 
serological markers for disease activity were affected by liarozole and acitretin treatment. 
During both treatments, the markers for inflammation (elastase-positive cells), 
proliferation (Кі-67-positive nuclei), normal differentiation (transglutaminase)[31,32] and 
disturbed differentiation (cytokeratin 16, SKALP)[18,23] decreased significantly after a 
treatment period of 12 weeks compared with baseline levels. However, the levels of 
expression as seen in uninvolved skin were not achieved for all markers. From this study 
and from a previous study describing the effect of a mild potency corticosteroid on 
different immunohistological markers[12], i t is clear that the response of the different 
markers to treatment varies widely. Cytokeratin 16 shows a rapid downregulation, even 
before clinical improvement. The Ki-67 positive nuclei, transglutaminase, elastase and 
SKALP seem to coincide with the clinical resolution of the lesion. E-FABP is a slow marker, 
which remains markedly increased, even after substantial clinical improvement. Therefore, 
although the mechanism of action differs fundamentally, acitretin and liarozole revealed a 
similar response pattern, as evaluated by a broad spectrum of markers. In this study, we 
demonstrated that serum levels of SKALP correlate with clinical severity of disease as 
measured by PASI score. However, the kinetics of the decrease of SKALP levels is much 
slower than that found with cyclosporin A treatment.[22] 
A strong argument for a similar biological effect of acitretin and liarozole on human 
epidermis was found in the data on the uninvolved skin of treated patients. A remarkable 
finding was the expression of SKALP in biopsies of uninvolved skin after treatment with 
liarozole (5 out of 5), or acitretin (2 out of 4). This staining was very subtle, and i t was 
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restricted to areas in the granular layer. Whether this is an entirely retinoid-specific 
phenomenon is not yet clear. However, treatment of normal skin with a potent 
corticosteroid (class IV) for 2 days does not induce SKALP expression (unpublished data). 
Furthermore, the expression of E-FABP in uninvolved skin was increased after both 
acitretin and liarozole treatment. Normally, E-FABP is restricted to the granular layer and 
the upper layer of the stratum spinosum. In a model in which the barrier function is 
disturbed by application of sodium dodecyl sulphate, E-FABP was strongly upregulated 
within 24 h, with a peak on day 7.[13] I t is speculated that increased E-FABP expression 
reflects an increased lipid traffic, which appears to be associated with abnormal 
keratinocyte differentiation. [24] In contrast to E-FABP and SKALP, the expression of 
transglutaminase was restricted to the granular layer, which is the normal pattern.[20] 
Cytokeratin 4 is found suprabasally in stratifying, non-cornifying epithelia. The 
induction of cytokeratin 4, combined with induction of cytokeratin 13 and 19, is assumed to 
be a marker for retinoid effect.[8] The induction of cytokeratin 4 in reconstructed epidermis 
by all-irons RA and acitretin has been reported in vitro.[8] Lucker et at.[7]reported an 
induction of cytokeratin 4 in several ichthyosis patients treated with liarozole. However, in 
the present study on a different patient group, cytokeratin 4 was not induced by acitretin or 
liarozole. Therefore, the expression of cytokeratin 4 cannot be regarded as a side effect that 
is necessarily associated with a substantial clinical effect in psoriasis. 
In summary, although the mode of action of liarozole and acitretin is different, we 
conclude that liarozole is an effective antipsoriatic agent. Liarozole modulates cell 
biological parameters in lesionai and uninvolved skin in a manner that is indistinguishable 
from acitretin. 
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PART 
THE ROLE OF SKALP IN THE 
PATHOGENESIS OF PUSTULAR 
PSORIASIS 
Introduction 
Pustular psoriasis is characterized by a massive influx of PMN in the epidermis, 
resulting in the formation of macroscopic pustules. As discussed in the introduction, the 
aetiology of pustular psoriasis is unknown. In a pilot study we found free elastase activity 
in scale extracts of patients with pustular psoriasis, indicating saturation of all available 
anti-proteinases. Furthermore, the levels of SKALP were decreased in pustular psoriasis 
compared to scale extracts of plaque psoriasis. We addressed the following question: What 
is the role of the proteinase-SKALP equilibrium in the pathogenesis of pustular psoriasis? 
In this part of the thesis the appearance of SKALP is studied in different 
manifestations of pustular psoriasis. In chapter 7 the SKALP expression levels in vivo in 
scale extracts and in biopsies from patients with chronic plaque psoriasis and pustular 
psoriasis are studied on both the protein and mRNA level. Chapter 8 presents the SSCP 
analysis of exon 1 and 2 of the SKALP gene of plaque and pustular psoriasis patients, 
studying the presence of a genetic abnormality in the SKALP gene. In chapter 9 the in 
vitro expression levels of keratinocytes of plaque and pustular psoriasis patients are 
studied. Furthermore, the susceptibility of SKALP for degradation or oxidative inactivation 
is described. A comparison is made with levels of SLPI, another locally produced 
proteinase inhibitor. In chapter 10 a patient with impetigo herpetiformis is described, of 
whom serial measurements of SKALP in serum and scale extracts were performed. In 
chapter 11 we describe the topographic relation between SKALP and HLE in the different 
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Skin-derived antileukoproteinase (SKALP, also known as elafin) is an inducible 
epidermal serine proteinase inhibitor, that we have recently characterized at the protein 
and DNA levels. SKALP is a strong and specific inhibitor of PMN elastase, and is putatively 
involved in the regulation of cutaneous inflammatory processes. In order to investigate 
the role of SKALP in the control of elastase in psoriatic epidermis, we compared SKALP 
expression in normal skin, and in skin from patients with chronic plaque psoriasis and 
pustular forms of psoriasis. Epidermal scales and biopsies were collected and SKALP 
expression was studied at the mRNA level and at the protein level both functionally and 
immunochemically. In epidermal scales, we found that the levels of both free and total 
SKALP activity in pustular psoriasis were far lower than in plaque psoriasis. A significant 
number of pustular psoriasis patients showed latent SKALP activity, which represents the 
amount of SKALP putatively complexed to elastase. In addition, we found free elastase 
activity in 25% of the pustular psoriasis patients, indicating a total saturation of 
epidermal SKALP activity. In epidermal biopsies from pustular psoriasis patients, SKALP 
activity was significantly decreased compared with those from plaque psoriasis patients. 
Northern blot analysis did not reveal differences in epidermal mRNA levels between chronic 
plaque psoriasis and pustular psoriasis. We hypothesize that a reduced amount of 
epidermal SKALP contributes to an imbalance between elastase and its inhibitor, thereby 
promoting the formation of epidermal pustules. We suggest that these findings could 
provide a rationale for the treatment of pustular psoriasis with inhibitors of PMN-derived 
proteinases, as a new therapeutic modality. 
Introduction I 
Several cutaneous manifestations of psoriasis are known.[1] Erythematosquamous 
lesions can vary in size from pinpoint to large plaques or even erythroderma. Psoriatic 
lesions can also be present as pustules rather than the more usual plaques. These lesions 
may be localized (persistent pustulosis palmoplantaris) or generalized (generalized 
pustular psoriasis). The aetiology of psoriasis (or its subforms) is unknown. Both a defect 
in the growth control mechanisms of keratinocytes [2], and an underlying (auto)immune 
process have been implicated.[3] Recently, alterations in cytokine production and 
responsiveness to cytokines have been described which may be causally related to the 
disease process. [4] 
One of the main features of psoriatic lesions is the presence of polymorphonuclear 
leukocytes (PMN) in the epidermis, either scattered or in the form of micropustules or 
microabscesses. In pustular forms of psoriasis an extreme local infiltration of PMN occurs. 
Although it is unlikely that PMN infiltration is a primary event related to the aetiology of 
the disease, the formation of spongiform pustules resulting from PMN infiltration is 
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considered a disease-specific process. Activated PMN induce tissue damage, and perpetuate 
the inflammatory response by the secretion of proteinases (e.g. elastase), reactive oxygen 
metabolites, and prostanoids. We have shown in previous studies that most antipson'atic 
agents interfere in vivo with Leukotriene B¿-induced PMN infiltration in human skin, 
suggesting that this might be one of the antipsoriatic mechanisms of corticosteroids, 
dithranol, retinoids and methotrexate.[5] 
Recently we have described a new, inducible, keratinocyte-derived serine proteinase 
inhibitor found in psoriatic skin but absent in normal skin.[6-8] The inhibitor, termed 
skin-derived antileukoproteinase (SKALP), has been shown to be a potent inhibitor of 
human leukocyte elastase (HLE). HLE is a PMN-derived neutral proteinase implicated in 
PMN migration and tissue destruction in many conditions including lung emphysema [9], 
arthritis [10], glomerulonephritis [11] and bullous dermatoses.[12,13] We have 
characterized SKALP, which is also known as elafin [14,15] or ESI [16], at the biochemical 
level [7], and have shown its presence in urine and serum of psoriatic patients.[17,18] 
Furthermore, we have located its expression in differentiated epidermal keratinocytes.[8] 
The SKALP cDNA and gene have been cloned [19,20] and we have been able to assign the 
chromosomal localization of the SKALP gene to chromosome 20q.[21] The gene has been 
given the approved name of protease inhibitor, skin derived (SKALP), symbol PI3, in the 
Genome Data Base of the HUGO nomenclature committee. 
Although the induction of SKALP in inflammatory dermatoses (e.g. psoriasis) and its 
substrate specificity suggest that SKALP is involved in the regulation of cutaneous elastase 
activity, no data so far exist to support this presumed role. We reasoned that under 
conditions of excessive elastase secretion, SKALP should be present in a complexed form 
with elastase. In extreme cases, when all available SKALP is consumed, one would expect 
free elastase activity. We therefore investigated the amounts of free and latent SKALP in 
scales and biopsies from patients with chronic plaque psoriasis or pustular psoriasis. To 
study local differences in one individual, biopsies were taken from lesionai skin with 
pustules and without pustules. Different methods were used for studying SKALP levels 
including functional measurement, immunochemical techniques, immunohistochemical 
staining and Northern blot analysis. We indeed found that in the majority of the patients 
with pustular forms of psoriasis, SKALP was decreased at the protein level. The mechanism 
of pustule formation, and the therapeutic implications of these findings are discussed. 
« a Materials and methods 
Patients 
Scales were collected from 16 patients with chronic plaque psoriasis and 19 patients 
with pustular psoriasis, either localized or generalized (acrodermatitis continua of 
Hallopeau, n=l ; pustulosis palmoplantaris, n=13; generalized pustular psoriasis von 
Zumbusch type, n=2; nongeneralized pustular psoriasis, n=3). All patients had active 
disease. Keratome biopsies (thickness 0.4 mm, area 1 cm2) for RNA and protein isolation 
were taken from 6 healthy controls from the skin of the back and from clinically involved 
118 
skin of 6 patients with plaque psoriasis. Two keratome biopsies were taken from six patients 
with pustular psoriasis (acrodermatitis continua of Hallopeau, n=l ; pustulosis 
palmoplantaris, n=3; erythroderma with pustule formation, n=2), one from a skin region 
with macroscopic pustules and one from a region without pustules. Punch biopsies (4 mm) 
for histology were taken from a patient with annular pustular psoriasis and from a patient 
with generalized pustular psoriasis. Before the biopsies were taken, permission of the 
medical ethical committee and written informed consent from the patients were obtained. 
Prior to analysis, scales and keratome biopsies were stored at -20°C and -80°C, respectively. 
Punch biopsies were fixed in buffered 4% formalin for at least 24 h and processed for 
routine histology. Tissue was embedded in paraffin and 5-pm sections were cut. 
Preparation of the antisera 
An antiserum against recombinant SKALP (a kind gift of Dr N. Russell, ICI 
Pharmaceuticals, UK) was obtained as described previously.[8] An antiserum against a 
synthetic peptide comprising amino acid 23 to 36 of preSKALP (Eurosequence, Groningen, 
The Netherlands) was prepared. This peptide was coupled via a C-terminal cystein residue 
to chicken ovalbumin (Sigma, St Louis, Mo., USA), using the sulfo-SMCC procedure (Pierce, 
Rockford, III., USA). This preparation was used for immunization of a rabbit according to 
previously described protocols.[7] Preimmune serum was drawn as a control. 
Preparation of scale extracts 
Scales were processed for determination of SKALP activity as described previously.[6] 
In brief, scales were weighed and then homogenized (100 mg/mt) in a glass-glass grinder 
in phosphate buffered saline (PBS) and centrifuged (15 min, 12000 g). The clear 
supernatant was divided into two equal portions. One portion was boiled for 2 min to 
inactivate elastase and to liberate the elastase-bound inhibitor and then again centrifuged 
(15 min, 12000 g). Colorimetrie quantification of the protein concentration was performed 
using the Bio-Rad DC Protein Assay according to the recommendations of the supplier (Bio-
Rad Laboratories, Richmond, Calif., USA). 
Protein and RNA extraction 
From the keratome biopsies RNA and protein were simultaneously isolated using Tri 
Reagent (MRC, Cincinnati, Ohio, USA), according to the manufacturer's guidelines. In brief, 
samples were homogenized in 1 ml Tri Reagent and separated with chloroform in an aqueous 
phase, an interphase and a phenol-chloroform phase. RNA was precipitated in the aqueous 
phase with 0.5 ml isopropanol, washed with 75% ethanol and subsequently after air drying 
dissolved in NSE buffer (50 mM NaAc, 0.2% SDS, 2 mM EDTA). Samples were stored after 
adding 100% ethanol at -80°C until further study. After precipitation of DNA with 100% 
ethanol, proteins were precipitated from the phenol ethanol supernatant with isopropanol. 
The protein pellet was washed three times in 0.3 M guanidine hydrochloride in 95% ethanol 
and once with 100% ethanol. After vacuum drying, the protein pellet was dissolved in PBS 
and stored at 4°C. Colorimetrie quantification of the protein concentration was performed 
using the Bio-Rad DC Protein Assay. 
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Functional measurement of SKALP activity in scales and biopsies 
Because of the complex situation of both free elastase and elastase complexée! with 
inhibitor, we used a protocol, previously described for the measurement of anti-elastase 
activity in urine [17] based on the differential heat stability of elastase and SKALP. 
Elastase is denatured by boiling the scale extract for 2 min, whereas SKALP is heat stable. 
The bound elastase inhibitor (latent SKALP) is released from the enzyme-inhibitor 
complex. In all scale extracts we measured the free SKALP activity in untreated samples 
and the total (latent plus free) SKALP activity in heat-inactivated samples. In protein 
solutions of biopsies only total SKALP activity could be measured because of the 
denaturing isolation procedure. 
Serial dilutions were made from the samples in assay buffer (1 M NaCl, 0.4% СТАВ, 
0.1 M Tris pH 8.5). Elastase activity was measured as the release of the fluorogenic 
substrate methoxy-succinyl-alanyl-alanyl-prolyl-valyl-amino-4-methylcoumarin (MAAPV-
AMC, Sigma, St Louis, Mo., USA) as described previously.[11] Fluorescence was measured at 
375 nm (excitation) and 440 nm (emission) in a Perkin-Elmer LS-5 fluorimeter. 
SKALP activity was measured as the percentage inhibition of a standard amount of 
elastase using the same assay. An extract of 500 PMN in assay buffer (equivalent to 
approximately 1 ng HLE) to a total volume of 10 μΐ was mixed with 10 μΐ serial-dilutions of 
scale extract and then incubated for 15 min at 37°C. Elastase substrate solution (20 μ I, 250 
mM) was then added and the reaction was allowed to proceed for 15 min at 37°C. The 
incubation was terminated by the addition of 1 ml stop buffer (100 mM Na2C03, pH 10.5). 
Inhibition of elastase activity in this assay was calculated as the percentage inhibition of 
the activity of 500 PMN, within the linear range of the assay. Recombinant SKALP (a kind gift 
from Dr. N. Russell, ICI Pharmaceuticals, UK) was used to obtain a calibration curve from 
which the SKALP concentration in the scale extracts was read. After correction for protein 
concentration, SKALP activity was expressed as nanograms SKALP per milligram protein. 
Enzyme-linked immunosorbent assay for measurement of SKALP levels 
SKALP concentrations were measured in scale and biopsy extracts, using a 
competitive-type ELISA, as described previously.[18] Scale extracts were boiled and 
supernatants were taken for quantification of SKALP. Biopsy isolates were measured directly. 
In brief, the following mixture was prepared to contain 80% sample, 0.1 M Tris, 0.1% 
Tween-20, 1% BSA, and rabbit antiserum against recombinant SKALP (1:9500 diluted), and 
incubated overnight. Microtitre plates (96 flat bottom wells) were coated overnight with 50 
ng/ml recombinant SKALP in PBS. After washing of the plate with PBS/0.05% Tween-20, 
microtitre plates were blocked, probed with the test samples, and developed for 60 min 
with peroxidase-conjugated swine-anti-rabbit Ig using o-phenylenediamine dihydrochloride 
(0PD) as chromogenic substrate for 15 min. Human recombinant SKALP in PBS with 0.1% 
BSA was used as a standard: a calibration curve was prepared using recombinant SKALP in 
the range of 2.9-36 ng/ml. The SKALP concentrations in scales or biopsy samples were read 
from this curve. All ELISA steps were performed at 4°C, except development with 0PD which 
was done at room temperature. The results were read with a Biorad ELISA reader, and 
evaluated using the Excel spreadsheet program. After correction for protein concentration, 
SKALP activity was expressed in nanogram SKALP per milligram protein. 
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Northern blot analysis 
For Northern blot analysis, 10 pg of total RNA was electrophoresed on a 1.4% 
agarose gel following standard procedures.[22] In brief: 10 pg total RNA was dissolved in 
3 μΐ RNAse-free water (prepared using a Milli-Q ultrafiltration apparatus, Millipore), and 
then 2 μΐ 0.1 M sodium phosphate (pH 7.0), 10 μΐ dimethyl sulfoxide (DMSO) and 4.5 μΐ 6 
M glyoxal was added. The mixture was incubated for 60 min at 50°C. After cooling the RNA 
samples to 0°C, 3.5 μΐ glyoxal/DMSO gel-loading buffer was added and the mixture 
immediately loaded into the wells of the gel. The gel was poured and run in 10 mM sodium 
phosphate. The buffer was recirculated to maintain the pH within acceptable limits. The 
gel was then blotted by capillary transfer on a nylon membrane (Boehringer, Mannheim, 
Germany). After transfer, RNA was fixed to the membrane by ultraviolet irradiation (312 
nm, 0.2 J/cmJ). Hybridization was performed as previously described, using a 0.42 kbp 
PvuII/EcoRI fragment of the SKALP cDNA clone pGESKA as a probe.[19] Control 
hybridizations for equal loading were performed using a human 28S ribosomal RNA probe. 
The probe was labelled with 32P by random priming, following standard procedures. 
Autoradiography was done using an X-Omat S film (Kodak, France) at -80°C with an 
intensifying screen. 
Histology and immunohistochemistry 
Paraffin sections were deparaffinized, rehydrated and immunostaining was performed 
according to a previously described method.[8] First, the sections were preincubated with 
normal swine serum and incubated with antiserum against recombinant SKALP at a dilution 
of 1:100. Detection of SKALP with an antiserum raised against a synthetic peptide gave an 
essentially similar localization pattern (not shown). After incubation with peroxidase-
conjugated swine anti rabbit Ig (Dako, Glostrup, Denmark), the sections were developed 
with aminoethylcarbazole as the chromogenic substrate. Preimmune serum from the 
immunized rabbit was used as a control. 
Statistics 
For statistical evaluation the Mann-Whitney test was used for unpaired samples and 
the Wilcoxon Signed Ranks' test for paired samples. 
Results 
SKALP in scale extracts 
In all samples we measured the free SKALP activity in untreated samples and the 
total (latent plus free) SKALP activity in heat-inactivated samples using a functional assay. 
The values in the scales of patients with pustular psoriasis (n=19) and patients with 
chronic plaque psoriasis (n=16) are presented in Fig. 1. A remarkable finding was that 
SKALP activity was significantly lower in the pustular psoriasis group than in the plaque 
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Figure I. SKALP concentration in 
scale extracts from patients with 
chronic plaque psoriasis (n= I 6) 
and pustular psoriasis ( n= l9 ) . 
SKALP was determined using a 
functional assay after heat mactiva-
tion, i.e. boiling for 2 min to inacti-
vate elastase and to liberate the 
elastase-bound inhibitor (black 
bars) and directly (gray bars). The 
white bars represent SKALP con-
centration as measured using an 
ELISA. SKALP levels were signifi-
cantly lower in the pustular pso-
riasis group than in the plaque 
psoriasis group. This was found 
with functional measurements as 
well as wi th ELISA (p< 0.01. 
Mann-Whitney test). Heat macti-
vation resulted in a significant 
increase in SKALP concentration 
in the pustular psoriasis patients 
(p< 0.03, Wilcoxon Signed Ranks' 
test for paired samples). Bars: 
means ± SE. 
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plaque pustular 
psoriasis group (p< 0.01, Mann-Whitney test). This was found both for total SKALP and for 
free SKALP. Heat inactivation of the scale extracts revealed latent SKALP activity in a 
considerable number of patients in the pustular psoriasis group, while in the plaque 
psoriasis group no latent SKALP was found. In contrast, SKALP activity was higher after 
direct measurement of the scale extracts than after heat inactivation. 
In some patients SKALP activity was undetectable; in these patients free elastase 
activity was measurable. In the pustular psoriasis group this was found in 5 patients out of 
19 (elastase activity equivalent to 41 ± 29 χ IO3 PMN per mg scales), and in the plaque 
psoriasis group only one patient was found with a small amount of free elastase (6000 PMN 
per mg scales). Remarkably, in both patients with generalized pustular psoriasis of the von 
Zumbusch type, free elastase activity was found. In all б patients with free elastase activity, 
latent SKALP activity could be recovered after heat inactivation of elastase (not shown). 
SKALP levels as measured using the ELISA in the supernatant of boiled scale extracts 
were the same as those obtained using the functional assay. The SKALP concentration was 
significantly lower in patients with pustular psoriasis than in those with plaque psoriasis 
(p < 0.01, Mann-Whitney test). The SKALP levels measured using the ELISA were within the 
same range as those found with the functional assay, indicating that the anti-elastase 
activity found was indeed largely due to SKALP. 
SKALP in skin biopsies 
Biopsies were taken from 6 healthy volunteers and from involved skin of 6 patients 
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Figure 2. SKALP concentration m 
epidermal biopsies from healthy 
controls (n = 6). patients wi th 
chronic plaque psoriasis (n=6) 
and patients with pustular psona-
sis (n=6). From the last group 2 
biopsies per patient were taken: 
one from a region with macrosco­
pic pustules (pustular +) and one 
from a region without pustules 
(pustular -). SKALP was measured 
using a functional assay (black 
bars) and an ELISA (white bars). 
SKALP activity as measured using 
the functional assay was signifi­
cantly lower in the pustular + 
biopsies than in plaque psoriasis 
biopsies (p< 0.01, Mann-Whitney 
test). Bars: means ± SE. 
Figure 3. Northern blot of SKALP 
mRNA in skin biopsies of patients 
with chronic plaque psoriasis and 
pustular psonasis (lower panel). In 
normal skin no expression of 
SKALP could be demonstrated 
(lanes I and 2), whereas skin from 
plaque psoriasis patients showed 
strong expression (lanes 3 and 4). 
Paired biopsies in 3 patients with 
pustular psonasis from regions 
with macroscopic pustules and 
without pustules are shown (lanes 
5 and 6. 7 and 8. 9 and 10. 
respectively). Compared with pla­
que psoriasis skin, SKALP mRNA 
is equally expressed in both 
regions. The upper panel shows 
control hybridizations using a 
human 28S nbosomal RNA probe 
to check for equal RNA loading. 
from a region with pustules and one from an involved region without pustules to check for 
local differences in the same individual. These biopsies were processed for simultaneous 
extraction of both the protein and RNA. The denaturating isolation procedure led to the 
measurement of total SKALP in all protein-fractions. SKALP activity as obtained from 
functional measurements of anti-elastase activity is shown in Fig. 2. In normal skin no 
SKALP activity was found, whereas in psoriatic skin high levels were found. SKALP activity 
in biopsies from the pustular region of pustular psoriasis patients was significantly 
decreased compared with the activity in plaque psoriasis (p < 0.01, Mann-Whitney test). 
The ELISA showed lower SKALP levels in both the pustular region and the involved skin 
without pustules of pustular psoriasis patients than in plaque psoriasis patients, but the 
difference did not reach significance. 
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Northern blot analysis 
Fig. 3 shows the presence of SKALP mRNA in the biopsies from normal skin, lesionai 
skin from chronic plaque psoriasis patients and lesionai skin from pustular psoriasis 
patients. In plaque psoriatic skin a strong expression of SKALP mRNA was found (lanes 3 
and 4), whereas the normal skin showed no expression (lanes 1 and 2). In paired biopsies 
from 3 patients with pustular psoriasis (lanes 5 and 6, 7 and 8, 9 and 10, respectively) 
similar levels of SKALP mRNA expression were found as in psoriatic skin. The expression in 
pustular regions (lanes 5, 7 and 9) did not differ from the areas without macroscopic 
pustules (lanes 6, 8 and 10). 
Histology and immunohistochemistry 
We have previously reported that normal human skin and nonlesional psoriatic skin 
are negative for SKALP. Lesionai skin of chronic plaque psoriasis shows cytoplasmic 
staining of the upper layers of the suprabasal compartment.[8] Here we performed 
immunohistochemical staining for SKALP in lesions of pustular psoriasis patients and 
compared the expression patterns with those obtained from psoriasis lesions. The SKALP 
expression pattern was similar in pustular and plaque psoriasis, i.e. basal cells were 
negative and there was positive staining in the upper suprabasal layers. In the epidermis 
near pustules, SKALP expression was clearly, but variably, affected by the presence of large 
amounts of PMN. Figure 4a shows that several layers of SKALP-positive cells were present 
in the intact epidermis underlying a subcorneal pustule. No damage to the epidermis was 
evident. Figure 4b shows a pustule where the upper layers of the epidermis were 
destroyed; here, only a few SKALP-positive cells were present with low levels of expression. 
Figure 4a. Expression of SKALP in a 
pustular area of psoriatic skin, with an 
increased number of SKALP-positive 
cells present in the intact epidermis 
underlying a subcorneal pustule. 
Figure 4b. A pustular area of psoriatic 
skin, with destruction of the upper layers 
of the epidermis (arrow). Note the 
absence of SKALP-positive cells in the 




One of the putative functions of PMN elastase is to facilitate migration through 
connective tissue and basal membranes, towards inflammatory foci. Speculatively, SKALP 
would counteract this process since it is synthesized in the upper epidermis and provides a 
gradient of anti-elastase activity from epidermis to dermis. In support of this concept, we 
and others have indeed recently shown that SKALP can be found in the urine [17,23] and 
serum [18] of psoriatic patients. In our view, the induction of SKALP in human epidermis is 
a negative feedback on cutaneous inflammation, to control PMN migration and protect 
against proteolysis of structural proteins. 
In human skin at least three different high-affinity elastase inhibitors can be 
present simultaneously, either free or complexed: alpha-1-antitrypsin (alpha-1-AT), 
secretory leukocyte protease inhibitor (SLPI) and SKALP. From previous studies we know 
that SLPI activity in scales is low compared to SKALP, and disturbance by alpha-1-AT 
activity is eliminated in the assay by the presence of cetyltrimethylammoniumbromide 
(СТАВ). We therefore assume that most anti-elastase activity measured in our assay 
represents SKALP activity. Furthermore, we are dealing in the epidermis with a complex 
situation. In psoriatic scales both free elastase and elastase complexed with inhibitor was 
found, and direct quantification of the total amount of biologically active SKALP was not 
possible. Therefore, we used a protocol, previously described in the measurement of anti-
elastase activity in urine [17], which is based on the differential heat stability of elastase 
and SKALP. 
In this study we examined the amounts of SKALP in scales and biopsies of psoriatic 
patients, either of the plaque type or pustular type of psoriasis. Most striking was the 
finding that in scale extracts the levels of free and total SKALP were considerably lower in 
pustular psoriasis than in plaque psoriasis; this was highly significant in all subtypes of 
pustular psoriasis, despite the large variation in SKALP presence in each group. 
Furthermore, an unexpected finding was that SKALP activity after boiling of the scale 
extracts was lower than after direct measurement. We have previously studied [17] the 
effect of boiling on the elastase activity. Boiling for 1-2 min gives an optimal recovery of 
anti-elastase activity. Prolonged boiling causes denaturation of SKALP. This could be a 
fraction of SKALP, which is already in a partly denatured state. Therefore, a possible 
explanation for this observation is that a certain amount of SKALP is denatured by boiling 
the scale extracts. Alternatively, i t could be due to the presence of small amounts of other 
heat-Labile proteinase inhibitors. 
In biopsies from pustular psoriasis patients from a region with pustules, SKALP levels 
as measured using the functional assay were significantly decreased compared with plaque 
psoriasis. This discrepancy is not related to differences in the body region, since in both 
scales and biopsies from patients with generalized pustular psoriasis (obtained from trunk 
and extremities) and in samples from pustulosis palmoplantaris patients (all obtained from 
the palms) low amounts of free and total SKALP were found. In scales from 5 patients with 
pustular psoriasis no free SKALP activity could be measured. In these cases free elastase 
activity was found, indicating that all available SKALP was saturated with elastase. Latent 
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SKALP in these scales was liberated by heat inactivation of the scale extracts. This 
phenomenon has been found previously in urine of patients with severe erythrodermic 
psoriasis.[17] Apart from these 5 patients in whom all SKALP activity was in a latent form, 
we found that a considerable number of the pustular psoriasis patients had SKALP partially 
in a latent form. These findings support the notion that SKALP has a biological function in 
vivo to control elastase activity. Interestingly, i t has recently been reported by others [24] 
that free elastase activity can be extracted from lesionai psoriatic skin by a non-invasive 
method, suggesting that in the stratum corneum of plaque type psoriasis a local imbalance 
of elastase and inhibitor might also exist. 
From our results we clearly can not conclude whether the appearance of pustules is a 
consequence of saturation of epidermal SKALP with elastase, or vice versa. We would 
hypothesize that in psoriatic skin (or under inflammatory conditions in general) SKALP 
activity in the epidermis attenuates accumulation of PMN in the epidermis. In the case of 
a large, continuous PMN influx with subsequent secretion of elastase, SKALP is consumed 
by complex formation with elastase. Whether SKALP-elastase complexes are cleared by 
endocytosis as described for other proteinase inhibitors [25], is not known. However, this 
could explain the low amounts of SKALP in pustular psoriasis patients. Gene expression of 
SKALP as visualized by Northern blot analysis demonstrated similar amounts of mRNA in 
pustular and plaque psoriasis, and in both a transcript length of approximately 0.8 kb was 
found. These findings make i t less likely that the observed low SKALP levels have a genetic 
base, although this possibility cannot be totally dismissed. 
The role of SKALP in the mechanism of pustule formation is unclear. Speculatively, 
SKALP consumption could lead to local SKALP deficiencies which allow the formation of 
pustules of Kogoj or microabscesses of Munro as seen in psoriasis vulgaris. In extreme 
cases, macroscopic pustules arise as seen in pustular forms of psoriasis. Three basic 
findings in patients with pustular psoriasis support this concept: (1) the presence of latent 
(complexed) SKALP in scale extracts (2) the presence of free elastase in 25% of the 
patients, and (3) low levels of SKALP in pustular psoriasis. 
The fact that in the pustular psoriasis group not all patients showed significant 
amounts of latent SKALP activity in the scale extracts could be explained by the 
methodology. We used scales obtained from the entire surface of the trunk or the hand. 
Since pustule formation is a localised phenomenon, the information we obtain in our 
measurements is an average in which the information concerning the local situation of a 
pustule is 'diluted'. Furthermore, we showed with immunohistology that SKALP expression 
can vary between individual patients. 
Irrespective of the mechanism for SKALP deficiency, which could have a genetic base 
or be an extracellular mechanisms, i t is clear that i t would lead to excessive proteolysis of 
structural epidermal proteins. The data from the present study provide evidence that 
control of elastase activity is a pathogenic factor in pustular forms of psoriasis. We would 
hypothesize that the use of (preferably topical) low molecular weight drugs with anti-
elastase activity could be a new therapeutic modality in pustular forms of psoriasis. 
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Psoriasis is a multifactorial skin disease characterized by epidermal abnormalities 
and infiltration by lymphocytes and polymorphonuclear leukocytes (PMN). Skin-derived 
antileukoproteinase (SKALP), also known as elafin, is a potent inhibitor of human 
leukocyte elastase and proteinase 3, two PMN-derived proteinases implicated in tissue 
destruction and leukocyte migration. We have shown that, at least at the protein level, 
SKALP is significantly decreased in lesionai skin of patients with pustular psoriasis 
compared with plaque-type psoriasis. This finding raised the possibility that SKALP could 
be one of the candidate genes for pustular forms of psoriasis. We therefore performed 
single strand conformation polymorphism (SSCP) analysis on the SKALP gene to screen for 
mutations/polymorphisms in the exons of 30 patients with plaque-type psoriasis, 15 
patients with pustular psoriasis and 48 healthy controls. In exon 1 a polymorphism was 
detected at position +43 relative to the translation start site, resulting in a substitution of 
threonine for alanine in the signal peptide. In the promoter region a dinucleotide repeat 
polymorphism was identified. Both polymorphisms were not associated with pustular 
psoriasis, or psoriasis in general. Our data indicate that the decrease in SKALP activity in 
pustular psoriasis is not caused by mutations in the coding region of the gene, and that 
there is no allelic association between pustular psoriasis and SKALP gene polymorphisms. 
Introduction 
Psoriasis is a polygenic, chronic inflammatory skin disease of unknown aetiology. An 
underlying autoimmune process or a defect in keratinocyte growth control mechanisms has 
been implicated in the pathogenesis of this disease.[l,2] A genetic base for psoriasis is 
likely as indicated by family and .twin studies.[3] In a study of 61 monozygotic twins a 
concordance of 73% has been reported, indicating a major genetic component in 
psoriasis.[4] Recently, several groups have started genome-wide searches for genes 
conferring susceptibility to psoriasis.[5-8] Loci on chromosomes 2 [7], 4 [8], 8 [7], 17 
[5], 20 [7] and within the MHC cluster on chromosome 6p21 [7] were found to be linked 
with psoriasis of the chronic plaque type. Psoriasis pustulosa palmoplantaris is associated 
with and increased frequency of HLA B8 [9] and HLA DR9.[10] So far, no mutations or 
polymorphisms in individual genes have been found that are linked to plaque psoriasis or 
pustular psoriasis. 
Histologically, psoriasis is characterized by a disturbed epidermal proliferation and 
differentiation. In the psoriatic lesion a dense dermal infiltrate is present, composed of 
lymphocytes and polymorphonuclear leukocytes (PMN). PMN can also invade in the 
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epidermis, to form microabcesses of Munro or spongiform micropustules of Kogoj. A 
subform of psoriasis is pustular psoriasis, which can present itself as a localized form 
(psoriasis pustulosis palmoplantaris, acrodermatitis continua of Hallopeau) or a 
generalized form (generalized pustular psoriasis of von Zumbusch). The main characteristic 
of these conditions is the presence of macroscopic pustules, which are the result of an 
extreme epidermal infiltration of PMN. The pathogenetic events leading to the formation of 
macropustules in these diseases are unknown. Both an increase of epidermal chemotactic 
factors [11,12] and an increased chemotactic response of the PMN [13] have been 
implicated as a factor contributing to the massive PMN influx. 
PMN-derived neutral proteinases such as elastase, proteinase 3 and cathepsin G are 
important inflammatory mediators that have been implicated in tissue damage and PMN 
migration. The action of elastase and proteinase 3 is controlled by systemic proteinase 
inhibitors like alpha-1-proteinase inhibitor and by locally produced proteinase inhibitors like 
skin-derived antileukoproteinase (SKALP) [14], also known as elafin.[15] SKALP is a member 
of the Trappin gene family that we have recently described.[16] In normal epidermis SKALP 
is absent but i t is induced under inflammatory conditions.[14,17] We have recently shown in 
vitro that SKALP is a major inhibitor involved in the protection of the epidermis against 
PMN-dependent proteolysis.[18] Because of the pronounced presence of PMN in the 
epidermis of patients with pustular forms of psoriasis, we hypothesized that deregulation of 
epidermal anti-protease activity could contribute to PMN Chemotaxis and tissue destruction. 
We have recently shown that, at least at the protein level, SKALP is significantly decreased 
in lesionai skin of pustular psoriasis compared to plaque-type psoriasis.[19] These findings 
raised the possibility that SKALP could be one of the candidate genes for pustular forms of 
psoriasis. We therefore performed single strand conformation polymorphism (SSCP) analysis 
to screen for mutations/polymorphisms in the exons 1 and 2 of the SKALP gene of 30 
patients with plaque-type psoriasis, 15 patients with pustular psoriasis and 48 healthy 
controls. Here we report a polymorphism in exon 1, which results in an amino acid 
substitution. However, this polymorphism was equally distributed in the patient and in the 
control population. Similarly, we found a polymorphic CA-repeat in the promoter region 
which was not associated with pustular psoriasis, or psoriasis in general. 
Materials and methods 
Patients 
Five ml blood samples in ethylene diamine tetra-acetic acid (EDTA) coated containers 
were collected from 30 patients with chronic plaque psoriasis and 15 patients with a 
pustular form of psoriasis, either localized or generalized (pustulosis palmoplantaris n=12, 
acrodermatitis continua of Hallopeau n=l , generalized pustular psoriasis von Zumbusch 
type n-1, non-generalized pustular psoriasis n=l). All patients had active disease. 
Furthermore, blood samples were obtained from a three-generation family and from 48 
healthy controls, the latter via the transfusion department. Prior to analysis, blood samples 
were stored at -80°C. 
132 
Polymerase chain reaction (PCR) amplification 
Genomic DNA was isolated from peripheral blood lymphocytes by standard methods 
[20] and used as a template for amplification of exons 1 and 2 of the SKALP gene, coding 
for the primary translation product. When the 5'-non-coding region of the SKALP gene was 
sequenced a dinucleotide repeat in the promoter region of the gene was noted, which was 
polymorphic. For amplification of the regions of interest, oligonucleotide primers (Table I) 
were synthesized on the basis of intronic sequences and the nuclotide sequence of the 
flanking regions of the dinucleotide repeat (Isogen Bioscience, Maarssen, the Netherlands). 
Amplifications were performed in a total volume of 25 pi containing 200 ng genomic DNA, 
5-10 mM MgCl2, 50 mM KCl, 10 mM Tris, pH 8.3, 0.2 mM of each dNTP, 10 pM of each 
primer and 0.5 U Taq DNA polymerase. The PCR cycling profile for all PCR reactions was as 
follows: preheating to 95°C for 5 min, followed by 35 cycles of 94°C for 30 sec, annealing 
temperature for 1 min (Table I), 72°C for 2 min. The PCR was ended with a final extension 
at 72°C for 10 min. All PCR reactions were carried out in a Peltier-Thermal cycler (MJ 
Research, MA, USA). 
Non-radioactive single strand conformation polymorphism (SSCP) analysis 
Conformation polymorphisms were visualised by SSCP analysis.[21,22] For 
denaturation of the DNA, 3.5 μΐ of the PCR product was mixed with 7 μΐ of 50 mM NaOH 
and 1 mM EDTA, heated at 94°C for 5 min and subsequently placed on ice. Five μΐ of this 
mixture was loaded in 8 μ I wide slots on a CleanGel Polyacrylamide gel (Cleangel 10%, 
Pharmacia Biotech, Uppsala, Sweden), which was rehydrated in 112 mM Tris-acetate, pH 
6.4 with 0.006% bromophenol blue. Electrophoresis was carried out for each PCR product 
at two different temperatures (4 and 20°C) at 10 W for 20 min, and 20 W for 60 min in 0.2 
M Tris 0.2 M Tricine 0.55% (w/v) SDS, pH 8.3. Silver staining was performed according to 
the manufacturer's guidelines: After fixation of the gel for 30 min in 10% acetic acid 
solution, the gel was washed 3 times in demineralized water. Subsequently, staining with 
0.1% AgN03 with 0.037% formaldehyde was performed during 30 min followed by washing 
with demineralised water and development of the gel using 2,5% Na2C03 with 0.037% 
formaldehyde and 0.002% sodium thiosulphate. Development was stopped with 2% glycine 
0.5% EDTA-disodium solution and gels were impregnated with 5% glycerol. 
Cloning and DNA sequence analysis 
In exon 1 and in the promoter region variations in the mobility patterns in SSCP 
analysis were seen, which were further analyzed by DNA cloning and sequencing. PCR 
reactions were performed in 8-fold, pooled and treated with proteinase K. Subsequently, 
products were ligated into the pGEM T-vector (Promega, Madison, USA) according to the 
manufacturer's protocol and the clones were sequenced by the dideoxy chain termination 
method.[23] 
Radioactive PCR fragment length analysis 
The sizes of the PCR fragments comprising the dinucleotide repeat in the promoter 
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region were further analyzed on an 8% denaturing Polyacrylamide gel by comparison with 
a sequencing ladder, which was generated using the dideoxy chain termination 
method.[23] For visualising the PCR products, radioactive szpdCTP was added to the PCR 
reaction. For denaturation of the DNA, the samples were heated for 3 min at 94°C. 
Subsequently, 3.5 pi of the samples was loaded on an 8% denaturing Polyacrylamide gel 
and electrophoresed at 60 W during 2 h and developed overnight by autoradiography at 
-80°C. 
Statistical analysis 
Allele frequencies in patient and control groups were compared using a X2-test. 
ι Results 
SSCP and DNA sequence analysis of exons 1 and 2 of the SKALP gene 
The human SKALP gene contains 3 exons and 2 introns.[24] The first exon includes 
the 5'-non-coding region and the signal sequence as well as the first 4 amino acids of the 
transglutaminase substrate domain of the mature protein. The second exon encodes the 
rest of the transglutaminase substrate motifs, the proteinase inhibiting domain and 
contains the first nucleotide of the З'-non-coding region. The rest of this region, including 
the polyadenylation signal constitutes the third exon. 
SSCP analysis using primer pair 1 revealed sequence variation in exon 1 (Fig. l a ) , 
which suggested that 2 alleles were present with an estimated frequency of the minor 
allele of 0.095 in the control population. The allele frequencies in the plaque-type and 
pustular psoriasis group were both 0.12 and were not significantly different from the 
control group. One plaque psoriasis patient was homozygous for the minor allele. From this 
patient and from a patient who was homozygous for the other allele, the PCR product was 
cloned and sequenced. The obtained sequence was compared with published nucleotide 
sequences of the human SKALP gene and cDNA.[25-27] At position +43 from the 
translation start site a adenosine to guanosine transition was found. This mutation results 
in an amino acid substitution of threonine for alanine in the region coding for the signal 
peptide. In the SSCP analysis of PCR products from exon 2, using primer pairs 2 and 3, no 
altered migration patterns were detected. 
A dinucleotide repeat polymorphism in the 5'-upstream region 
When we sequenced the flanking region of the human SKALP gene, we noted a 
dinucleotide repeat in the 5'-upstream region of the gene at position -909 from the 
translation start site. The form of the repeat is ТСТ(СА)4А(СА)7СТ(СА)1гССС. PCR reactions on 
genomic DNA of 48 unrelated individuals using primer pair 4 (Table I ) , showed this repeat 
to be polymorphic. The sizes of the alleles were determined with radioactive PCR fragment 
analysis revealing a 156 bp PCR product and a 160 bp product. The estimated allele 
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Table I. PCR primers and conditions for PCR amplification of SKALP. 
a, numbers in parentheses are the 5' base position from the translation start site 
b. pnmer sequences are wntten 5' to 3'. 
primers* 
ΕΧΟΝ I 
Fori (pos.-46 to-25) 
Revi (pos.+103 to+84) 
ΕΧΟΝ 2 
For2(pos. +897 to+917) 
Rev2(pos.+1 181 t o + l 163) 
For3 (pos.+1049 t o + 1068) 
Rev3 (pos.+1236 to+1217) 
REPEAT PROMOTER 
For4 (pos. -989 to -968) 
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Figure I. Non-radioactive SSCP analysis 
of exon I (a) and the dinucleotide 
repeat in the 5' upstream region (b) of 
the SKALP gene, (a) Exon I. Different 
migration patterns were seen. Further 
analysis revealed an A • G 
polymorphism at position +43 from the 
transcnption start site. Lane I, 
homozygous A, lane 2 homozygous G, 
lane 3 the heterozygous pattern, (b) 
Dinucleotide repeat in 5'-upstream 
region. Different migration patterns 
were seen. Further analysis revealed two 
additional CA-repeats. Lane I 
homozygous for the allele with 6 CA-
repeats, lane 2 the heterozygous pattern 
showing 2 extra bands, lane 3 the single 
patient showing an aberrant pattern. 
Arrows mark the different allelic bands. 
frequencies are 0.135 for the 160 bp allele and 0.865 for the 156 bp in the control group. 
Mendelian inheritance was observed in one healthy three-generation family. In the plaque 
psoriasis patient group the allele frequency of the minor allele was 0.12 and in the pustular 
psoriasis patient group 0.07, which both were not significantly different from the control 
group. There was one homozygous patient for the 160 bp allele, who had a plaque-type 
psoriasis. From this patient and a control person who was homozygous for the 156 bp allele 
the PCR products were cloned and sequenced. The 160 bp allele contained two additional 
CA repeats, resulting in a sequence as follows: TCT(CA)4A(CA)9CT(CA)12CCC (Fig. 2a). 
Subsequently, SSCP analysis of PCR products from primer pair 4 was performed, which 
revealed different migration patterns. Two patterns could be contributed to the 
polymorphism in the repeat and were in concordance with the results of radioactive PCR 
fragment analysis (Fig. l b ) . However, one aberrant pattern was only found in a single 
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Fiq2 Figure 2. Identification of the diffe-
rent alleles of the imperfect dinu-
cleotide repeat by sequencing. 
Autoradiographs of sequencing 
patterns of 2 patients with abnor-
mal shift patterns in the SSCP 
analysis of the dinucleotide repeat 
in the 5' upstream region of the 
SKALP gene (see Fig lb) , (a) 
Patient homozygous for the extra 
dinucleotide repeats. Two extra 
CA repeats were seen (b) 
Patient with an aberrant SSCP 
pattern. In the third CA repeat an 
adenosine to guanosine transition 
can be seen (compare with Fig. 
2a). 




patient with a plaque-type psoriasis (Fig. l b ) . From this patient the PCR product was 
cloned and sequenced. The sequence revealed an adenosine to guanosine transition in the 
third CA-repeat at position -871 from the translation start site (Fig. 2b). 
Discussion 
Previous studies revealed decreased protein levels of SKALP in skin extracts of 
pustular psoriasis patients compared to plaque psoriasis patients.[19] The same 
observation was made in a patient with impetigo herpetiformis, a pregnancy induced form 
of generalized pustular psoriasis.[28] These findings made SKALP a candidate gene for 
pustular forms of psoriasis, and we therefore investigated whether disease-associated 
sequence variation was present in functionally significant areas of the SKALP gene. In this 
study an SSCP survey of the SKALP gene in patients with plaque-type and pustular 
psoriasis is presented. In exon 1 a polymorphism was found which results in an amino acid 
substitution of threonine for alanine in the signal peptide encoding region. Because it 
implies the change of a relatively hydrophobic amino acid into a hydrophilic amino acid, 
this could result in a functional change. However, since there was no association between 
psoriatic patients and the minor allele, we conclude that the decrease in SKALP activity in 
pustular psoriasis is not caused by or related to this particular polymorphism. The analysis 
described herein was carried out under conditions designed for optimal detection of 
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mutation. Nonetheless, we cannot exclude the possibility that mutations have been 
missed, as the detection efficiency of SSCP analysis is approximately 90-95%. 
When the flanking sequences of the SKALP gene were analyzed we noted a 
dinucleotide repeat in the promoter region of the gene, which was polymorphic. No 
association was found between pustular psoriasis and these alleles. We have recently 
determined multiple mRNA transcription start sites of the SKALP gene, and we have 
mapped relevant promoter elements for transcription factor binding (manuscript in 
preparation). Previously, Zhang et al. sequenced the promoter region and identified several 
putative transcription factor binding sites.[29] The dinucleotide repeat is situated at 
position -909, and so far does not coincide with the detected regulatory elements. It is 
therefore unlikely that the mutation found in this repeat in one psoriatic patient 
(adenosine to guanosine), or the variation in the number of CA repeats will be of 
functional significance. 
In summary, the data presented here strongly suggest that the genetic predisposition 
to pustular psoriasis is not primarily determined by variation in the SKALP gene. 
Furthermore, i t is unlikely that the observed decrease of SKALP protein levels in the 
epidermis are based on mutations in the coding regions of the gene. However, because we 
did not perform SSCP analysis on exon 3, which encodes the З'-non-coding region, i t is 
still possible that polymorphisms exist in this region that could control translation 
efficiency. Our present results are in line with our previous finding that in vivo the 
transcript levels of SKALP are equal in pustular and plaque psoriasis patients.[19] 




1 Elder J Γ, Fisher GJ Lmdquist PB, et al Overexpression of transforming growth factor alpha η psoriatic epidermis 
Science 1989.243 811-4 
2 Baadsgaard O. Tong Ρ, Elde^JT, et al LIM4D4+ (CDw60) Τ cells are compartmentalized into psonatic skin and release 
lymphognes that induce a keratinocyte phenotype expressed in psonatic lesions J Invest Dermatol 1990, 95 275-82 
3 Lomhort G Psonasis, prevalence, spontaneous course and genetics In-Anonymous Copenhagen GEC GAD. 1963, 
4 Färber EM Nail ML Watson W Natural history of psonasis in 61 twin pairs Arch Dermatol 1974 109 207-1 I 
5 Tomfohrde J, Silverman A, Barnes R, et ai Gene for familial psonasis susceptibility mapped to the distal end of human 
chromosome 17q Science 1994 264 1141 -5 
6 Nair RP, Guo SW, Jenisch S, et al Scanning chromosome 17 for psonasis susceptibility lack of evidence for a distal 
17q locus HumHered 1995,45 219-30 
7 Trembath RC. Clough RL Rosbotham Jl_ et al Identification of a major susceptibilrty >ocus on chromosome 6P and 
evidence for further disease loci revealed by a two stage genome wide search in psonasis Hum Mol Genet 
1997,6 813-20 
8 Matthews D, Fry L, Powles A, et al Evidence that a locus for familial psonasis maps to chromosome 4q Nat Genet 
1996 14 231-3 
9 Ward JM Barnes RM HLA antigens in persistent palmoplantar pustulosis and its relationship to psonasis Br J 
Dermatol 1978.99 477-83 
10 Τόπι H, Nakagawa H Ishibashi Y et al Genetic polymorphisms in HLA-A, -B. -C and -DR antigens in Japanese 
patients with palmoplantar pustulosis Dermatology 1994 188 290-2 
I I Takematsu H, Terui Τ Ohkohch1 К et al Presence of chemotactic peptides other than C5a anaphylatoxin in scales of 
psonasis and stenle pustular dermatoses Acta Derm Venereol Stockh 1986 66 93-7 
12 Temowrtz Τ Monocyte and neutrophil Chemotaxis in psonasis Relation to tne clinical status and tne type of psonasis 
J Am Acad Dermatol 1986, 15 I 191 -9 
13 Lundin A, Hakansson L, Michaelsson G. et al Neutrophil locomotion and serum chemotactic and chemoknetic activities 
in pustulosis palmoplantans compan=d with psonasis Arch Dermatol Res 1987, 2/9 385-91 
14, Schalkwijk J. de Roo С. de Jongh GJ Skin-denved antileukoproteinase (SKALP) an elastase inhibitor from human 
keratinocytes Punfication and biochemical properties Biochim Biophys Acta 1991, 1096 148-54 
15 W i e d o w O , Schroder JM, Gregory Η etol Elafin an elastase-specific inhibitor of human skin Punfication, charactenzation, 
and complete amino acid sequence J Biol Chem 1990, 265 14791 -5 
16 Zeeuwen PLJM Hendnks W , de Jong W W et al Identification and sequence analysis of two new members of the 
SKALP/eafin and SPAI-2 gene family Biochemical properties of the transglutaminase substrate motif and suggestions 
f o r a new nomenclature J Bio' Chem 1997, 272 2047Ι-Θ 
17 Chang A, Schalkwijk J, Happle R et al Elastase-inhibiting activity in scaling skin disorders Acta Derm Venereol 1990, 
70 147-51 
18 Pfundt R, van Ruissen F van Vlijmen-Willems IMJj et al Constitutive and inducible expression of SKALP/elafin provides 
anti elastase defense in human eprthelia J Clin Invest 1996 98 1389-99 
19 Kuijpers ALA, Zeeuwen PLJM, de Jongh G, et al Skin derived antileukoproteinase (SKALP) is decreased in pustular 
forms of psonasis A clue to the pathogenesis of pustule formation' Arch Dermatol Res 1996, 288 641 7 
20 Miller SA Dykes DD Polesky HF A simple salting out procedure for extracting D N A from human nucleated cells 
Nucleic Acids Res 1988. 16 1215 
21 Onta M Iwahana H, Kanazawa H, et al Detection of polymorphisms of human DNA by gel electrophoresis as single-
strand conrarmat'on polymorphisms Proc Natl Acad Sci U S A 1989 86 2766-70 
22 Sheffield VC Beck JS, Kwitek AF. et al The sensitivity of single-strand conformation polymorphism analysis for the 
detection of single base substitutions Genomics 1993 16 325-32 
23 Sanger F Nicklen S, Coulson AR. D N A sequencing with chain-terminating inhibitors. Pnx Natl Acad Sci U S A 1977, 
74 5463-7 
24 Molhuizen HOF, Schalkwijk J Structural, biochemical, and cell biological aspects of the senne proteinase inhibitor 
SKALP/fclafm/ESI Biol Chem Hoppe-Seyler 1995. 376 1-7 
25 Saheki T, Ito F. Hagiwara H, et al Pnmary structure of the human elafin precursor preproelafin deduced from the 
nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegment Brachem Biophys 
Res Commun 1992 185 240-5 
26 Sallenave JM Silva A Charactenzation and gene sequence of the precursor of elafin, an elastase-specific inhibitor in 
bronchial secretions Am J RespirCell Moi Biol 1993. 8 439-45 
27 Molhuizen HOF, Alkemade JAC, Zeeuwen PLJM, et al SKALP/elafin an elastase inhibitor from cultured human 
keratinocytes Punfication. cDNA sequence, and evidence for transglutaminase cross-linking J Biol Chem 1993. 268 
12028-32 
138 
28 Kuipers ALA Schalkwijk J Rulo HFC et al Extremely low levels of epidermal skin derived antileukoproteinase/elafiπ 
in a patient with impetigo herpetiformis Br J Dermatol 1997 137 123 9 
29 Zhang M 7ou Ζ Maass N et al Differential expression of elafin in human normal mammary epithelial cells and 




DECREASED LEVELS OF EPIDERMAL SKIN-DERIVED 
ANTILEUKOPROTEINASE IN 
PUSTULAR FORMS OF PSORIASIS ARE CAUSED BY 
POST-TRANSLATIONAL MECHANISMS 
Astrid L.A. Kuijpers 
Michelle M. van Rossum 
Fred van Ruissen 
Mieke Bergers 
Pieter S. Hiemstra1 
Peter CM. van de Kerkhof 
Joost Schalkwijk 
Department of Dermatology, University Hospital Nijmegen and 
'Department of Pulmonology, Leiden University Hospital 




The proteinase inhibitor skin-derived antileukoproteinase (SKALP), also known as 
elafin, is absent in normal skin but highly expressed in plaque-type psoriatic epidermis. 
Because SKALP is a major inhibitor of PMN-derived elastase and proteinase 3 i t is 
speculatively involved in regulation of tissue damage and PMN migration. We have recently 
shown that SKALP protein levels are strongly decreased in lesionai epidermis of pustular 
psoriasis compared with plaque type psoriasis. Here we have investigated whether there is 
an intrinsic defect in SKALP gene expression of keratinocytes from pustular psoriasis 
patients, and we have addressed the possibility that SKALP is post-translationally 
inactivated by PMN-derived mediators, which are abundantly present in pustular epidermis. 
In addition, we have studied to what extent the reduction of SKALP levels is a specific 
phenomenon, by comparison with another epidermal proteinase inhibitor Secretory 
Leukocyte Proteinase Inhibitor (SLPI). Using Northern blot analysis and ELISA we found no 
significant differences in transcript size or expression levels of SKALP between cultured 
keratinocytes from patients with pustular or plaque type psoriasis. Recombinant SKALP was 
found to be extremely resistant to degradation or inactivation by PMN-derived mediators 
such as elastase, superoxide anion and hydrogen peroxyde. Hypochlorous acid was found to 
cause oxidation of SKALP and, at high concentrations, caused a decrease in functional 
activity. Remarkably, we found that the levels of SLPI, a homologous epidermal proteinase 
inhibitor, were not significantly different in the epidermis of pustular and plaque-type 
psoriasis. We conclude that low levels of SKALP in lesionai skin of pustular psoriasis 
patients appear to be specific for this inhibitor, cannot be explained by decreased 
synthesis or secretion, and are due to post-translational mechanisms. 
Introduction 
Psoriasis is characterized by epidermal hyperproLiferation, disturbed differentiation 
and infiltration with inflammatory cells, consisting of T-lymphocytes and 
polymorphonuclear leukocytes (PMN). A subform of psoriasis is pustular psoriasis, which 
can be localized (pustulosis palmoplantaris, acrodermatitis continua of Hallopeau) or 
generalized (Zumbusch type). In general, pustular forms of psoriasis are disabling due to 
the localisation of the lesions, and difficult to treat. The clinical hallmark of pustular 
psoriasis are the pustules, which are formed by a massive accumulation of PMN in or just 
below the stratum corneum. The mechanism resulting in the formation of a pustule is not 
clear. One hypothesis includes an increased response of PMN to a chemotactic trigger from 
patients with pustular psoriasis compared with plaque psoriasis.[l] Another possibility is 
the abundant presence of chemotactic factors in the upper part of the epidermis.[2] 
However, other studies could not confirm these data, finding equally increased levels of 
chemoattractant in plaque- and pustular psoriasis.[3] 
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The proteinase inhibitor SKALP [4], also known as elafin [5], is a member of the 
Trappin gene family that we have recently described.[6] It is absent in normal skin, but 
highly upregulated in psoriatic epidermis.[7,8] SKALP is an inhibitor of human leukocyte 
elastase (HLE) and proteinase 3, two neutral proteinases secreted by activated PMN.[9] 
HLE and proteinase 3 are implicated in PMN migration towards inflammatory foci and 
subsequent tissue damage.[10] We have recently shown in vitro that SKALP expression by 
epidermal keratinocytes protects against elastase-mediated loss of cell adhesion.[11] In a 
previous study we demonstrated a decrease of SKALP in scale extracts and biopsies of 
patients with pustular forms of psoriasis compared with plaque psoriasis.[12] Based on 
this finding, we proposed a new mechanism for pustule formation: local SKALP 
deficiencies, caused by an until now unknown mechanism, allow a facilitated migration of 
PMN and local tissue destruction, resulting in the formation of macroscopic pustules. The 
observed deficiency for SKALP could be based on a genetic defect or polymorphism leading 
to reduced levels of SKALP mRNA or protein. Alternatively, SKALP once secreted in the 
extracellular space could be inactivated by metabolites derived from activated PMN. 
Previous studies in other systems have shown that the proteinase-antiproteinase balance 
can be disturbed via oxidative inactivation of а г -proteinase inhibitor (a! -PI) and ct2 -
macroglobulin.[13] In this way PMN can penetrate an antiproteinase barrier, allowing 
released elastase to attack the surrounding tissue. 
Here we have compared induction and expression of SKALP by cultured keratinocytes 
from patients with plaque type and pustular psoriasis at the mRNA and protein level. 
Furthermore, we have studied the potential of PMN-derived mediators to inactivate 
recombinant SKALP. Finally, we have addressed the question whether the observed decrease 
of SKALP in pustular psoriasis is specific for this molecule. We therefore investigated the 
levels of secretory leukocyte proteinase inhibitor (SLPI), a homologous epidermal 
proteinase inhibitor [14], in plaque type and pustular psoriasis. Our results indicate that 
post-translational mechanisms are involved in the relative SKALP deficiency in pustular 
psoriasis. SKALP was found to be unusually resistant to inactivation by PMN-derived 
mediators, and was only partially inactivated by high levels of hypochlorous acid. 
Furthermore, the decrease of SKALP in pustular psoriasis appears to be specific for this 
inhibitor as no decrease of SLPI was noted. 
Patients and methods 
Biopsies for keratinocyte culture 
Biopsies (0.3 mm thickness) of uninvolved skin of the back from 9 patients with 
plaque psoriasis and 4 patients with pustular psoriasis (acrodermatitis continua of 
Hallopeau with localized pustular psoriasis n=l, pustulosis palmo-plantaris n=3) were 
taken with a keratome as described previously [4] and used for primary keratinocyte 
cultures. Before the biopsies were taken, permission of the medical ethical committee and 
written informed consent from the patients were obtained. 
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Keratinocyte primary cultures 
Human epidermal keratinocytes were initially cultured according to the Rheinwald-
Green system.[15] Primary cultures of keratinocytes were seeded on lethally irradiated 
(3000 rad, 3 min.) Swiss mouse 3T3 fibroblasts in DMEM/F12 (3:1) (v/v) (Flow 
Laboratories, Irine, UK) supplemented with 0.4 pg/ml hydrocortisone (Collaborative 
Research, Inc., Lexington, MA), isoproterenol (106 M) (Sigma Chemical, St. Louis, M0), 100 
U/ml penicillin plus 100 pg/ml streptomycin (Gibco, Breda, the Netherlands), 6% fetal calf 
serum (FCS) (Seralab, Nistelrode, the Netherlands), and 10 ng/ml recombinant mouse 
epidermal growth factor (EGF) (Sigma). Cells were grown at 37°C, 95% relative humidity, 
and 8% C02 in air. EDTA-treated, trypsinized and liquid nitrogen-stored keratinocytes from 
the primary culture were used in further experiments. 
First passage and induction of keratinocyte differentiation 
For the experiments the human keratinocytes were seeded at 105 cells in keratinocyte 
growth medium (KGM) in 60 mm culture dishes as described before.[16] KGM was 
composed of keratinocyte basal medium (KBM; Clonetics, San Diego, CA; 0.15 mM calcium) 
supplemented with ethanolamine (0.1 mM) (Sigma), bovine pituitary extract (ΒΡΕ; 0.4% 
vol/vol) (Clonetics), recombinant mouse epidermal growth factor (EGF; 10 ng/ml) (Sigma), 
insulin (5 pg/ml) (Sigma), hydrocortisone (0.5 pg/ml) (Collaborative Research, Inc.), 
penicillin (100 U/ml) (Gibco), and streptomycin (100 pg/ml) (Gibco). For induction of 
differentiation, at confluence the culture medium was switched either to KGM depleted of 
growth factors (EGF, ΒΡΕ, insulin and hydrocortisone) (KGM/-GF), to KGM containing high 
calcium (1.8 mM; KGM/Ca) or to KGM supplemented with 5% FCS (KGM/FCS). After 48 h, 
the cultures were harvested (for RNA extraction) and culture media were stored at -80°C 
until use (for ELISA). 
RNA-isolation and Northern blot analysis 
Cultured cells from which total RNA was to be isolated were lysed in 1 ml RNase-ALL 
(2.1 M Guanidine-thiocyanate (Research Organics Inc., Cleveland USA), 8.5 mM N-
lauroylsarcosine (Sigma, St. Louis, USA), 12.5 mM NaAc pH 5.2, 0.35% v/v ß-mercapto-
ethanol (Merck, Darmstadt, Germany) and 50% v/. Tris-saturated biophenol pH 8.0 
(Biosolve, Amsterdam, the Netherlands), after lysis 100 pi chloroform was added. The 
samples were centrifuged for 15 minutes (13000 rpm, 4°C), and the aqueous phase was 
precipitated with 500 pi isopropanol on ice for 45 minutes, and centrifuged at 4°C for 15 
minutes. The pellet was washed with 70% ethanol and dried at room temperature for 5 
minutes. This RNA pellet was resuspended in 150 μΐ NSE (50 mM NaAc, 0.2% SDS and 2 mM 
EDTA) and 562 pi 100% ethanol was added. For quantification 62 μΐ of this RNA suspension 
was pelleted, resuspended in 625 μι H20 and spectrophotometrically analyzed at 260/280 
nm. Equal quantities of this total RNA (10 μg) were loaded on a 1% agarose gel and 
electrophoretically separated in 10 mM sodium phosphate buffer. The pH of the 
electrophoresis buffer was kept within acceptable limits by constant circulation of the 
buffer. The gels were blotted on positively charged nylon membranes (Boehringer, 
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Mannheim, Germany) using 10 χ SSC (1.5 M NaCl, 0.15 M sodiumcitrate). After RNA 
transfer, membranes were washed in 2 χ SSC, and RNA was cross linked to the membrane 
using ultraviolet irradiation (312 nm, 0.2 J/cm2). The blots were (pre)hybridized overnight 
at 65°C. Probes were used against SKALP using a 0.42 kbp PvuII/fcoRI fragment of the 
SKALP cDNA clone pGESKA as a probe [17], and for normalization of the amount of RNA 
loaded on the gel a probe against the ribosomal protein human Acidic Ribosomal 
Phosphoprotein (hARP) was used.[18] Autoradiography was performed using Kodak X-0mat 
X-ray films and Kodak BiomaxMS X-ray films. Quantification of mRNA levels on Northern 
blots was performed with a Biorad GS-525 Phosphor imaging system. 
Enzyme-linked immunosorbent assay (ELISA) for measurement of SKALP in culture 
media 
SKALP concentrations were measured in culture media, using a sandwich-type ELISA 
as described previously.[19] Samples were mixed to contain: 5% culture medium, 0.1 M 
Tris, pH 7.3, 0.1% Tween-20, 1% bovine serum albumin (BSA). Human recombinant SKALP 
in PBS with 0.1% BSA was used as a standard: a calibration curve was made, using 
recombinant SKALP in the range of 0.5 - 120 ng/ml. The SKALP concentrations in culture 
media were read from this curve. The ELISA that was used in this study was specific for 
SKALP and does not recognize SLPI (not shown). 
Enzyme-linked immunosorbent assay (ELISA) for measurement of SLPI levels in scale 
extracts 
Scale extracts of scales of 16 patients with chronic plaque psoriasis and 19 patients 
with pustular psoriasis were prepared and protein concentration was determined as 
described previously.[12] SLPI concentrations were measured in scale extracts directly. In 
brief, samples were mixed to contain 10% scale extract, 0.1 M Tris, pH 7.3, 0.1% Tween-
20, 1% BSA. Microtiter plates (96 flat bottom wells) were coated overnight at 4°C with 
monoclonal anti-SLPI. After washing of the plate with PBS/0.05% Tween-20, microtiter 
plates were blocked and probed with the test samples. Subsequently, rabbit anti-SLPI 
serum was added and developed during 60 min with peroxidase-conjugated swine-anti-
rabbit Ig using o-phenylenediamine di hydrochloride (0PD) as chromogenic substrate for 6 
min. Human recombinant SLPI in PBS with 0.1% BSA was used as a standard: a calibration 
curve was made, using recombinant SLPI in the range of 0.1 - 100 ng/ml. The SLPI 
concentrations in the scale extracts were read from this curve. After correction for protein 
concentration, SLPI activity was expressed in ng SLPI/mg protein. All ELISA steps were 
performed at 37°C. Data were read with a Biorad™ ELISA-reader, and evaluated using the 
Excel™ spread sheet program. The ELISA that was used in this study was specific for SLPI 
and does not recognize SKALP (not shown). 
Exposure of SKALP to PMN-derived mediators 
Recombinant SKALP was incubated at 37°C with various PMN-derived mediators: 
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human leukocyte elastase, hypochlorous acid (HOCl) (BDH Laboratory Supplies, Poole, 
England), hydrogen peroxide (H202) (E. Merck, Darmstadt, Germany) and superoxide anion 
(02-). HLE was purified from cells of a patient with chronic myeloid leukemia and 
calibrated as previously described.[4] SKALP (1 ng/μΐ) and HLE (1 ng/μΐ) were mixed in a 
ratio of 4:1, resulting in total inhibition of HLE. After incubation, samples for functional 
measurement were boiled for 2 min to liberate SKALP from the enzyme-inhibitor complex. 
Elastase is denatured by boiling for 2 min, whereas SKALP is heat-stable.[20] SKALP (2 
ng/μΐ) was incubated with HOCl in a range from 2 μΜ to 20 mM. Because functional 
inactivation of SKALP was seen at a concentration of 1 mM, an inhibition-curve was made 
with SKALP in a range from 0.05 - 20 ng/ml with and without the addition of 1 mM HOCl. 
H202 ranging from 2 μΜ to 20 mM was incubated with SKALP (2 ng/μΐ). Superoxide was 
generated by mixing a saturated hypoxantine solution 20 mg/ml (Sigma, St. Louis, M0, 
USA) with xantine-oxidase 1.5 mU/μΙ (Sigma, St. Louis, M0, USA) in a ratio of 30:1 and 
incubated with SKALP (2 ng/μΐ). Since in the hypoxantine/xantine-oxidase model both 
superoxide and H202 are produced, catalase (Sigma) was added in a concentration of 4U/pl. 
Because ferrichloride can facilitate the electron transfer [21], 1 mM FeCl3 was added. After 
0, 2, 4, 6, 8, 24, 48 and 72 hours of incubation, 2 samples were taken from the different 
mixtures and stored directly at -20°C until use. A functional assay and Western blot 
analysis were performed to investigate inactivation or degradation of SKALP. 
Functional measurement of anti-human leukocyte elastase activity 
Elastase activity was measured as the release of the fluorogenic substrate methoxy-
succinyl-alanyl-alanyl-prolyl-valyl-amino-4-methylcoumarin (MAAPV-AMC, Sigma, St Louis, 
M0, USA) as described before.[22] Anti-HLE activity was measured as the percentage 
inhibition of a standard amount of elastase using the same assay. Fluorescence was 
measured at 375 nm (excitation) and 440 nm (emission) in a Perkin-Elmer LS-5 fluorimeter. 
For all oxygen metabolites, a direct effect on HLE activity was excluded by incubating with 
HLE during 30 min at 37°C and subsequently measurement of remaining HLE activity. No 
inhibition of HLE by oxygen metabolites was found, which means that the inhibition of HLE 
can totally be contributed to SKALP. To exclude effects of the buffers, SKALP was incubated 
with CTAB-buffer (1 M NaCl, 0.4% СТАВ, 0.1 M Tris pH 8.5), PBS, BSA 1 ng/μΐ and BSA 10 
ng/μΐ during the same time period. No decrease in functional activity was found. 
Serial dilutions were made from the samples in СТАВ buffer. PMN were isolated from 
peripheral blood according to standard procedures involving dextrane sedimentation, 
separation on a Ficoll-paque gradient and hypotonic lysis. [23] Ten μ I containing an extract 
of 500 PMN in assay buffer (equivalent to approximately 1 ng HLE) was mixed with 10 μΐ 
of serial dilutions of scale extract and then incubated for 15 min at 37°C. Thereafter, 20 μΐ 
of 250 mM elastase substrate solution was added and the reaction was allowed to proceed 
for 15 min at 37°C. The incubation was terminated by the addition of 1 ml stop buffer 
(100 mM Na2C03, pH 10.5). Inhibition of elastase activity in this assay was calculated as 
the percentage inhibition of the activity of 500 PMN, within the linear range of the assay. 
Recombinant SKALP (a kind gift of Dr N. Russell, ICI Pharmaceuticals, UK) was used to 
obtain a calibration curve from which the anti-HLE concentration was read. 
147 
SDS-PAGE and Western blot analysis 
Samples were 1:1 diluted with non-reducing or reducing sample buffer (Laemmli) 
containing dithiothreitol and boiled for 2 min. Proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with the Pharmacia LKB Phast 
System and with the Biorad system (Biorad Laboratories, Hercules, CA, USA). For the 
Pharmacia LKB Phast System, Phast gel high density (Pharmacia Biotech AB, Uppsala, 
Sweden) and Phast gel SDS bufferstrips (Pharmacia Biotech AB) were used according to 
standard procedures with subsequent silverstaining.[24] For the Biorad system proteins 
were separated on a 16.5% gel (Ready gels, Bio-Rad) using Tris-tricine as electrophoresis 
buffer (20 mM Tris, 20 mM tricine, 0.02% SDS). Gels were electroblotted on 
polyvinylidenedifluoride (PVDF) membranes (MUlipore), and protein staining was performed 
with amido black according to standard procedures. 
Statistical analysis 
For statistical evaluation the Mann-Whitney test was used for unpaired samples. 
Results 
SKALP levels in cultured cells from plaque and pustular psoriasis 
Keratinocytes from 9 patients with plaque psoriasis and 4 patients with pustular 
psoriasis were cultured in KGM to form a confluent monolayer. At this stage, no 
differentiation is induced and SKALP is hardly expressed. Differentiation was induced either 
by growth factor depletion or by the addition of fetal calf serum. KGM depleted of growth 
factors (KGM/-GF) induces a differentiated phenotype, as assessed by type 1 
transglutaminase expression and resembles normal skin as witnessed by the expression of 
cytokeratin 1/10 and the absence of SKALP.[25] KGM with fetal calf serum (KGM/FCS) 
induces differentiation, as assessed by the expression of type 1 transglutaminase, with a 
psoriasiform phenotype such as sustained hyperproliferation and expression of SKALP. KGM 
containing high calcium (KGM/Ca) induces an intermediate phenotype, with a moderate 
expression of SKALP. After 48 h, the cultures were harvested. Total RNA was extracted and 
analyzed by Northern blot analysis. SKALP levels in the culture media were assessed with 
ELISA techniques. Fig. 1 shows the expression of SKALP in these culture systems at the 
mRNA level relative to the expression of a control gene (hARP). Fig. 2 shows the 
expression at the protein level as determined by ELISA. When keratinocytes were cultured 
in KGM/-GF, a condition that suppresses SKALP expression, cells from both pustular and 
plaque psoriasis produced low amounts of SKALP mRNA or lacked expression of mRNA (Fig. 
la ) . Although in vivo SKALP protein levels are lower in pustular psoriasis epidermis than in 
plaque psoriasis epidermis, no difference in SKALP mRNA and protein levels was found in 
keratinocytes cultured in KGM/FCS, which allows maximal SKALP expression (see Fig. lb 
and Fig. 2). No differences in transcript size were found between SKALP mRNA from plaque 
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Figure la, Ib. Human keratinocy­
tes of 9 plaque and 4 pustular 
psonasls patients were cultured in 
KGM to form a confluent mono­
layer. Subsequently, differentiation 
was induced either by growth fac­
tor depletion or by the addition of 
fetal calf serum. After 48 h the cul­
tures were harvested. Total RNA 
was extracted and Northern blot 
analysis performed. Lanes 1-9 
represent patients with plaque 
psoriasis, lanes 10-12 represent 
pustular psonasis patients. 
(a) keratinocytes cultured in 
KGM/-GF. Upper panel: In both 
pustular and plaque psoriasis low 
amounts of SKALP mRNA were 
produced or expression of mRNA 
lacked. 
(b) keratinocytes cultured in 
KGM/FCS. Upper panel: 
Comparable levels of SKALP 
mRNA were seen in keratinocytes 
from plaque and pustular psonasis 
patients. No difference in trans-
cnpt size was seen. 
Lower panels: a probe for hARP 
was used to check for equal RNA 
loading. 
Figure I с Quantif ication of the 
Northern blot signal for SKALP in condi­
tioned media of cultured human kerati­
nocytes of plaque (black bars) and 
pustular (white bars) psoriasis patients 
relative to the signal obtained by the 
reference probe for hARP expressed as 
mean values ± SEM. SKALP mRNA pro­
duction in pustular and plaque psonasis 
showed comparable levels of expression 
in the different culture systems. 
KGM/-GF KGM/Ca KGM/FCS 
KGM/-GF KGM/Ca KGM/FCS 
Figure 2. SKALP levels in culture media 
of cultured human keratinocytes of 
plaque (black bars) and pustular (white 
bars) psoriasis patients. Differentiation 
was induced either by growth factor 
depletion (KGM/-GF), by high calcium 
(KGM/Ca) or by the addition of fetal calf 
serum (KGM/FCS). After 48 h the cul­
tures were harvested and SKALP levels 
were measured using a sensitive ELISA. 
No significant difference in SKALP levels 
were seen between keratinocytes from 
plaque and pustular psoriasis patients 
cultured in the different media. 
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were found in the culture media in both groups, in all culture systems (Fig. 2). Taken 
together, these data show that keratinocytes from patients with pustular psoriasis are not 
intrinsically programmed to express low levels of SKALP. 
Effect of PMN-derived mediators on activity and degradation of SKALP 
As the decreased levels of SKALP in pustular psoriasis were not likely to be caused by 
diminished production we investigated the possibility that SKALP is degraded or 
inactivated after synthesis and secretion. In pustular psoriasis a massive amount of PMN-
derived mediators is present which can affect the integrity of proteins by oxidative and 
proteolytic mechanisms. The effect of the PMN-derived mediators (elastase, hydrogen 
peroxide, superoxide anion, hypochlorous acid) on activity and degradation of SKALP was 
assessed using a functional assay and SDS-PAGE. None of the oxygen metabolites had a 
direct effect on elastase-activity in the assay, so all remaining inhibiting activity could be 
contributed to SKALP. Preincubation of SKALP with HLE during a period up to 72 hours, did 
not change the inhibitory capacity of SKALP (not shown). Incubation with the reactive 
oxygen species H202 and 02- had no effect on functional activity of SKALP, even not at 
prolonged incubation at high concentrations. However, incubation with a high 
concentration (1 mM) of HOCl reduced the inhibitory activity of SKALP. An inhibition curve 
of native and oxidized SKALP with HLE revealed that the reduced activity of HOCl-treated 
SKALP was due to an increase of the K¡, as shown in Fig. 3. 
The effect of PMN-derived mediators on degradation of SKALP was studied, using 
SDS-PAGE. Incubation of recombinant SKALP with HLE (SKALP in excess) up to 90 h did not 
cause degradation of SKALP as seen on silver stained gels (Fig. 4a). HLE alone was 
completely degraded after 90 h due to autolysis. Incubation with H202 (Fig. 4b) and 
superoxide (not shown) did not cause degradation or altered mobility of SKALP on SDS-
PAGE. After incubation with HOCl, a dose-dependent decrease of silver staining intensity of 
the SKALP bands was observed (Fig. 4b). However, no degradation products were seen. 
Since silver staining relies on the presence of reducing groups in the protein [24], this 
result suggested that the decrease in staining was caused by oxidation of the protein 
rather than degradation or precipitation. To investigate this, the HOCl treated samples 
were also stained with amido black for total protein. This revealed bands of equal 
intensity, irrespective of the HOCl treatment (Fig. 4c). 
Levels of SLPI in scale extracts are not decreased in pustular psoriasis 
The finding that SKALP levels were very low in scale extracts of patients with 
pustular psoriasis compared to plaque psoriasis raised the question to what extent this 
phenomenon was specific for SKALP, or could also be demonstrated for other proteins. We 
therefore measured the concentrations of SLPI in scale extracts. SLPI is a proteinase 
inhibitor that is partially homologous to SKALP, and was shown to be present in- human 
epidermis.[14,26] SLPI was measured in scale extracts using an ELISA. Comparison was 
made with SKALP levels in the same scale extracts as reported previously.[12] The mean 
level of SLPI in scale extracts of the plaque psoriasis group was 90.7 ± 21.8 ng/mg 











Figure 3 Inhibition curve of a fixed 
amount of HLE and variable concentra­
tions of SKALP (ranging from 0 05 to 20 
ng/ml) (triangles) In the same way an 
inhibition curve was made of HLE with 
SKALP, which was incubated with I mM 
HOCI for 30 mm (dots) HLE was 
measured wi th a functional assay 
Incubation with HOCI decreases the 
inhibiting activrty of SKALP An apparent 
increase of the dissociation constant for 
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Figure 4 SDS-PAGE with subse­
quent silverstainmg demonstrating 
the effect of PMN-denved meta­
bolites on SKALP 
(a) incubation with HLE up to 90 
h did not degrade SKALP HLE 
alone was completely degraded 
after 90 h due to autolysis 
(b) Incubation with H 2 0 2 did not 
degrade SKALP After incubation 
with HOCI, the bands of SKALP 
stained less intense with incre­
asing concentrations HOCI No 
degradation products were seen 
(c) W i t h amidoblack staining 
bands of equal intensity are 
shown, irrespective of the HOCI 
treatment This indicates that the 
decrease in staining as shown in 
(b) was caused by oxidation of 
SKALP rather than degradation or 
precipitation 
ο ίο2 ίο3 ίο4 μΜ 
SKALP + HOCL 
SLPI levels was not statistically significant. These figures also indicate that in psoriatic 
scales SLPI levels are low compared to SKALP levels, as we reported previously [12], which 
establishes SKALP as the major source of anti-elastase activity in psoriatic skin. 
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Discussion 
Here we have investigated the mechanisms that could lead to the observed 
deficiency for SKALP protein in the epidermis of pustular psoriasis patients, that we 
demonstrated in earlier studies.[12,19] To examine whether keratinocytes of pustular 
psoriasis patients were programmed to produce or secrete decreased levels of SKALP, 
keratinocytes were cultured from non-lesional skin, assuming that genetically determined 
deficiencies would also be detected in these cells. To test the ability of keratinocytes 
derived from patients with pustular psoriasis to produce and secrete SKALP, we used 3 
different well-defined culture models.[25] In this culture models that allow low and high 
levels of SKALP expression no significant decrease of SKALP protein secretion or SKALP 
mRNA production was found in the cells derived from pustular psoriasis patients. In 
contrast to the in vivo situation, pustular keratinocytes in vitro can produce and secrete 
SKALP protein at the same rate as plaque psoriasis keratinocytes. From these in vitro 
results we concluded that the mechanism for SKALP deficiency in pustular psoriasis in vivo 
might be based on posttranslational and/or extracellular events. We showed previously 
that in vivo the levels of mRNA in plaque and pustular psoriasis are comparable.[12]. These 
results were in line with the finding that with in situ hybridisation an intense expression 
of mRNA was seen under the subcorneal pustule in localized pustular psoriasis.[27] 
Furthermore, we found no mutations in the coding region of the SKALP gene.[28] 
In respiratory epithelial cell cultures the effect of HLE on SLPI production has been 
extensively studied. HLE decreased SLPI at the protein level, whereas SLPI mRNA was 
upregulated.[29,30] Pustular psoriasis is characterized by an extreme epidermal infiltration 
of PMN, leading to high levels of HLE. Whether a similar kind of interaction between HLE 
and keratinocytes is occurring in pustular psoriasis, increasing SKALP mRNA and decreasing 
SKALP protein levels, remains to be investigated. 
Because in the epidermis of pustular psoriasis patients massive numbers of PMN are 
present, PMN-derived mediators were likely candidates to be involved in inactivation and 
degradation of SKALP. A plausible scenario could be that SKALP complexed with its target 
proteinases (elastase and proteinase 3) is subsequently clipped and released from the 
complex in an inactive form. However, previous studies have shown that SKALP is a fully 
reversible inhibitor, distinct from the serpins.[31] The present study shows that even 
prolonged incubation of SKALP with elastase does not lead to overt degradation of the 
inhibitor. We therefore conclude that proteolytic inactivation of SKALP does not 
significantly contribute to the observed deficiency. 
From studies on many other serine proteinase inhibitors i t is known that functional 
activity of the inhibitor can be destroyed by oxidative mechanisms. Extensive studies have 
been performed on oxidation of сц-proteinase inhibitor (a^PI), a plasma-derived 
antiproteinase, in the pathogenesis of lung emphysema [32,33], adult respiratory distress 
syndrome [34,35] and glomerulonephritis.[36] I t was shown that α Γ Ρ Ι can be inactivated 
partially by chlorinated oxidants, via oxidation of a critical methionine residue in the 
active site. Oxidation of physiologic concentrations of a^PI increases the half life of 
I 
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elastase from 0.64 ms to 1.3 s.[37] Furthermore, the ability of triggered neutrophils to 
fragment α,-ΡΙ has been described.[37] The susceptibility for oxidative inactivation of 
members of the serpin family of serine protease inhibitors is dependent on the presence of 
oxidatively susceptible amino acids like methionine closely to the reactive site. 
Plasminogen activator inhibitor-2 is a serpin that lacks a methionine in the reactive site 
and therefore is insensitive to oxidative inactivation.[38] SKALP, although not structurally 
related to the serpin family, has two methionine residues in the elastase inhibiting 
domain, that are potentially oxidation-sensitive. In the present study we investigated the 
effects of different oxygen metabolites and HLE on the inhibiting capacity and degradation 
of SKALP. Hydrogen peroxide is a potent oxidant and superoxide is an oxygen metabolite 
with mild oxidizing and reducing properties. None of these mediators had an effect on 
inhibitory activity or integrity of SKALP. The most potent oxidant tested was hypochlorous 
acid. A moderate concentration of HOCl caused oxidation of SKALP as demonstrated by the 
loss of silver staining after SDS-PAGE. At a concentration of 1 mM a decrease of SKALP 
activity was found, which was caused by an apparent decrease of the affinity for elastase. 
It remains to be investigated whether a concentration of 1 mM is relevant for the in vivo 
situation. Because lower concentrations of HOCl cause oxidation of SKALP (without 
apparent loss of activity), this could potentially affect the biological half-life of the 
molecule. To date i t is not known whether a receptor for SKALP or SKALP/elastase 
complexes exist, analogous to the receptor for сц-PI/elastase [39] or for SLPI.[40] 
Speculatively, oxidized SKALP (either in free form or complexed with elastase) could be 
cleared from the tissue at a faster rate than native SKALP, which would lead to reduced 
levels of SKALP in the epidermis and in the stratum corneum. Future research will be 
directed to address this possibility. 
Recently i t was shown that in addition to SKALP, SLPI is highly expressed in 
psoriatic epidermis.[14,26] However, we did not find evidence for reduced levels of SLPI in 
pustular psoriasis. The reason for this discrepancy with SKALP is not clear at the moment. 
Although the presence of SLPI in psoriatic scales has been documented before [26], we 
now have quantitative data on the relative contribution of SLPI and SKALP with respect to 
anti-elastase activity. On the basis of these findings we conclude that the bulk of 
epidermal anti-elastase activity in psoriatic skin is derived from SKALP rather than from 
SLPI. SLPI can be inactivated by oxidation of the methionine residues in the active 
site.[41,42] Oxidation of SLPI resulted in substantial reduction of its elastase inhibitory 
activity, which could almost completely be restored by glycosaminoglycans like heparin or 
heparan sulfate.[41] 
In summary, from these studies we conclude that the phenotype of pustular psoriatic 
skin is not caused by a defect in the keratinocyte at the level of SKALP synthesis and 
secretion. The observed deficiency of SKALP in pustular forms of psoriasis is caused by 
posttranslational mechanisms, which might include oxidation and rapid clearance of the 
molecule. Regardless of the mechanisms involved, uncontrolled proteinase activity will 
destroy epidermal integrity, and we would suggest that treatment of pustular psoriasis 
with pharmacological inhibitors of PMN-derived proteinases could therefore be a useful 
new therapeutic modality. 
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Impetigo herpetiformis (IH) is a rare pustular dermatosis with unknown aetiology, 
typically occurring during pregnancy. Based upon a similar clinical and histological 
presentation, i.e. spongiform accumulation of polymorphonuclear leukocytes in the stratum 
corneum, several authors consider IH as a variant of generalized pustular psoriasis (GPP), 
while others state that IH is a separate entity. 
Skin-derived antileukoproteinase (SKALP) is a strong and specific inhibitor of human 
leukocyte elastase (HLE) and proteinase 3, two neutral proteinases that have been 
implicated in leukocyte migration and tissue destruction. Previously, we reported decreased 
SKALP activity in pustular forms of psoriasis compared with plaque psoriasis. 
In this study we present a case study of a patient with IH. SKALP activity was 
measured using biochemical and immunochemical techniques. Epidermal scales and sera 
were collected during the course of the disease. Comparison was made with 3 patients with 
GPP and 6 patients with plaque psoriasis. Initially,. anti-HLE activity in epidermal scales of 
the patient with IH was comparable with values in patients with GPP, i.e. decreased 
compared with plaque psoriasis. During the course of the disease, anti-elastase activity 
dropped to undetectable levels, concomitant with the appearance of free elastase activity. 
This finding suggests a total saturation of epidermal anti-HLE activity. Low levels of SKALP 
presumably complexed with HLE, could be measured immunochemically in scale extracts. 
Serum levels of total SKALP correlated with the disease activity. We suggest that a reduced 
amount of epidermal SKALP contributes to an imbalance between elastase and its 
inhibitor, resulting in the formation of epidermal pustules. This mechanism of pustule 
formation could apply both to GPP and IH, suggesting a final common pathway in the 
pathogenetic mechanisms of IH and GPP. 
Introduction 
Impetigo herpetiformis (IH) is a rare pustular dermatosis with unknown aetiology, 
that typically affects pregnant women. Both the clinical and the histological presentation 
resemble the generalized form of pustular psoriasis. Apart from erythema and scaling, the 
main characteristic of both these conditions is the presence of macroscopic pustules, 
which are the result of an extreme epidermal infiltration of polymorphonuclear leukocytes 
(PMN). The pathogenetic events leading to the formation of macropustules in these 
diseases are unknown. Both an increase of epidermal chemotactic factors[l,2] and an 
increased chemotactic response of the PMN[3] have been implicated as a factor 
contributing to the massive PMN influx. 
Activated PMN secrete a variety of destructive products, for example proteinases 
(e.g. human leukocyte elastase (HLE) and proteinase 3). One of the putative functions of 
HLE is to facilitate migration through connective tissue and basal membranes towards 
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inflammatory foci. The activity of proteinases is regulated systemically by numerous 
plasma-derived inhibitors, such as aj-proteinase inhibitor and cx2-macroglobulin. We and 
others have characterized an inducible epidermal proteinase inhibitor, which is absent in 
normal skin and upregulated in inflammatory skin diseases such as psoriasis.[4,5] This 
inhibitor has been named skin-derived antileukoproteinase (SKALP) [6] also known as 
elafin [7], or elastase-specific inhibitor (ESI).[8] SKALP has been shown to be a potent 
inhibitor of human leukocyte elastase and proteinase 3.[9] We also showed that SKALP 
expression by epidermal keratinocytes protects against elastase-mediated loss of cell 
adhesion.[10] We found that the levels of SKALP in scale extracts from patients with a 
pustular form of psoriasis were far lower than in chronic plaque psoriasis. Furthermore, free 
elastase activity was found in the scale extracts of 25% of the pustular psoriasis patients, 
indicating a total saturation of epidermal SKALP activity.[11] Based on these findings, we 
proposed a new mechanism for pustule formation: consumption of SKALP, which is extreme 
in pustular psoriasis, can lead to local SKALP deficiencies which allow a facilitated 
migration of PMN, resulting in the formation of pustules. 
A similar mechanism for pustule formation could apply to IH. Here we present a case 
report of a patient with IH, in which we studied the SKALP activity in scale extracts and 
serum levels during the course of the disease. 
Case report 
A 31-year old pregnant woman was admitted with a sudden onset of erythema, 
scaling and pustule formation at 31 weeks gestation. The lesions started on the dorsum of 
the hands and spread rapidly. She complained about burning sensations in her skin and 
general malaise. This was her third pregnancy. The first one ended in a spontaneous 
abortion at 11 weeks gestation, with the second pregnancy resulting in delivery of a 
healthy fullterm child. During these previous pregnancies she did not suffer from any skin 
problems. The patient had no history of psoriasis or other skin diseases, nor did psoriasis 
occur in her family. She was not receiving any medication except for ferrous fumarate 
because of low haemoglobin. 
On the trunk she had polycyclic, confluent, sharply demarcated, bright red lesions 
with scales and pustule formation (Fig. 1). The face, inguinal folds, anal region and knee 
folds were also involved. The pustules did not coalesce; they occurred predominantly at 
the periphery of the lesions, encircling a central area with desquamation. The oral cavity 
was also involved, showing pustules on the mucosa and tongue. The nails showed no 
abnormalities. She did not have a fever. 
Laboratory investigations showed decreased haemoglobin (6.3 mmol/l), an increased 
white blood cell count (20.9 χ lO'/l), increased sedimentation rate (52 mm in the first 
hour), normal creatinine, electrolytes, glucose and liver enzymes. The phosphate level was 
low normal, and the calcium level (2.01 mmol/l) was just in the normal range after 
compensation for a low albumin level (27 g/l). Serum levels of parathyroid hormone and 
1,25 dihydroxyvitamin D3 were normal; however, serum 25 hydroxyvitamin D3 was slightly 
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Figure I. A typical lesion in a 
patient with impetigo herpetifor­
mis. Pustules are predominantly 
present in the penphery encircling 
a central area with desquamation. 
fig> · > ..;• •· , .' ··· . ,•'•"•• j-"^ . 
Figure 2. Acanthotic epidermis 
with hyperkeratosis. PMN are infil­
trating in the stratum spinosum 
and stratum comeum and form an 
intracomeal pustule. In the dermis 
a slight mixed perivascular infil­
trate composed of lymphocytes 
and PMN is present (Haematoxi-
lineosm staining). 
1 ' U-Л ' m 
decreased. Bacterial cultures of the pustule content were sterile. HLA B27 typing was 
negative. 
Histopathological investigation of a macroscopic pustule showed an acanthotic 
epidermis with slight hyperkeratosis. PMN accumulated subcorneal and in the upper part of 
the stratum spinosum, accompanied with spongiosis. The dermis showed a slight 
perivascular inflammatory infiltrate composed of lymphocytes and PMN, the latter tending 
to migrate to the upper part of the dermis (Fig. 2). 
In view of the clinical and histological findings the diagnoses of impetigo 
herpetiformis was established. Treatment was started with moderate potency local 
corticosteroids. The albumin level was normalized by an intravenous infusion of 20% 
albumin solution. Subsequently, the patient was transferred to the department of 
obstetrics for intensive foetal monitoring. After 5 days without clinical improvement, 
therapy was started with prednisone, initially 30 mg daily later increased to 50 mg daily 
and calcitriol, in a dosage of 0.5 pg daily; however, without clinical response. At 37 weeks 
gestation, labour started spontaneously and she delivered a healthy child. Improvement in 
the skin lesions after delivery was slow; after 2 weeks isotretinoin was started in a dosage 
of 20 mg daily, and prednison was gradually reduced over a 3-month period. The pustules 
and erythema disappeared within 2 weeks from starting isotretinoin. Local emollients were 
started. After 4 months no skin lesions remained and isotretinoin was discontinued. She 
has remained disease free for 2.5 years. 
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Materials and methods 
Clinical scores for pustulation were made at regular intervals: 0 = no pustulation, 1 = 
slight pustulation, 2 = moderate pustulation, 3 = severe pustulation. Epidermal scales and 
sera were collected from our patient during the course of the disease. Epidermal scales 
could only be collected in the initial phase, because later there was insufficient scaling. In 
addition, epidermal scales were collected from 3 patients with GPP and 6 patients with 
plaque psoriasis. Scales and sera were stored at -20°C for later analysis. 
Scales were processed for determination of SKALP activity.[l l] They were weighed, 
homogenised (100 mg/ml) in a glass-glass grinder in phosphate-buffered saline (PBS) and 
centrifuged (15 min, 12000 g). The clear supernatant was divided into two equal portions. 
One portion was boiled for 2 min to inactivate elastase and to liberate the elastase-bound 
inhibitor and then centrifuged again (15 min, 12000 g). Colorimetrie quantification of 
protein concentration was performed using the Bio-Rad DC Protein Assay (Bio-Rad 
Laboratories, Richmond, CA, USA). 
Functional measurement of anti-human leukocyte elastase activity in scales 
In epidermal scales a direct quantification of the total amount of biologically active 
SKALP is not possible, because both free elastase and elastase complexed with inhibitor can 
be found. Our method, used for the measurement of anti-elastase activity in urine [12], is 
based on the differential heat-stability of elastase and SKALP. Elastase is denatured by 
boiling the scale extracts for 2 min, whereas SKALP is heat-stable, and latent SKALP is 
released from the enzyme-inhibitor complex. In all scale extracts we measured the free 
SKALP activity in untreated samples and the total, latent plus free, SKALP activity in heat-
inactivated samples. Another complicating factor is the possible presence in human skin of 
at least two other high-affinity elastase inhibitors beside SKALP, either free or complexed. 
These are alpha-1-antitrypsin (alpha-1-AT) and secretory leukocyte protease inhibitor 
(SLPI), which is identical to antileukoproteinase (ALP).[13] From previous studies we know 
that SLPI activity is present in scales [9], but in relatively low concentration compared with 
that of SKALP (unpublished data), and disturbance by alpha-1-AT activity is eliminated in 
the assay by the presence of cetyltrimethylammoniumbromide (СТАВ).[14] Therefore, almost 
all of the anti-elastase activity measured in our assay represents SKALP activity. 
Elastase activity was measured as the release of the fluorogenic substrate methoxy-
succinyl-alanyl-alanyl-prolyl-valyl-amino-4-methylcoumarin (MAAPV-AMC, Sigma, St Louis, 
MO, USA).[15] Anti-HLE activity was measured as the percentage inhibition of a standard 
amount of elastase using the same assay. Fluorescence was measured at 375 nm 
(excitation) and 440 nm (emission) in a Shimadzu RF-5001 PC spectrofluorophotometer 
(Shimadzu Corp., Kyoto, Japan). 
Serial dilutions were made from the samples in assay buffer (1 M NaCl, 0.4% СТАВ, 
0.1 M Tris pH 8.5). Ten μΐ containing an extract of 500 PMN in assay buffer (equivalent to 
approximately 1 ng HLE) was mixed with 10 μΐ of serial dilutions of scale extract and then 
incubated for 15 min at 37°C. Thereafter, 20 μΐ of 250 mM elastase substrate solution was 
162 
added and the reaction was allowed to proceed for 15 min at 37°C. The incubation was 
terminated by the addition of 1 ml stop buffer (100 mM Na2C03, pH 10.5). Inhibition of 
elastase activity in this assay was calculated as the percentage inhibition of the activity of 
500 PMN, within the linear range of the assay. Recombinant SKALP/elafin (a kind gift of Dr 
N. Russell, Zeneca, UK) was used to obtain a calibration curve from which the anti-HLE 
activity in the scale extracts was read. After correction for protein concentration, anti-HLE 
activity was expressed in nanograms of SKALP per milligram protein. 
Enzyme-linked immunosorbent assay (ELISA) for measurement of SKALP levels 
SKALP concentrations were measured in scale extracts and sera, using a sandwich-
type ELISA. Scale extracts were boiled and supematants were taken for quantification of 
SKALP, sera were measured directly. Samples were mixed to contain 10% sample, 0.1 M 
Tris, 0.1% Tween-20, 1% bovine serum albumin (BSA). Microtiter plates (96 flat bottom 
wells) were coated overnight with goat anti-SKALP antiserum. After washing of the plate 
with PBS with 0.05% Tween-20, microtiter plates were blocked and probed with the test 
samples. Subsequently, rabbit anti-SKALP antiserum with 2.5% normal goat serum was 
added and developed for 60 min with peroxidase-conjugated swine-antirabbit 
immunoglobulin with 2.5% normal goat serum using o-phenylenediamine dihydrochloride 
(OP0) as chromogenic substrate for 15 min. Human recombinant SKALP/elafin in PBS with 
0.1% BSA was used as a standard: a calibration curve was made, using recombinant 
SKALP/elafin in the range of 0.5 - 120 ng/ml. The SKALP concentrations in scales or serum 
samples were read from this curve. All ELISA steps were performed at room temperature. 
Data were read with a Biorad™ ELISA-reader, and evaluated using the Excel™ spread sheet 
program. After correction for protein concentration, SKALP activity was expressed in 
nanograms of SKALP per milligram of protein. The ELISA used in this study was specific for 
SKALP and does not recognise SLPI (not shown). 
Results 
Anti-human leukocyte elastase activity in scale extracts 
Using a functional assay we measured the free anti-HLE activity in untreated samples 
and the total, latent plus free, anti-HLE activity in heat-inactivated samples. In the 
untreated samples of our patient with IH anti-HLE activity could be measured during the 
first 7 days after admission. In all subsequent samples, anti-HLE activity was undetectable; 
but free elastase activity could be measured. Anti-HLE activity could be detected after 
heat inactivation (Fig. 3a); however, the amounts were low compared with that in the 
patients with plaque psoriasis. In the patients with GPP similar results were found; direct 
measurement showed free elastase activity in 2 of the 3 patients, whereas heat-
inactivation liberated the anti-HLE activity. Anti-HLE values in IH and GPP were in the 
same range. In the patients with plaque psoriasis no free elastase activity was present, and 
total anti-HLE activity was high compared with that in patients with IH and GPP (Fig. 3b). 
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SKALP levels in scale extracts and in serum 
In order to study the SKALP levels without possible interference by other elastase 
inhibitors, we used a specific sandwich-type ELISA. SKALP levels, as measured with ELISA 
in the supernatant of boiled scale extracts, were higher than those obtained with the 
functional assay. (Fig. 3b). This is probably due to the fact that in the ELISA both 
biologically active intact SKALP and degraded SKALP are measured. As with the functional 
assay, the SKALP concentration was significantly lower in IH and in GPP compared with 
plaque psoriasis. 
In the serial serum samples of our patient with IH we measured SKALP levels using 
ELISA technique. Serum levels of SKALP correlated with the disease activity as presented 
by the formation of pustules (Fig. 4). After the delivery the formation of pustules 
diminished, followed by a reduction of SKALP levels to normal values. 
Discussion 
I t is still a matter of debate whether IH should be considered as a separate entity or 
as a variant of GPP. Some authors consider both to be the result of a final common 
pathway induced by different pathogenic factors.[16] However, others regard IH as a 
separate entity because of its different clinical features and a distinctive typical 
history.[17,18] Our patient presented with the characteristic clinical signs of IH. She had 
no history of skin disorders until her third pregnancy. In contrast with reports in the 
literature, her skin did not clear quickly after the delivery. Treatment with isotretinoin was 
started after 2 weeks. 
As IH is predominantly presenting during pregnancy, there is probably an aetiological 
relationship between IH and pregnancy. After IH has once affected a patient, an earlier 
presentation in each subsequent pregnancy has been reported.[19-21] Oral contraceptive 
pills appeared to induce IH in a patient, who previously had IH in successive 
pregnancies.[20] No certain pathological mechanism has been determined so far. 
Hypocalcemia is presumed to be of importance; i t has been associated with IH.[22] 
Patients with GPP and psoriasis vulgaris can experience reactivation of their disease during 
episodes of hypocalcaemia.[17,23,24] One report of GPP patients found hypocalcaemia in 
only 5 out of 57 patients, and i t was not found in subsequent equally severe periods of 
disease. The authors suggested that hypocalcaemia is a secondary phenomenon, due to a 
transient state of malabsorbtion or low serum albumin.[17] Whether hypocalcaemia is 
really a pathogenic factor in IH, as suggested in a patient with hypocalcaemia due to 
congenitial rickets who developed IH [25], or a phenomenon secondary to the loss of 
albumine[26,27] remains debatable. Another factor contributing to hypocalcaemia is the 
physiological decrease of total serum calcium level by 5-6% during pregnancy.[25] In our 
patient the calcium level was in the normal range after correction for a low albumin level. 
The serum level of 25-hydroxyvitamin D3 was slightly decreased, with normal 1,25 
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Figure За. Anti-human leukocyte elastase 
(HLE) activity in serial scale extracts of a 
patient with impetigo herpetiformis (IH). 
Day 0 is the day of admission. Anti-HLE 
activity was measured with a functional 
assay directly (triangles) and after heat 
inactivation (dots). Initially, the untreated 
samples show SKALP activity; however, 
after 9 days in all the following samples 
free elastase activity is present. In all 
those samples, SKALP activity could be 
recovered after heat inactivation. 
IH ( n = l ) G P P ( n = 3 ) plaque (n=6) 
Figure 3b. Anti-HLE activity and SKALP 
levels in scale extracts of patients with 
IH (n=l), generalized pustular psoriasis 
(GPP) (n=3), chronic plaque psoriasis 
(n=6). For the values of the patient with 
IH the mean value of I I samples collec­
ted in a period of 20 days was used (see 
Fig. a). Anti-HLE activity was determined 
with a functional assay directly (black 
bars) and after heat-inactivation (open 
bars). Heat inactivation releases SKALP, 
which is complexed with HLE. Note the 
increase in anti-HLE activity following 
heat inactivation of scale extracts from 
the GPP patients and the IH patient. The 
grey bars represent SKALP levels as 
measured with ELISA. SKALP levels 
were substantially lower in the patient 
with IH and in the GPP group compared 
with the plaque psoriasis group. This was 
found both with functional measure­
ments, which measure anti-HLE activity 
and with ELISA techniques, which meas­
ure ¡mmunoreactive SKALP. 
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Figure 4. SKALP levels in serial serum 
monsters ( • , left y-axis) and pustula-
tion ( · , right y-axis) of a patient with 
impetigo herpetiformis. Day 0 is the day 
of admission. After delivery both the 
pustulation and the SKALP level in 
senjm decreased to normal values. 
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In inflammatory skin diseases such as psoriasis [6,28] and in epidermal tumours [29] 
SKALP is induced in the epidermis forming a gradient of anti-elastase activity from 
epidermis to dermis. One of the putative functions of HLE is to facilitate migration of PMN 
through connective tissue and basal membranes, towards inflammatory foci. In our patient 
with IH, we examined the amounts of SKALP in scales and serum during the course of the 
disease. Most striking was the lack of free anti-HLE activity from 9 days after admission. In 
these samples free HLE activity was found, indicating a total saturation of all available 
anti-HLE activity. After heat inactivation, anti-HLE activity was found, due to the 
liberation of SKALP from its complex with HLE. However, the amount of total anti-HLE 
activity is lower by a factor of 5 than in plaque psoriasis. In the three patients with GPP 
we found similar results. We suggest that the local deficiency of SKALP as found in IH and 
GPP facilitates PMN migration into the epidermis, leading finally to a massive 
accumulation of PMN in the epidermis. I t is not clear which mechanism leads to the 
decreased levels of SKALP. In keratotome biopsies of patients with plaque psoriasis and 
pustular psoriasis no difference was seen in SKALP expression at the mRNA level.[ l l ] 
Whether the decrease of SKALP is caused by an enhanced inactivation and subsequent 
clearance needs to be studied in the future. 
As SKALP is a cationic, low molecular weight protein, i t can easily cross the basal 
membrane, penetrate the connective tissue and reach the circulation. SKALP can be 
demonstrated in the urine of psoriatic patients.[12] Furthermore, we have reported a 
correlation of SKALP levels in serum with disease activity in patients with psoriasis who 
were treated with cyclosporin A.[30] In our patient serum levels of SKALP correlated well 
with the pustulation; however, the decrease of SKALP lags slightly behind the clearance of 
the pustules. Compared with patients with plaque psoriasis with a similar area of skin 
affected, the SKALP levels in IH are rather low (not shown). 
In the patient with IH we have demonstrated a dynamic variation of SKALP in scales 
and serum during the course of the disease. In scales, anti-elastase activity dropped to 
undetectable levels, while free elastase activity appeared. Serum levels of SKALP correlated 
with the disease activity. We suggest that in both GPP and IH a final common pathway is 
involved in the pathogenic mechanism of pustule formation. In both diseases a deficiency 
of SKALP could be of importance in pustule formation. These findings would imply that in 
both GPP and IH the use of a low molecular weight drug with anti-elastase activity could 
be a new therapeutic modality. 
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We have assessed the distribution pattern of a new epidermal elastase inhibitor, skin-
derived antileukoproteinase (SKALP) and polymorphonuclear leukocytes (PMN) in a patient 
with annular pustular psoriasis, using immunohistochemical methods. In the clinically 
uninvolved skin SKALP was not expressed and only occasionally a few PMN could be 
identified. In the erythematous distal margin of the lesion, expression of SKALP was shown 
in suprabasal keratinocytes. Although PMN were present in the dermis, no transepidermal 
PMN migration had occurred in this stage. In the pustular region a dense SKALP-positive 
zone was demonstrated in the suprabasal compartment. In the centrally healed area neither 
SKALP expression nor PMN accumulation was shown. The present case report suggests that 
the induction of SKALP expression does not result from the passage of PMN through the 
epidermis. The offswitch of SKALP expression coincides with the disappearance of the PMN 
infiltration and not with the resolution of the mononuclear infíltrate. 
Introduction 
Several data suggest a role for polymorphonuclear leukocytes (PMN) in the 
pathogenesis of psoriasis.fi] Especially in early and active psoriatic lesions, intraepidermal 
accumulation of PMN is a characteristic feature. Activated PMN can cause tissue damage 
and contribute to the inflammatory response by the release of proteinases (elastase, 
proteinase 3 and cathepsin G), reactive oxygen intermediates and several other mediators 
of inflammation.[2] Elastase is a neutral proteinase that is found predominantly in PMN 
and can therefore be used as a marker enzyme for PMN.[3] Also monocytes contain 
elastase, though only 5% of the activity found in PMN.[4] Elastase is putatively involved 
in the extravasation of PMN and the migration of PMN through the dermo-epidermal 
junction into the epidermis.[5] 
In chronic plaque psoriasis the PMN accumulate in the epidermis forming the so-
called micro-pustules of Kogoj, while in pustular psoriasis infiltration of PMN results in the 
formation of macroscopic pustules. Chronic plaque psoriasis as well as pustular psoriasis 
are both représentants of the psoriasis spectrum and transition may occur from one into 
the other variant.[6] 
In previous papers we have described an epidermal proteinase inhibitor, skin-derived 
antileukoproteinase (SKALP). SKALP is identical to elafin, an elastase-inhibitor described 
by others.[7] SKALP inhibits the activity of the enzymes elastase and proteinase 3 [8], 
released by PMN during the process of extravasation. We have characterized SKALP at the 
biochemical and molecular level [9,10], showed its presence in the urine of psoriatic 
patients [11] and localized the SKALP gene to chromosome 20q.[12] Immunohistochemical 
staining located the expression of SKALP in the upper layers of the suprabasal 
compartment in psoriatic skin, whereas normal skin showed no expression.[13] 
171 ; 
Because of the functional relationship between SKALP and PMN-derived proteinases, 
studies on the topographic relation between SKALP and PMN are indicated. I t is a practical 
approach to study this relation in pustular forms of psoriasis in which PMN are abundantly 
present. Pustular psoriasis is a spectrum which comprizes the localized forms (psoriasis 
pustulosa palmoplantaris, acrodermatitis continua of Hallopeau) and generalized forms 
(acute generalized pustular psoriasis von Zumbusch type, annular pustular psoriasis). 
Annular pustular psoriasis (APP) is a special form of generalized pustular psoriasis (GPP). 
Whereas the dynamics of GPP is phasic in time, APP is phasic in place and characterized by 
a centrifugal expansion of the lesions and a central healing.[14] 
In this study simultaneous assessment of the distribution of PMN and SKALP was 
performed. Using a double labelling method we investigated the topographic relation 
between SKALP and PMN during the induction, the summit and the regression of 
pustulation in APP. 
Case report 
A 71-year-old woman presented with recurrent episodes of APP, complicated by 
psoriatic arthropathy of the right knee and the distal interphalangeal joints of both hands. 
From the age of 55 years she had had several episodes of APP, accompanied by fever and 
general body weakness. The lesions were composed of a sharply demarcated polycycLic 
erythema with peripheral pustules and expanded by centrifugal spreading within a few 
days. Central healing of the Lesions occurred, and the zone of central healing appeared to 
have the same dynamics as the centrifugal expansion of the lesions. At the inner margin 
between lesionai and centrally healed skin a colerette scaling was visible. 
Relapses of chronic plaque psoriasis and inverse psoriasis interchanged with the 
episodes of APP. Besides local therapy treatment subsequently consisted of several 
systemic treatments, including methotrexate, PUVA therapy and etretinate in dosages 
between 25 and 75 mg per day. 
Materials and methods 
Biopsies 
From a typical lesion (Fig. 1) 4 mm punch biopsies were taken. In total 5 biopsies 
were taken from different zones: (a) clinically uninvolved skin, (b) the distal erythematous 
margin of the lesion, (c) the pustular region, (d) the paracentral erythematous zone with 
colerette desquamation and (e) the clinically healed centre. Biopsies were fixed in buffered 
4% formalin for at least 24 h and processed for routine histology. Tissue was embedded in 
paraffin and 5 pm sections were cut. 
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Figure I. A typical lesion of 
annular pustular psoriasis from 
the presented patient. The dif-
ferent zones for histological 
examination are indicated (a-e). 
Figure 2a. SKALP and human leukocyte 
elastase immunodouble staining in diffe-
rent zones of annular pustular psonasis, 
as indicated in Fig. I. SKALP staining is 
marked with an arrow and elastase stai-
ning with an arrowhead. No SKALP 
expression and only a few PMN are pre-
sent. 
Figure 2b. In the two uppermost cell lay-
ers of the stratum spmosum SKALP 
expression is seen. In the dermis an 
increased number of PMN is present. 
$ 
Figure 2c. Massive accumulation of PMN 
in the stratum comeum and in the der-
mis. SKALP expression is seen in the 
uppermost 5-6 cell layers of the stratum 
spmosum. 
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Fig2d Figure 2d. Similar to с. although PMN 
infiltration and SKALP expression are 
less abundant. Most of the PMN ac­
cumulated in the stratum comeum are 
degenerated. 
Figure 2e. No SKALP expression and no 
PMN are visible. Only a perivascular 
mononuclear infiltrate is present. 
b-'f' ' Ä ' i S S i k · . <"•*-. ..s i '.. 
Antibodies 
In the present study the following antibodies were used: monoclonal mouse antibody 
to human neutrophil elastase and swine-anti-rabbit Ig conjugated with horseradish 
peroxidase (SWARPO) both obtained from Dakopatts, Glostrup, Denmark. Polyclonal rabbit 
anti-serum against recombinant elafin was raised as described before.[13] Recombinant 
elafin was a kind gift from Dr. Norman Russell, ICI Pharmaceuticals, UK. Goat-anti-mouse 
Ig conjugated with alkaline phosphatase (GAMAP) was obtained from TAGO, Burlingame, 
CA, USA. 
Immunohistochemistry 
Immunodouble staining was performed, according to standard protocols. After 
deparaffinizing and rehydration, pre-incubation was performed using 10% normal swine 
serum and 10% normal goat serum dissolved in phosphate-buffered saline (PBS) to prevent 
aspecific staining. The sections were then incubated for 60 min with anti-SKALP serum (at 
a dilution of 1:500) and anti-elastase (at a dilution of 1:250) in PBS with 1% bovine 
serum albumine (BSA). 
After washing in PBS, sections were incubated during 30 min with SWARPO and 
GAMAP at a dilution of 1:50 and 1:20, respectively, in PBS with 1% BSA and 5% human AB 
serum. Subsequently, sections were washed in 100 mM NaCl, 5 mM MgCl2 and 10 mM Tris 
in destilled water (AP buffer) and developed using a mixture of 0.33% 5-bromo-4-chloro-3-
indolyl-phosphate-toluidine and 0.66% nitro-blue-tetrazolium in AP buffer. Finally, 
sections were washed in PBS and sodium-acetate buffer and development was performed, 
using aminoethylcarbazole as chromogenic substrate. 
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Results 
The immunohistochemical findings observed in the 5 zones of APP are illustrated in 
Fig. 2 a-e. 
In clinically uninvolved skin no significant SKALP expression could be demonstrated 
and only few PMN could be identified, scattered as single cells (Fig. 2a). 
In the erythematous distal margin conspicious changes were observed. SKALP 
expression was markedly present in the two uppermost cell layers of the stratum spinosum 
(Fig. 2b). The density of PMN had increased in the dermis. However, no single PMN or any 
elastase positive material or any material which could be suspected to be a PMN remnant, 
was identified in the stratum corneum. Occasionally, some PMN were observed in the basal 
and midepidermal compartments. 
In the pustular region (Fig. 2c) a dense accumulation of PMN was present in the 
dermis and a massive accumulation of PMN was observed within the stratum corneum. In 
contrast, only occasionally was an isolated PMN observed in the basal zones of the 
epidermis. The suprabasal compartment was characterized by a continuous SKALP-positive 
zone which was at least 5-6 cellayers thick. 
In the paracentral erythematous zone, a SKALP-positive suprabasal compartment and 
dermal PMN accumulation were observed (Fig. 2d). The intracorneal PMN accumulation was 
difficult to identify as such, due to degeneration of the PMN. 
In the centrally healed zone, neither SKALP expression nor PMN accumulation was 
observed (Fig. 2e). A perivascular mononuclear infiltrate was the last testimony of the 
pustular wave. 
Control staining, performed with pre-immune serum of the same animal instead of 
anti-SKALP and control isotype monoclonal antibodies instead of anti-elastase, was 
negative with all the 5 zones (not shown). 
Discussion 
In normal human skin and non-lesional psoriatic skin SKALP is not expressed. 
However, in lesionai skin of patients with chronic plaque psoriasis a cytoplasmic 
distribution of SKALP, restricted to the upper layers of the suprabasal compartment, has 
been reported.[13] Also in lesionai skin of patients with a pustular form of psoriasis 
SKALP expression is present, but i t is less pronounced than in plaque psoriasis. Functional 
measurement of SKALP activity in epidermal scales from patients with chronic plaque 
psoriasis and pustular psoriasis, using a sensitive microassay [3], revealed that SKALP 
activity in pustular psoriasis was significantly lower than in plaque psoriasis (unpublished 
data). 
In scales of patients with atopic dermatitis and the поп-inflammatory disorders of 
keratinization, functional measurement of SKALP showed a moderate presence. In scales of 
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patients with erythrodermic autosomal recessive lamellar ichthyosis and Netherton 
syndrome a pronounced presence of SKALP, comparable to psoriasis, could be 
demonstrated.[16] Also after sellotape stripping of psoriatic non-lesional skin and normal 
skin of healthy individuals SKALP was induced in equal amounts.[17] Other conditions in 
which SKALP expression was shown are keratinocyte culture [18] and several epidermal 
tumours.[19] Therefore, SKALP induction can not be regarded as specific for psoriasis. 
SKALP was shown to be a potent inhibitor of human leukocyte elastase, which 
belongs to the PMN neutral proteinases. Elastase can damage extracellular matrix proteins, 
basement membranes and desmosomal structures [2] and is putatively of relevance for the 
migration of PMN into the skin.[5] Speculatively, SKALP functions as an inhibitor of PMN 
migration and provides protection against elastase-mediated damage. 
How induction of SKALP expression by keratinocytes is initiated is not yet clear. An 
interesting point is whether or not PMN play a role in this process. The present study in a 
patient with APP provides the possibility to study the kinetics of the topographic relation 
between PMN trafficking and SKALP expression. In the section of the peripheral margin of 
the lesion (Fig 2b), a very clear positive cell layer with SKALP expression was present. In 
the same section no single PMN was detected in the stratum corneum or in the suprabasal 
layers of the stratum spinosum. This fact suggests that, in the order of events in the 
pathogenesis of the psoriatic lesion, the presence of PMN in the epidermis is not 
obligatory for SKALP transcription. Our observations are compatible with the finding that 
cultured human epidermal keratinocytes express SKALP in the absence of PMN.[18,20] We 
therefore conclude that not the presence of PMN but another, hitherto unknown factor is 
responsible for induction of SKALP expression. 
At the area of pustulation and the area with paracentral erythema the SKALP 
expressing zone is remarkably free from PMN, whereas dermis and stratum corneum are full 
of PMN (Fig. 2c, d). Despite the presence of SKALP in several cell layers, PMN showed a 
maximal transgression into the stratum corneum, resulting in pustule formation. In 
contrast to the situation in chronic plaque psoriasis, with a limited invasion of PMN, in 
pustular psoriasis PMN invasion and elastase release is massive. This could lead to a 
situation that in pustular psoriasis all SKALP is saturated with elastase and that free 
elastase is active despite the abundant presence of SKALP. Presence of free elastase may 
lead to the formation of macroscopic pustules, characteristic of pustular psoriasis. 
In the central area of the clinically healed skin mononuclear infiltration is present in 
the absence of PMN and SKALP (Fig. 2e). Downregulation of SKALP was found to correlate 
with the disappearance of PMN. 
The present study indicates that the induction of SKALP expression in psoriatic skin 
does not result from the passage of PMN through the epidermis, but is manifest before 
epidermal transgression of PMN has taken place. The expression of SKALP in psoriatic skin 
might be an attempt to downmodulate PMN migration. Furthermore, the expression of 
SKALP and PMN transgression are coupled processes. SKALP appears in the first stages of 
PMN infiltration and disappears when the composition of the infiltrate changes. We 
hypothesize that the off-switch of PMN migration is caused by SKALP expression. The 
ultimate reality test for this hypothesis is to answer the question whether (synthetic) 
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The subject of study in this thesis are the severe forms of psoriasis, as represented 
by the extensive forms of plaque psoriasis, erythrodermic psoriasis and the pustular forms 
of psoriasis. At the end of the general introduction three aims were formulated, which were 
subsequently subject of study in part I to I I I of the thesis. Besides the study of 
therapeutic approaches for severe psoriasis (part I ) , the role of the proteinase inhibitor 
skin-derived antileukoproteinase (SKALP) was investigated. Herein we focused on the 
effect of treatment on expression levels of SKALP (part I I) and the role of SKALP in the 
pathogenesis of pustular psoriasis, as investigated in part I I I . Here we summarize and 
discuss the separate parts of the thesis. 
The efficacy and safety of systemic and combined treatments in severe forms of ι 
psoriasis (Part I) 
12.1.1 The efficacy and safety of MTX in the treatment of severe psoriasis 
In chapter 2 a risk-benefit assessment of long-term methotrexate (MTX) treatment of 
severe psoriasis was made. This risk-benefit assessment was based on 3 clinical studies and 
an extensive literature study. MTX is an established and highly effective systemic drug for 
the treatment of severe psoriasis, including the pustular and erythrodermic forms. I t is 
widely used since a period of 3 decades. This is the reason that the long-term side effects 
of MTX are well known, in contrast to other relatively new systemic treatments like 
cyclosporin A and retinoids. In a retrospective study we reported on the efficacy of MTX 
treatment in 113 patients with severe psoriasis. In 81% of the patients the response was 
good. The most frequent side effects occurring during MTX therapy were abnormal liver 
function tests, nausea and gastric complaints. The most feared side effects of MTX therapy 
are myelosuppression and hepatotoxicity. In our study in 13% of the patients liver fibrosis 
was seen and in 4% liver cirrhosis. No clear relation between liver biopsy classification and 
cumulative dosage or duration of therapy could be established. Monitoring of liver enzymes 
was found to be of limited value in the detection of histological liver damage, as in 4 out 
of 9 patients with fibrosis or cirrhosis the liver function tests were normal. 
Recently, the psoriasis task force revised the latest guidelines of 1988 for the 
administration and monitoring of MTX.[1] In the new guidelines a liver biopsy has to be 
performed after a cumulative dose of 1.5 gram and repeated after 3.0 and 4.0 gram in 
patients with no significant risk factor for liver abnormalities (i.e. history of past or 
current excessive alcohol intake, persistent abnormal liver chemistry results, history of 
prior liver disease, history of intravenous drug abuse, diabetes or obesity, history of 
exposure to known hepatotoxic drug). The pre-MTX liverbiopsy is restricted to the patients 
with risk factors, while in the guidelines of 1988 a pre-MTX biopsy was advised for all 
patients. 
Several attempts are made in the search for a non-invasive screenings method for MTX-
induced liver damage. In this thesis the results of a prospective study have been reported, 
evaluating the value of PIIINP measurement and dynamic hepatic scintigraphy (DHS). 
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Although the mean PIIINP values in patients with abnormal liver histology were 
significantly higher than those of the patients with normal liver histology, isolated PIIINP 
values did not discriminate between individuals with and without hepatic damage. In the 
total patient group we have studied, three of the 9 patients (33%) with abnormal 
histology had normal PIIINP values. This was also confirmed by other studies[2-4], finding 
a percentage false-normal values varying between 22 and 40%. This indicates that the 
number of liver biopsies may not be reduced based on one single PIIINP measurement. 
However, regular monitoring of PIIINP levels can be of value for reducing the number of 
liver biopsies.[2] In our study we also showed that DHS is a promising technique for 
detection of liver damage. A clear-cut separation between the portal contribution of the 
MTX patients with a normal liver histology and patients with abnormal liver histology 
(varying from steatosis to cirrhosis) could be demonstrated. DHS appeared not suitable to 
grade the severity of hepatic damage. 
Because hepatotoxicity seems to be related to a high cumulative dose of MTX, an 
intermittent instead of a continuous treatment schedule is advised. After interruption of 
MTX treatment in 10 patients with extensive psoriasis, 3 patients experienced a quick 
relapse and MTX was re-introduced within 4 weeks. Seven patients had an MTX free interval 
of at least 11 weeks, with a mean value of 23 weeks (11-41 weeks). The mean reduction in 
cumulative MTX dose was 76 mg. 
In conclusion, low dose MTX therapy is a relatively safe therapy, provided that a 
careful patient selection and regular monitoring for side effects and drug interactions 
during MTX therapy is carried out. The long-term clinical efficacy and relative safety of MTX 
remain impressive. To assess liver damage, the performance of liver biopsies, according to 
the international guidelines, remains the gold standard, until new non-invasive screening 
methods for liver damage, like measurement of serum levels of PIIINP and DHS are further 
evaluated. At the moment the study in which the value of PIIINP and DHS are evaluated, is 
still ongoing. A second evaluation will be performed in the near future. 
12.1.2 The efficacy of acitretin and liarozole in the treatment of severe psoriasis 
Liarozole is an inhibitor of the cytochrome P¿50-dependent 4-hydroxy latió η of 
endogenous a[[-trans retinoic acid. In an earlier study by Dockx et σ/.[5] the efficacy of 
liarozole in the treatment of extensive plaque psoriasis was demonstrated. In chapter 6 the 
clinical efficacy of liarozole was compared with acitretin in 20 patients with severe plaque 
psoriasis, as part of a large, double-blind clinical study. The extent and severity of the skin 
lesions as recorded by the PASI score were significantly reduced after 12 weeks of 
treatment in both the acitretin and liarozole treated group. Only in the acitretin treated 
group a significant further reduction of the PASI score was achieved, after a total 
treatment period of 24 weeks. 
12.1.3 The efficacy and safety of combination therapies in the treatment of severe 
psoriasis 
In chapter 3, three patients with psoriatic erythroderma were described, who did 
not respond to monotherapy with acitretin in adequate dosages. Subsequently, they were 
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treated with combined therapy consisting of acitretin and cyclosporin A. No additional 
effect was achieved after addition of cyclosporin A. All 3 patients suffered from side 
effects, 2 patients from cyclosporin A induced side effects, all 3 from side effects due to 
the use of retinoids. 
In chapter 4 a case report was presented. A patient with acrodermatitis continua of 
Hallopeau was treated with acitretin combined with calcipotriol ointment and the 
ointment base. The side treated with calcipotriol as adjunct therapy showed an impressive 
improvement, well beyond the degree of improvement at the side treated with the 
ointment base only. 
As discussed in the general introduction, severe forms of psoriasis, like pustular 
psoriasis and erythrodermic psoriasis, are difficult to treat. The therapeutic response in 
mentioned patient groups to well-established treatment protocols, may be variable and 
sometimes disappointing. Acitretin as monotherapy is the treatment of choice in the 
erythrodermic variants of psoriasis and in severe pustular psoriasis, including 
acrodermatitis continua of Hallopeau. If insufficient clinical response is achieved with 
monotherapy, like in the patients presented in chapter 3 and 4, adjuvant therapy is 
indicated. The combination of treatments allows a lower dose than that used in 
monotherapy, which reduces the side effects. Furthermore, the efficacy can be increased by 
combination of therapies with a different mode of action. Considering the different mode 
of action and different side effect profile, the combination of acitretin and cyclosporin A is 
a rational option. However, in our 3 patients side effects occurred already after a short 
treatment period and the clinical efficacy was poor. We can conclude that the combination 
of acitretin and cyclosporin A in the treatment of erythrodermic psoriasis is not a major 
therapeutic option. 
The combination of acitretin and calcipotriol was investigated in a placebo-
controlled study in 135 patients with severe plaque psoriasis. Calcipotriol treatment proved 
to have an additional effect to acitretin therapy compared to placebo and reduced the 
cumulative dose of acitretin.[6] The good clinical efficacy of retinoids in pustular forms of 
psoriasis might be explained by the effect on the function of PMN. The chemotactic 
activities of PMN in pustular psoriasis patients decreased significantly after etretinate 
treatment,[7] which results were confirmed in an in vivo study using a model for pustule 
formation.[8] Furthermore, the respiratory burst of PMN of psoriatic patients, which is 
increased compared to control PMN, was normalized during treatment with etretinate.[9] 
In an immunohistochemical study in psoriasis treated with calcipotriol was shown that 
calcipotriol reduced the number of PMN already in an early phase of treatment.[10] So far, 
we can only speculate on the exact mechanism in the acitretin and calcipotriol 
combination, leading to the impressive clinical result in the treatment of acrodermatitis 
continua of Hallopeau. 
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Expression of SKALP as a marker for disease activity in psoriasis; effect of 
topical and systemic treatment (part II) 
12.2.1 The effect of anti-psoriatic treatment on the epidermal expression of SKALP 
In the general introduction several aspects of skin-derived antileukoproteinase 
(SKALP) have been described. SKALP is present in the upper part of the stratum spinosum 
in psoriatic epidermis, whereas normal epidermis shows no SKALP expression. In chapter 5 
the effect of topical treatment with a mild potency corticosteroid on SKALP expression in 
psoriasis is studied. In a double-blind left-right study hydrocortisone 17-butyrate 0.1% 
was compared with vehicle during a 4 weeks treatment period. Using 
immunohistochemistry, the expression pattern of SKALP following treatment with steroid 
was nearly undetectable. In contrast, the placebo-treated lesions showed no significant 
decrease of SKALP expression. Also cellular proliferation as marked by the number of Ki-67 
positive nuclei and cytokeratin 16 (CK 16) expression were completely normalized in most 
patients after treatment with steroid. Analysis of SKALP mRNA showed after 2 days of 
treatment no decrease compared to mRNA levels in untreated psoriatic skin. Equal levels 
were seen in the steroid-treated and placebo-treated lesions. After 4 weeks of treatment 
with placebo SKALP mRNA expression was still high, whereas a weak signal was found in 
the steroid-treated lesion. However, no downregulation to the undetectable levels as seen 
in uninvolved skin was achieved. This is not completely in agreement with the 
immunohistochemical results, showing no SKALP expression after 4 weeks of treatment in 
most patients. The equal SKALP mRNA levels in steroid and placebo treated skin after 2 
days of treatment, suggest that SKALP is not affected at the transcriptional level by 
topical steroids. Therefore, the expression of SKALP in psoriatic skin is not directly affected 
by steroid, but follows clinical improvement. This would imply that serum levels of SKALP 
might provide a tool for monitoring and quantification of disease activity. This will be 
further discussed in chapter 12.2.2. 
In chapter 6 the cell biological alterations of SKALP expression after treatment with 
either liarozole or acitretin were studied. Using immunohistochemistry, a significant 
decrease of SKALP expression was seen after 12 weeks of treatment in both groups. 
However, in most of the patients a substantial expression of SKALP was still visible. The 
markers for inflammation (elastase-positive cells), proliferation (Ki-67 positive nuclei), 
normal differentiation (transglutaminase) and disturbed differentiation (CK 16) all showed 
a significant decrease after 12 weeks of treatment. However, the levels of expression as 
seen in uninvolved skin were not achieved. A remarkable finding was that SKALP 
expression was induced in the uninvolved skin of patients treated with liarozole, and also 
in most of the patients treated with acitretin. 
Topical steroid treatment induced a more pronounced decrease in SKALP expression 
than systemic treatment with acitretin or liarozole. After treatment with steroid the mean 
expression level of SKALP was 0.3, and after 12 weeks of treatment with liarozole or 
acitretin 0.8 and 1.6, respectively. This apparent difference can be explained by the fact 
that the individual scores for erythema, induration and desquamation after treatment with 
topical steroid were more improved than after treatment with liarozole or acitretin. SKALP 
expression showed a similar response to topical steroid treatment and treatment with 
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acitretin and liarozole as the cellular proliferation and the expression of CK 16. 
Another novel marker for disturbed epidermal differentiation was studied: epidermal 
fatty acid-binding protein (E-FABP). E-FABP is highly upregulated in psoriatic epidermis, i t 
is expressed in all suprabasal layers. In contrast to SKALP, E-FABP is expressed in the 
stratum granulosum and in the upper third of the stratum spinosum in normal skin and 
non-lesional psoriatic skin. The expression of E-FABP remains increased after 4 weeks of 
steroid therapy and after 12 weeks of treatment with acitretin or liarozole. All suprabasal 
layers remained positively stained for E-FABP. Remarkably, after 2 days of steroid treatment 
the E-FABP mRNA expression was decreased in the steroid treated lesion, compared to the 
placebo treated lesion. This might indicate that steroids have a direct influence at the 
transcriptional level. 
Remarkable findings were the presence of a subtle expression of SKALP and a more 
pronounced E-FABP expression in the uninvolved skin during treatment with liarozole and 
acitretin. The markers for epidermal differentiation (CK 16, transglutaminase) and 
epidermal proliferation (Ki-67) showed in the uninvolved skin the same expression pattern 
as in normal skin. Presumably, this phenomenon is retinoid specific, because no induction 
of SKALP could be shown after treatment of normal skin with a potent topical 
corticosteroid (unpublished data). We conclude that the effects of retinoid and liarozole 
are different for lesionai and non-lesional skin. This has also been observed with topical 
retinoids. Tazarotene, a novel topical retinoic acid receptor-specific retinoid, down-
regulated the expression of SKALP, CK 16, involucrin and transglutaminase in psoriatic 
skin.[11,12] However, treatment of normal skin with topical retinoic acid increased the 
number of cell layers expressing transglutaminase, involucrin and fillagrin.[13] 
To summarize, topical treatment with steroid and systemic treatment with acitretin 
and liarozole have comparable effects on SKALP expression; the expression of SKALP is 
down-modulated, however not to the levels as found in the uninvolved skin. The response 
of SKALP to anti-psoriatic treatment is comparable with the responses of the proliferation 
marker Ki-67 and the differentiation marker CK 16. The exception on the described 
dynamical pattern is E-FABP, which is a slow marker. The subtle presence of SKALP and the 
more pronounced presence of E-FABP in uninvolved skin after treatment with acitretin and 
liarozole are difficult to explain. 
12.2.2 The effect of anti-psoriatic treatment on the serum levels of SKALP 
SKALP is a low-molecular weight protein which easily can cross the basal lamina, 
penetrate the connective tissue and reach the circulation. In previous studies we 
demonstrated increased levels of SKALP in urine and in serum of psoriatic patients.[14] 
After treatment with cyclosporin A during 16 weeks the decrease of PASI scores correlated 
well with the decrease of serum SKALP levels. In chapter 6 the serum levels of SKALP were 
measured using a specific sandwich-type ELISA, during treatment with either liarozole or 
acitretin. The SKALP levels were correlated to the PASI score, a marker for severity of 
psoriasis. During treatment with both acitretin and liarozole, SKALP levels decreased in 
parallel with the PASI score with similar kinetics. The SKALP levels showed a significant 
correlation with clinical scores. 
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The calculation of the PASI score is a generally accepted method to evaluate the 
clinical efficacy of an antipsoriatic treatment. However, several studies have shown the 
limitations of the PASI score[15-17] and therefore alternative scores for assessment of 
disease activity are desired. Previously i t has been reported that the serum levels of 
circulating soluble forms of the intercellular adhesion molecules ICAM-3[18]and ICAM-
1[18,19], interleukin-2 receptor[20], tumor necrosis factor receptor[18] and soluble E-
selectin[21,22] are increased in psoriatic patients and correlate with the disease activity 
as represented by the PASI score. Therefore, these serum markers might provide a tool for 
monitoring of disease activity. However, a prerequisite for a useful marker of disease 
activity is that the dynamic picture of the disease and the serum marker are corresponding, 
i.e. clinical improvement of psoriasis must coincide with reduction of levels of the serum 
marker. Improvement of the PASI score following UVB/anthralin therapy did not reduce 
cICAM-1 and E-selectin serum levels,[21,23] excluding these parameters as markers for 
disease activity. The interleukin-2 receptor correlated well with decrease in disease activity 
during immunosuppressive treatment.[20] Also serum SKALP levels correlate well with the 
disease activity. We showed that the serum SKALP levels increased in the same time period 
as the PASI score in patients experiencing a relapse after discontinuation of MTX treatment 
(unpublished data). Unfortunately changes in SKALP levels did not precede the clinical 
course, which would allow the start of therapy before a full relapse of psoriasis was 
experienced. 
The role of SKALP in the pathogenesis of pustular psoriasis (part III) 
12.3.1 Proteinases and proteinase inhibitors in the pathogenesis of diseases 
At the site of an inflammatory reaction, several proteolytic enzymes are secreted by 
activated PMN. The main role of these proteolytic enzymes is to prevent microbial invasion 
of the host. However, also host tissue is exposed to the proteolytic action, which may lead 
to tissue damage. At the site of inflammation, extracellular proteolysis is prevented by the 
presence of proteinase inhibitors. Serum contains several proteinase inhibitors like d i -
proteinase inhibitor (α,-ΡΙ) and ct2-macroglobulin, but proteinase inhibitors can also be 
locally produced, like SKALP and SLPI. As introduced in chapter 1, disturbance of the 
balance between proteinase and inhibitor has been shown to be of importance in tissue 
destruction in several diseases. In part I I I of the thesis we investigated whether this 
balance is disturbed in pustular psoriasis, a skin condition characterized by accumulation 
of PMN in the epidermis. 
12.3.2 Discussion of methods and techniques 
Before discussing the results of this part of the thesis, some aspects of the 
methodology need to be addressed. Different methods for measurement of SKALP levels 
were used. A functional measurement was performed, in which the inhibition of a fixed 
amount of elastase was used to measure anti-elastase activity. Because apart from SKALP, 
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also other locally or systemically produced proteinase inhibitors can be present in scale 
extracts or biopsies, the anti-elastase activity does not directly reflect the amount of 
SKALP. In a previous study, we showed that the inhibitory activity in scale extracts was 
not due to traces of plasma in the sample, which may contain сц-РІ. The amount of 
inhibitory activity was equal after extraction of scale extracts either in PBS or in buffer 
containing high salt and detergent.[24] This showed that o^-PI did not contribute to the 
anti-elastase activity, because c^-PI does not bind to human leukocyte elastase (HLE) in 
the presence of the cationic detergent СТАВ, which we also use in our sample buffer.[25] 
Furthermore, the scale extracts were boiled for 2 min., causing denaturation of the plasma-
derived antiproteinases (personal communication). However, the contribution of SLPI to 
the anti-elastase activity could not be excluded. We showed that recombinant SLPI is 
rather resistant to heat inactivation. Boiling of recombinant SLPI during 2 min. resulted in 
a minimal decrease of the elastase inhibiting capacity (unpublished data). In chapter 7 we 
measured SKALP levels in scale extracts, both functionally and immunochemically. Because 
the amount of SKALP as measured with the functional assay was in the same range as the 
amount of SKALP as measured with ELISA, we concluded that the anti-elastase activity 
found indeed was largely due to SKALP. In chapter 9 this conclusion was confirmed by the 
measurement of SKALP and SLPI levels in the same scale extracts with specific ELISAs. 
Due to the complex situation of both elastase and inhibitor being present in scale 
extracts, a direct quantification of the amount of biologically active inhibitor 
underestimates the amount of inhibitor. The inhibitor will be partially complexed with HLE, 
which represents the latent amount of anti-elastase activity present. Because HLE will be 
denatured by boiling and SKALP, in contrast, is heat stable, the total amount of anti-
elastase activity (free and latent) can be measured after boiling the scale extracts during 2 
min.[26] 
Furthermore, the total amount of SKALP protein could be measured 
immunochemically, for which we used a sensitive ELISA. In scale extracts we measured 
SKALP levels after boiling, which means that the total amount of SKALP is investigated. We 
did not measure scale extracts directly using the ELISA, because it is not clear whether the 
anti-SKALP IgG binds to the complex HLE-SKALP as efficiently as to SKALP alone. 
12.3.3 In vivo levels of SKALP in plaque and pustular psoriasis 
In chapter 7 the expression of SKALP in vivo in the lesionai skin of psoriatic patients 
and pustular psoriasis patients was studied. SKALP levels were determined in scale extracts 
and in keratome biopsies. SKALP levels were studied at the protein level, both functionally 
and immunochemically, and at the mRNA level. In scale extracts, both free and total SKALP 
activity were significantly lower in pustular psoriasis than in plaque psoriasis. In 5 of 19 
patients with pustular psoriasis free elastase activity could be detected after direct 
measurement, indicating total saturation of all available anti-elastase activity. Latent 
SKALP activity could be recovered after heat inactivation. Also SKALP levels as measured 
with ELISA showed significantly lower amounts of SKALP in scale extracts of patients with 
pustular psoriasis. In biopsies, the SKALP activity in biopsies from the pustular region of 
pustular psoriasis patients was significantly decreased compared with the activity in 
plaque psoriasis. Northern blot analysis revealed similar levels of SKALP mRNA expression 
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in plaque and pustular psoriasis. No difference in transcript size was found. 
The quantification of SKALP in scale extracts, as we performed in this study, might 
be difficult to interpret. Because in the pustular forms of psoriasis the inflammatory 
component dominates, one would expect that the amount of inflammatory exudation is 
increased compared to plaque psoriasis. I t was demonstrated that during inflammation the 
epidermis becomes more permeable to plasma derived proteins.[27] This would mean that 
the amount of total protein might be increased in scale extracts of pustular psoriasis 
patients. The levels of SKALP are calculated in ng/mg protein. If the total amount of 
protein is increased in pustular psoriasis, the amount of SKALP could be artificially 
lowered. However, we calculated the total protein concentration in scale extracts from 
plaque and pustular psoriasis patients, which were 8.3 and 8.9 mg/ml, respectively. We 
therefore conclude that SKALP levels are lower in pustular psoriasis patients and that the 
difference is not caused by an artefact of the methodology. 
We demonstrated in this study that in scale extracts of plaque psoriasis patients heat 
inactivation resulted in slightly lower levels of anti-elastase activity, while one would 
expect higher levels due to liberation of SKALP of the SKALP-HLE complex. In chronic 
stable plaque psoriasis the amount of PMN in the centre is rather low,[28] thus the amount 
of SKALP complexed to HLE will also be rather low. Furthermore, low amounts of heat-labile 
proteinase inhibitors like α,-ΡΙ or a certain amount of SKALP might be denatured by 
boiling. Because in pustular psoriasis this effect might also occur, the amount of latent 
SKALP might be underestimated. 
In conclusion, in vivo in both scale extracts and skin biopsies SKALP is decreased at 
the protein level in pustular psoriasis patients. SKALP mRNA levels were equal in plaque 
and pustular psoriasis. 
12.3.4 Screening of the SKALP gene for mutations or polymorphisms 
The results as described in the previous chapter raised the possibility that SKALP 
could be one of the candidate genes for pustular forms of psoriasis. The finding of 
decreased SKALP levels might be a result of a heterozygosity for an inactivating point 
mutation, or a polymorphism leading to reduced activity of the SKALP protein. In chapter 
8 we performed single strand conformation polymorphism analysis on the SKALP gene to 
screen for a genetic abnormality in exon 1 and 2 of plaque and pustular psoriasis patients. 
We indeed found a polymorphism in exon 1, resulting in an amino acid substitution. 
Furthermore a polymorphism in a dinucleotide repeat in the promoter region was found. 
Both polymorphisms were not associated with pustular psoriasis, or psoriasis in general. 
The human SKALP gene contains 3 exons and 2 introns, in which exon 1 and 2 are the 
coding regions. Because we did not perform SSCP analysis on exon 3, which encodes the 
З'-noncoding region, i t is still possible that polymorphisms exist in this region that could 
control translation efficiency. 
We conclude that i t is unlikely that the observed decrease in SKALP protein levels in 
pustular psoriasis are caused by mutations in the coding region of the gene. 
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12.3.5 Levels of SKALP in cultured keratinocytes of plaque and pustular psoriasis 
patients 
To further elucidate the in vivo finding of low levels of SKALP, we investigated 
whether keratinocytes from patients with pustular psoriasis are intrinsically programmed to 
express or secrete low levels of SKALP. In chapter 9 we studied in vitro whether 
keratinocytes of pustular psoriasis patients produce or secrete decreased levels of SKALP 
compared to keratinocytes of plaque psoriasis patients. The advantage of the use of in vitro 
models in this study, is that the ability of production and secretion of SKALP by the 
different types of keratinocytes can be quantified and compared, because the environment 
is identical. The possible influence of differences in inducing and regulating factors of 
SKALP expression, as might be encountered in in vivo studies, is excluded. 
We set up keratinocyte cultures from biopsies of 4 pustular psoriasis patients. A 
collection of 9 cell lines from plaque psoriasis patient was already available. We studied 
the induction kinetics of SKALP and the expression levels at the mRNA and protein level, 
comparing keratinocytes of plaque psoriasis patients with keratinocytes of pustular 
psoriasis patients. In various culture models that allow low and high levels of SKALP 
expression no significant decrease of SKALP protein secretion was found in the cells 
derived from pustular psoriasis patients. The levels of SKALP mRNA were comparable in 
cells derived from pustular and plaque psoriasis patients. No differences in transcript size 
was found between SKALP mRNA from plaque and pustular psoriasis patients. 
With this study, we confirmed the data as obtained with the in vivo studies, 
showing equal levels of mRNA in keratome biopsies from plaque and pustular psoriasis 
patients. A point of discussion might be that biopsies for keratinocyte culture were taken 
from uninvolved skin on the back of the patients. With this study, we can exclude 
generalized intrinsic gene defects, but not defective gene expression in lesionai skin. 
However, in the in vivo study we demonstrated that in lesionai skin of pustular psoriasis 
patients the mRNA levels are comparable with mRNA levels as found in lesionai skin of 
plaque psoriasis patients. 
In conclusion, in vitro studies showed equal transcription levels in both plaque and 
pustular psoriasis keratinocytes and also equal concentrations of SKALP in the culture 
media. We can conclude from these data that keratinocytes from patients with pustular 
psoriasis are not intrinsically programmed to express low levels of SKALP. 
12.3.6 The role of post-translational inactivation of SKALP in pustular psoriasis 
Since the active site of SKALP contains a methionine residue, we investigated in 
chapter 9, analogous to findings with сц-РІ and SLPI, whether the molecule is sensitive to 
oxidation. Furthermore, the interaction of SKALP with its target proteinase HLE was studied 
using recombinant SKALP. SKALP was complexed in vitro with HLE. Even prolonged 
incubation of SKALP with HLE did not lead to degradation of the inhibitor. Incubation of 
SKALP with hydrogen peroxide and superoxide had no effect on inhibitory activity or 
integrity of SKALP. A concentration of ΙΟ2 μΜ hypochlorous acid (HOCl) caused oxidation 
of SKALP as demonstrated by the loss of silver staining after SDS-PAGE. After incubation 
with HOCl in a concentration of 1 mM a decrease of SKALP activity was found. We 
concluded that the decrease of SKALP is likely to be caused by posttranslational 
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mechanisms, which might include oxidation and subsequently rapid clearance of the 
molecule. 
Besides the oxidative inactivation of SKALP by HOCl, we do not have experimental 
evidence for the post-translational mechanism involved in the decrease of SKALP. In fact, 
we did not exclude the role of translational mechanisms in vivo in our experiments. Defects 
of protein translation from mRNA, or transport of mRNA from the nucleus to the cytoplasm 
might also explain the results we found. 
12.3.7 Levels of SLPI in plaque and pustular psoriasis 
Besides SKALP, another locally produced proteinase inhibitor is upregulated in 
psoriatic epidermis: secretory leukocyte proteinase inhibitor (SLPI).[29,30] We questioned 
whether the observed decrease of SKALP in pustular psoriasis is specific for SKALP, or is 
also present for SLPI. In chapter 9, we measured SLPI levels in scale extracts and 
compared them with SKALP levels. SLPI levels in plaque and pustular psoriasis were 
comparable. SLPI is known to be susceptible for oxidative inactivation. Because of the 
high amount of PMN in pustular psoriasis, one can expect that in pustular psoriasis SLPI is 
largely present in an oxidized form. Because there is no difference between plaque and 
pustular psoriasis in SLPI levels, we may conclude that oxidation of SLPI does not 
influence the clearance of this molecule. Because of the homology with SKALP, oxidation 
and subsequent increased clearance might also be not of relevance for SKALP. Furthermore, 
we demonstrated that the levels of SLPI in scale extracts are a factor 10 lower than SKALP 
levels, at least in plaque psoriasis. In pustular psoriasis the contribution of SLPI to the 
total anti-elastase activity is high, levels of SLPI differ less than factor 2 of levels of 
SKALP. We conclude that the low levels of SKALP in pustular psoriasis are specific for this 
inhibitor. 
12.3.8 The role of SKALP in the dynamic process of pustule formation 
In chapter 10 we described a patient with impetigo herpetiformis, which is a form of 
generalized pustular psoriasis induced by pregnancy. Serial SKALP levels were measured in 
scale extracts and in serum from this patient. During the course of the disease, anti-
elastase activity in epidermal scales of the patient dropped to undetectable levels in the 
untreated samples. After heat-inactivation, latent anti-elastase activity could be 
recovered. In this patient the dynamic process of saturation of SKALP is clearly shown. In 
the initial phase of the disease, free SKALP is available. However, 9 days after admission, 
all SKALP available is bound to H LE. One can hypothesize that released H LE encounters an 
insufficient anti-proteinase shield, and can, not hindered by SKALP, cause epidermal tissue 
damage. To what extent otj-PI can provide protection is not known. One can imagine that 
in the situation of extreme skin-inflammation as in this patient, the amount of α,-ΡΙ can 
be rather high, due to an increased permeability of the blood vessels. However, the mean 
total amount of protein in the scale extracts was 8.3 mg/ml, which is comparable with the 
scale extracts from plaque psoriasis patients. 
What we also can conclude from this case report is that the initial process of pustule 
formation and tissue destruction is not provoked by the low levels of SKALP. At admission, 
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the patient showed pustules and an extensive erythema and desquamation, while at that 
moment unsaturated SKALP was still available, however in lower amounts than in plaque 
psoriasis patients. In the prolongation-phase SKALP may play a role, because by the 
absence of unsaturated SKALP, the migration of PMN and tissue destruction by proteinases 
is largely unhindered. 
12.3.9 Immunohistochemical localization of SKALP in pustular psoriasis 
In chapter 7 we describe the immunohistochemical localization of SKALP in a patient 
with annular pustular psoriasis and in a patient with generalized pustular psoriasis. The 
patient with annular pustular psoriasis is also discussed in chapter 11. The SKALP 
expression pattern was similar in pustular and plaque psoriasis, i.e. basal cells are negative 
and the suprabasal layers showed expression of SKALP. Apparently, there are different forms 
of pustules; in the pustule from the patient with APP, the epidermis underlying a pustule is 
intact and shows several layers of SKALP expression, comparable with the SKALP pattern in 
plaque psoriasis. The PMN are compartmentalised in the stratum corneum. In a pustule from 
a patient with GPP, SKALP expression is clearly present, however less layers of the 
suprabasal compartment are stained. Furthermore, PMN are present scattered in the 
epidermal layers, destroying the SKALP producing cells. Because of the decreased levels of 
SKALP, the SKALP producing keratinocytes of the stratum spinosum are exposed to the 
destructive metabolites, released by the PMN. In consequence of this, the SKALP production 
is decreased which will disturb the proteinase-anti-proteinase balance in the epidermis even 
further. 
In chapter 11 the topographic relation between HLE and SKALP in the different 
zones of a typical lesion in a patient with annular pustular psoriasis is described. In the 
erythematous distal margin of the Lesion, expression of SKALP was shown in suprabasal 
keratinocytes, although PMN migration into the epidermis had not occurred. This indicates 
that the induction of SKALP expression does not result from the passage of PMN through 
the epidermis. Furthermore, in the central area of the clinically healed skin, mononuclear 
infiltrate is present in the absence of PMN and SKALP. In contrast to our findings, other in 
vivo studies studying the time-dependent relationship between SKALP and PMN either with 
a functional assay (after standardised injury[31] and in the spreading psoriatic lesion[32]) 
or with immunohistochemical staining (after excisional wounding[33]) indicate that SKALP 
expression follows the influx of PMN. 
12.3.10 General conclusions and suggestions for further research 
From the results presented in part I I I of the thesis the following conclusions can be drawn: 
• In vivo SKALP protein levels in pustular forms of psoriasis are decreased, whereas 
the m RNA levels of SKALP are equal to plaque psoriasis patients. 
• The decrease of SKALP levels is not caused by mutations in the coding region of the 
gene, and no allelic association between pustular psoriasis and SKALP gene 
polymorphisms could be demonstrated. 
• In vitro the protein and transcription levels are equal in keratinocytes derived from 
plaque and pustular psoriasis patients. 
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• Recombinant SKALP was extremely resistant to degradation or inactivation by PMN-
derived mediators such as elastase, superoxide anion and hydrogen peroxide. 
Hypochlorous acid was found to cause oxidation of SKALP and, at high 
concentrations, caused a decrease in functional activity. 
• The decrease of SKALP in pustular psoriasis was not paralleled by a decrease of 
SLPI, a related molecule, and therefore seems to be specific for SKALP. 
Based on these results, we can conclude that the observed deficiency of SKALP in vivo is 
not caused by a defect in the keratinocyte at the level of SKALP mRNA synthesis. We 
hypothesize that the decrease of SKALP is caused by translational or posttranslational 
mechanisms, which might include oxidation and subsequently rapid clearance of the 
molecule. Up to date i t is not known whether a receptor for SKALP or SKALP/elastase 
complexes exists, analogous to the receptor for aa-PI/elastase[34] or for SLPI.[35] 
Speculatively, oxidized SKALP (either free or complexed with elastase) could be cleared 
from the tissue at a faster rate than native SKALP, which would lead to reduced levels of 
SKALP in the epidermis and in the stratum corneum. The study, in which the presence of a 
receptor for SKALP in epidermal keratinocytes is investigated, is scheduled for the near 
future. 
In respiratory epithelial cell cultures the effect of HLE on SLPI production has been 
extensively studied. HLE decreased SLPI at the protein level, whereas SLPI mRNA was 
upregulated.[36,37] Whether this kind of interaction between HLE and keratinocytes will 
affect SKALP mRNA production or secretion remains to be investigated. One can 
hypothesize that in pustular psoriasis the amount of HLE excreted by the PMN is much 
higher than in plaque psoriasis, giving rise to a more pronounced effect of HLE in pustular 
than in plaque psoriasis. Previously i t was shown that HLE can induce bronchial cells in 
culture to synthesise IL-8, a potent neutrophil-chemoattractant[38]. Whether the same 
mechanism is of relevance in keratinocytes is not known to date. It might be that this 
"vicious circle" of HLE, inducing IL-8 production by keratinocytes, with subsequently 
accumulation of PMN, which secrete again HLE, is insufficiently downregulated in pustular 
psoriasis. 
Regardless of the mechanisms involved in causing a decrease of SKALP, localized 
excess of HLE causes a proteinase-antiproteinase imbalance, leading to uncontrolled 
proteinase activity and destruction of epidermal integrity. Therefore, we expect that 
treatment of pustular psoriasis with pharmacological inhibitors of PMN-derived proteinases 
is a useful new therapeutic modality. A beneficial effect of proteinase inhibitors as 
adjuvant therapy has been demonstrated in vivo in the treatment of pemphigus 
vulgaris.[39] Preliminary data show that topical application of сц-РІ exerts beneficial 
therapeutic effects in the therapy of atopic dermatitis.[40] In organ culture of normal 
human skin, the synthetic serine proteinase inhibitor camostat mesylate proved to inhibit 
blistering induced by dystrophic epidermolysis bullosa. Therapeutical use by topical 
application in patients with epidermolysis bullosa seemed promising.[41] Because our 
experience is that pustular forms of psoriasis are difficult to treat with the conventional 
modalities, local therapeutical use of pharmacologically produced proteinase-inhibitors 
might be a promising therapy in the future. 
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SAMENVATTING 
Dit proefschrift richt zich op de bestudering van de ernstige vormen van psoriasis, 
waaronder worden verstaan de uitgebreide vormen van chronische plaque psoriasis, 
erythrodermie op basis van psoriasis en psoriasis pustulosa. In dit proefschrift worden 
enerzijds klinische studies beschreven betreffende de therapeutische mogelijkheden bij de 
ernstige vormen van psoriasis en anderzijds basaal wetenschappelijke studies, waarin de 
rol van skin-derived antileukoproteinase (SKALP) bij ernstige psoriasis wordt geëvalueerd. 
Het proefschrift is opgebouwd uit 3 delen met de volgende onderwerpen van studie: 
1. De effectiviteit en veiligheid van systemische behandelingen, als mono- of 
gecombineerde therapie, bij ernstige vormen van psoriasis (deel I ) . 
2. De celbiologische effecten van lokale en systemische behandelingen, met de nadruk 
op interferentie met SKALP produktie (deel I I ) . 
3. De rol van de proteinase-SKALP balans in de Pathogenese van psoriasis pustulosa 
(deel I I I ) . 
Hoofdstuk 1 geeft een algemene inleiding bij dit proefschrift. Er wordt een 
beschrijving gegeven van de etiologische en klinische kenmerken van psoriasis vulgaris en 
psoriasis pustulosa, een vorm van psoriasis waarbij pustels op de voorgrond staan. Verder 
worden de gangbare lokale en systemische anti-psoriatische behandelingen geïntroduceerd. 
Tevens worden diverse aspecten besproken van ontstekingsprocessen in de huid, waarbij de 
nadruk ligt op de rol van eiwitafbrekende enzymen, Proteinasen genaamd, en remmers van 
deze Proteinasen, de proteinase-remmers. Een overzicht wordt gegeven van de 
biochemische en celbiologische eigenschappen van SKALP, een lokaal in de huid 
geproduceerde proteinase-remmer. SKALP is afwezig in de normale huid en wordt o.a. bij 
psoriasis in de huid gevormd. De mogelijke rol van een verstoord evenwicht tussen 
Proteinasen en proteinase-remmers in de Pathogenese van psoriasis pustulosa wordt 
geïntroduceerd. 
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Deel I van de dissertatie omvat de hoofdstukken 2 tot en met 4 en betreft de 
systemische behandeling van ernstige vormen van psoriasis. In hoofdstuk 2 wordt een 
analyse van de effectiviteit en de risico's van langdurige methotrexaat (MTX) behandeling 
bij ernstige psoriasis verricht. Dit hoofdstuk is gebaseerd op 3 klinische studies. De eerste 
studie is een retrospectieve studie waarin de effectiviteit en bijwerkingen bij 113 
patiënten die MTX hebben gebruikt worden geëvalueerd. De tweede studie betreft de 
evaluatie van 2 nieuwe, niet invasieve screeningsmethoden voor het vaststellen van 
leverschade: de PIIINP bepaling en de dynamische hepatische scintigraphie. In de derde 
studie wordt bekeken in hoeverre een intermitterend behandelingsschema een besparing in 
cumulatieve MTX dosis oplevert. De resultaten van deze studies worden bediscussieerd en 
vergeleken met andere studies. Wij concluderen dat behandeling met lage doseringen MTX 
een veilige therapie is, mits patiënten zorgvuldig worden geselecteerd en regelmatig 
gecontroleerd op bijwerkingen en geneesmiddelen interacties. Om leverschade vast te 
stellen blijft het verrichten van leverbiopten volgens de internationale richtlijnen 
aanbevolen, tot nieuwe niet-invasieve screeningsmethoden voldoende zijn geëvalueerd. 
In hoofdstuk 3 worden 3 patiënten met een erytrodermie op basis van psoriasis 
beschreven, die kortdurend behandeld werden met de combinatie acitretine en 
cyclosporine A. Gezien het ontbreken van klinische verbetering en het snelle optreden van 
bijwerkingen, lijkt dit geen goed alternatief voor behandeling van uitgebreide psoriasis. In 
hoofdstuk 4 wordt een goed klinisch resultaat getoond van gecombineerde behandeling 
van acitretine met calcipotriol bij een patiënte met acrodermatitis continua van Hallopeau, 
een vorm van psoriasis pustulosa. 
Deel I I omvat hoofdstukken 5 en б en beschrijft het effect van anti-psoriatische 
therapie op de expressie van SKALP. In hoofdstuk 5 wordt het effect van lokale 
behandeling op de expressie van SKALP beschreven. In een links-rechts studie wordt 
corticosteroid met placebo vergeleken. Na 4 weken behandeling is de expressie van SKALP 
nagenoeg afwezig na steroid behandeling, terwijl het expressiepatroon aan de placebo 
behandelde zijde onveranderd is. Analyse van SKALP mRNA liet na 2 dagen behandeling 
geen verschil zien tussen steroid- en placebo-behandelde zijde, na 4 weken werd een 
verminderde expressie gezien aan de steroid-behandelde zijde. 
In hoofdstuk 6 wordt de expressie van SKALP bestudeerd na behandeling met 
acitretine of met liarozole, een afbraakremmer van endogeen geproduceerd all-trans 
retinoic acid. Na 12 weken behandeling werd een significante daling in SKALP expressie 
gezien, echter in het merendeel van de patiënten was nog duidelijk expressie van SKALP 
aantoonbaar. Een opvallende bevinding was de aanwezigheid van SKALP in de niet-
aangedane huid van zowel patiënten behandeld met acitretine als liarozole. Tevens werden 
serumspiegels van SKALP bepaald tijdens behandeling met acitretine en liarozole. De PASI 
score, een maat voor de ernst en uitgebreidheid van psoriasis, vertoonde een significante 
relatie met de serum spiegels van SKALP, wat bepaling van de SKALP serum spiegel tot een 
geschikte marker voor ziekteactiviteit maakt. 
Deel I I I omvat de hoofdstukken 7 tot en met 11 en bestudeert de rol van SKALP in 
de Pathogenese van psoriasis pustulosa. In hoofdstuk 7 wordt de aanwezigheid en 
functionaliteit van SKALP in schilferextracten en biopten van pustuleuze en plaque 
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psoriasis patiënten bestudeerd. Zowel functioneel als immunochemisch bepaald, is de 
hoeveelheid SKALP in de schilferextracten van psoriasis pustulosa patiënten verlaagd. 
Tevens werd in 5 van de 19 patiënten met pustuleuze psoriasis vrije elastase activiteit 
gevonden, wat duidt op saturatie van al het aanwezige SKALP. Na verhitten kon latent 
SKALP worden aangetoond. Ook in de biopten werd een significante daling van SKALP 
gevonden in de psoriasis pustulosa patiënten. Northern blot analyse liet gelijke 
hoeveelheden SKALP mRNA zien in plaque en pustuleuze psoriasis. 
In hoofdstuk 8 en 9 wordt gezocht naar een mogelijke verklaring voor de lage 
waarden van SKALP in pustuleuze psoriasis. Hoofdstuk 8 vermeldt de bevindingen van de 
screening van exon 1 en 2 van het SKALP gen op genetische afwijkingen middels single 
strand conformation polymorphism analyse. Er werd een polymorphisme in exon 1 en in de 
promoter regio gevonden, welke beiden echter niet geassocieerd waren met psoriasis 
pustulosa of psoriasis in het algemeen. In hoofdstuk 9 wordt de produktie en secretie van 
SKALP in vitro bestudeerd met behulp van verschillende kweeksystemen voor 
keratinocyten, welke geringe tot maximale expressie van SKALP induceren. Hiertoe werden 
keratinocyten afkomstig van plaque psoriasis patiënten vergeleken met keratinocyten van 
pustuleuze psoriasis patiënten. Er werd geen verschil gevonden in SKALP eiwit in het 
kweekmedium en in SKALP mRNA tussen plaque en pustuleuze keratinocyten. Hiermee werd 
uitgesloten dat keratinocyten van patiënten met een pustuleuze psoriasis intrinsiek 
geprogrammeerd zijn om lage hoeveelheden SKALP tot expressie te brengen. In analogie 
tot de bevindingen met arantiproteinase, een andere proteinase remmer, is de 
gevoeligheid van SKALP voor oxidatieve inactivatie en degradatie door mediatoren 
afkomstig van polymorfkernige granulocyten (PMN) bestudeerd. SKALP was ongevoelig voor 
degradatie of inactivatie door elastase, waterstofperoxide en superoxide. Hypochloriet kan 
SKALP oxideren en inactiveert SKALP bij hoge concentraties. Naast SKALP kan in 
schilferextracten secretory leukocyte proteinase inhibitor (SLPI), een andere lokaal 
geproduceerde proteinase-remmer, aanwezig zijn. De hoeveelheden SLPI zijn gelijk in 
schilferextracten van plaque en pustuleuze psoriasis, waarmee de daling van SKALP in 
pustuleuze psoriasis specifiek voor deze proteinase-remmer lijkt te zijn. Hoewel enkele 
mogelijke verklaringen voor de verminderde hoeveelheid SKALP in psoriasis pustulosa zijn 
uitgesloten, kan er nog geen definitieve verklaring worden gegeven. 
In hoofdstuk 10 wordt een patiënte met impetigo herpetiformis, een door 
zwangerschap geïnduceerde vorm van gegeneraliseerde pustuleuze psoriasis, gepresenteerd. 
Tijdens het ziektebeloop kan in eerste instantie SKALP activiteit in schilferextracten 
worden aangetoond, terwijl 9 dagen na opname vrije elastase activiteit wordt gevonden. 
Na verhitten wordt latent SKALP gevonden. Deze casus illustreert het dynamisch verloop in 
SKALP expressie. 
In hoofdstuk 11 wordt een patiënt met annulaire pustuleuze psoriasis beschreven, bij 
wie in de verschillende klinische stadia van de laesies de mate van SKALP expressie en de 
aanwezigheid van PMN is bestudeerd. In de perifere rand van de laesie komt SKALP tot 
expressie zonder dat PMN aanwezig zijn in de epidermis. 
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In hoofdstuk 12 worden de resultaten van dit proefschrift samengevat en 
bediscussieerd. De doelstellingen zoals geformuleerd in hoofdstuk 1, worden nader 
toegelicht. Verschillende verklaringen voor de gevonden lage waarden van SKALP in 
pustuleuze psoriasis zijn uitgesloten. Er kan op dit moment echter nog geen afdoende 
verklaring worden gegeven. Verder onderzoek in de toekomst kan uitsluitsel geven, ook wat 
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wetenschappelijk onderzoek niet aan mij besteed was. Na mijn wetenschappelijke stage op 
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dit proefschrift gekomen, mede dankzij de motiverende en uiterst prettige samenwerking 
met een groot aantal mensen op de afdeling dermatologie. Ik wil jullie allemaal hiervoor 
danken, alleen was me dit nooit gelukt. Een aantal mensen wil ik met name noemen. 
Om te beginnen mijn promotor Peter van de Kerkhof en mijn co-promotor Joost Schalkwijk. 
Peter, bedankt voor de aan mij geboden kans mij verder te bekwamen in het 
wetenschappelijk onderzoek, voor je inspiratie, motivatie en het vertrouwen in mij gesteld. 
Joost, j i j bent degene die het AGIKO project heeft geschreven en in mij een geschikte 
kandidaat daarvoor zag. Jij had altijd alle tijd en geduld om in alle rust te overleggen, 
bedankt daarvoor. 
Rens van Dooren-Greebe, na mijn terugkomst uit Tanzania begon ik met een 
wetenschappelijke stage bij jou. Ik heb erg veel van je geleerd, met name jouw 
nauwgezetheid en doorzettingsvermogen waren een voorbeeld voor mij. 
Gijs de Jongh, mijn steun en toeverlaat wat betreft de SKALP-ELISA's en de celkweek 
experimenten, wil ik danken voor zijn geweldige, geduldige uitleg. Samen hebben we heel 
wat uren doorgebracht in "de koude kamer": j i j in een T-shirtje, ik in een dikke jas, en dit 
I 
199 
alles ter optimalisering van onze experimenten. Patrick Zeeuwen, bedankt voor al je hulp 
bij het moleculair biologisch werk wat ik gedaan heb. Wat mij duidelijk is, is dat jouw ogen 
een stuk beter zijn dan de mijne bij het ontdekken van pellets. Mieke Bergers, bedankt 
voor je hulp en uitleg bij de Western blots. Ivonne van Vlijmen, bedankt voor je hulp bij de 
verschillende immunohistochemische kleuringen. Diana Melchers, de SSCP methode is 
dankzij jou een succes geworden. Hans Alkemade en Henri Molhuizen, samen met jullie heb 
ik mijn eerste stapjes in de basale wetenschappen mogen zetten. Bedankt voor jullie hulp. 
Verder wil ik Michelle van Rossum bedanken, die als studente een enthousiaste en kritische 
bijdrage leverde aan mijn onderzoek. Jacky den Bakker, bedankt voor jouw bijdrage aan de 
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Fred van Ruissen, Rolph Pfundt en Miriam Wingens, ik heb ontzettend prettig 
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mijn onderzoek. Verder wil ik mijn collega-assistenten, de stafleden, de verpleegkundigen, 
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paranimf. 
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Astrid Kuijpers werd op 1 juli 1967 geboren in het Brabantse Volkel (gemeente Uden). In 
1985 behaalde zij haar VWO diploma aan het Rivendell College te Uden. In datzelfde jaar 
begon zij met haar studie geneeskunde aan de Katholieke Universiteit Nijmegen. In 
augustus 1989 behaalde zij haar doctoraalexamen geneeskunde, waarna werd begonnen 
met de co-assistentschappen. Van december '91 tot april '92 was zij werkzaam als 
"student-doctor" in het Sengerema hospital te Tanzania, in het kader van een keuzestage 
gezondheidszorg in ontwikkelingslanden. Direct na het behalen van haar artsexamen, trad 
zij op 15 december 1992 in dienst als assistent-geneeskundige op de afdeling dermatologie 
van het Academisch Ziekenhuis Nijmegen. In aanvang verrichtte zij klinisch onderzoek naar 
de systemische behandelingen bij psoriasis onder supervisie van dr. R.J. van Dooren-
Greebe. Op 15 mei 1995 kreeg zij, via de Nederlandse Organisatie voor Wetenschappelijk 
Onderzoek (NWO), een aanstelling als Assistent Geneeskundige in Opleiding tot Klinisch 
Onderzoeker (AGIKO). Met deze aanstelling werd basaal-wetenschappelijk onderzoek 
verricht onder supervisie van dr. J . Schalkwijk, in combinatie met de opleiding tot 
dermatoloog (opleider: Prof. dr. dr. P.C.M, van de Kerkhof). De resultaten van het 
onderzoek wat zij in dit kader verrichtte en het eerdere klinisch onderzoek, resulteerde in 
deze dissertatie. 
Op 3 april 1998 is zij gehuwd met Bennie Cuijpers. 
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Stellingen behorende bij het proefschrift: 
"Severe forms of psoriasis, clinical and experimental studies" 
door Astrid L A. Kuijpers. 
Nijmegen, woensdag 30 september 1998 
1 Het feit dat methotrexaat momenteel, ruim 30 jaar na de introductie, nog steeds gebruikt 
wordt voor behandeling van ernstige vormen van psoriasis komt door een gunstig "risk -
benefit" profiel, -dit proefschrift-
2 Zolang niet-invasieve technieken voor het vaststellen van leverschade tijdens methotrexaat 
behandeling niet voldoende gevalideerd zijn, blijft een leverbioptie hiervoor noodzakelijk, 
-dit proefschrift-
3 Een lokaal tekort aan SKALP lijkt een rol te spelen bij pustelvorming in pustuleuze psoriasis, 
-dit proefschrift-
4 De verlaagde aanwezigheid van SKALP in de epidermis bij pustuleuze psoriasis patiënten 
wordt niet veroorzaakt door een verlaagde produktie. -dit proefschrift-
5 Impetigo herpetiformis dient als een vorm van gegeneraliseerde pustuleuze psoriasis te wor-
den beschouwd en niet als een aparte entiteit, -dit proefschrift-
6 De grote hoeveelheden proefmonsters die de kosmetische industrie aan dermatologen stuurt, 
doet vrezen dat het predikaat "dermatologisch getest" verantwoord is. 
7 Bij een onverwachte bevinding bij een experiment dient men eerst de houdbaarheidsdatum 
van de gebruikte materialen te controleren, alvorens aan publiceren te denken. 
8 De Tanzaniaanse levensbeschouwing "Mungu akipenda", maakt het werk voor de tropendokter 
een stuk gemakkelijker. 
9 De biologische klok van een vrouw in opleiding tot dermatoloog tikt te snel voor de oplei-
dingsduur. 
10 De in het AGIKO-model nagestreefde integratie van klinische en wetenschappelijke opleiding 
vereist een grote flexibiliteit van opleiders en collega's, maar vooral van de AGIKO in kwes-
tie. 
11 Zoek nooit het geluk, want je zoekt je een ongeluk. 
-August Willemsen-
12 Een patiënt met een huidziekte moet veel smeren en krijgt daarnaast ook veel te slikken. 



























— - Ч 
"*"'« 
* 
m 
0 
